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Ik ben lekker stout
Ik wil niet meer, ik wil niet meer!
Ik wil geen handjes geven!
Ik wil niet zeggen elke keer:
Jawel mevrouw, jawel meneer...
nee, nooit meer in m’n leven!
Ik hou m’n handen op m’n rug
en ik zeg lekker niks terug!
Ik wil geen vieze havermout,
ik wil geen tandjes poetsen!
Ik wil lekker knoeien met het zout,
ik wil niet aardig zijn, maar stout
en van de leuning roetsen
en schipbreuk spelen in de teil
en ik wil spugen op het zeil!
En heel hard stampen in een plas
en dan m’n tong uitsteken
en morsen op m’n nieuwe jas
en ik wil overmorgen pas
weer met twee woorden spreken!
En ik wil alles wat niet mag,
de hele dag, de hele dag!
En ik wil op de kanapee
met hele vuile schoenen
en ik wil aldoor gillen: nee!
En ik wil met de melkboer mee
en dan het paardje zoenen.
En dat is alles wat ik wil
en als ze kwaad zijn, zeg ik: Bil!
Annie M.G. SCHMIDT (1911 - 1995)
General introduction
1
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General introduction
This dissertation is the culmination of a variety of experiences and interests 
accumulated during my work as a clinical psychiatrist. Working as a consultant 
in an addiction treatment centre, I was surprised to find patients similar to 
those I had encountered during my earlier work in inpatient and outpatient 
psychiatry. The main difference was the overpowering presence of substance use 
disorders (SUDs). The similarities in psychiatric diagnosis helped me recognise 
the complexities in the association of psychiatric symptoms and disorders with 
addictive disorders. My interest in the early antecedents of this chronic and 
dynamic interaction led me to recognise the prevalence of ADHD in this patient 
population, as well as its role – in combination with other childhood conduct 
disturbances – in the emergence of problematic substance use.
 I was fortunate to have had the opportunity to combine these different 
interests in a scientific project, which I am proud to present here. I will start by 
framing the clinical and scientific concepts that served as building blocks in the 
formulation of the research questions I have tried to answer in this study. 
Concepts
1. Addiction – Substance Use Disorders
The central tenet of addiction is the loss of control: willful, purposeful behaviour 
is replaced by uncontrollable actions directed only at the continuation of 
problematic substance use1, even to the point where the patient’s vital interests 
no longer seem to matter. The intake of psychoactive substances is pursued 
despite the clear and immediate negative consequences for users and their 
environment. 
 The use of psychoactive substances has been a universal characteristic of 
human civilisation throughout history; however the ability to control this use 
varies widely across individuals 1. These two facts are at odds with each other, 
which helps explain why society has struggled to acknowledge the pathology 
underlying problematic substance use 2. This struggle is apparent even in the 
nomenclature used in this dissertation. The term “drug dependence”, the official 
(and neutral) name given in the DSM-IV-TR chapter on Substance Use Disorders 
1   In this dissertation, only the addictive use of psychoactive substances is discussed. Research has shown 
that the same neurobiological mechanisms found in substance use disorders are involved in other forms 
of psychological dependency (e.g., eating and fasting, sex, pornography, sports, internet use, gambling, 
shopping). These other addictive behaviours are not covered in this dissertation. 
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2. Psychiatric comorbidity 
Psychiatric comorbidity is both a scientific abstraction and a clinical reality 19. 
Originating in the wake of modern diagnostic classification systems, the concept 
has been avidly embraced by clinicians hoping to disentangle the often complex 
and diverse symptomatology found in most chronically ill psychiatric patients. 
The concept of comorbidity originated in medical epidemiology. It describes the 
co-occurrence of an additional and distinct clinical disease in a patient during 
the course of the index disease under study 20. Comorbidity has become a useful 
concept to describe the frequently simultaneous occurrences of different 
psychiatric syndromes. Its growing popularity in both psychiatric epidemiology 
and clinical psychiatry has much to do with the current diagnostic categorical 
classification systems (notably the DSM-IV-TR) and the standardised research 
instruments based on these systems. There is clearly a need for such a concept, as 
psychiatric disorders (especially chronic ones such as SUDs) are characterised by 
a high prevalence of co-occurring psychiatric disorders. 
 However, adverse effects of the overuse of the term “comorbidity” were 
quickly discovered 21. In general medicine, this epidemiological construct is 
based on a classification model that clearly defines distinct diseases; for the most 
part, however, this is not true for psychiatry. In general medicine, comorbidity is 
defined by co-occurrence at both the descriptive and etiological levels, whereas 
in psychiatry it is mainly used at the descriptive level, primarily because 
knowledge at the etiological level is insufficient. Because it includes descriptions 
of single (non-composite) disorders, the currently dominant DSM-IV-TR 
classification system generates a lot more comorbidity than its ICD-10 
counterpart. This practice ignores the problem of the validity of current 
diagnostic constructs in psychiatry, posing the risk of reifying abstract diagnostic 
entities as “real” diseases 22;23. Apparent comorbidity can arise from various 
nosological considerations. These include the use of categories where dimensions 
might be more appropriate, overlapping diagnostic criteria, artificial subdivisions 
of syndromes, and one disorder being an early manifestation or component of 
another 24.
 But even at the merely descriptive level, the concept of comorbidity is quite 
useful in documenting diversity in psychopathology. This practice, however, 
offers little understanding of the etiology and pathogenesis of a disorder, and it 
provides for only the simplest forms of causality while ignoring the complex 
developmental interactions between different factors and problem areas 25. 
Nevertheless, identifying the prevalence of comorbid psychiatric syndromes is a 
first step in improving psychiatric nosology. Specifically, it encourages further 
study “of the factors – genetic structures and environmental processes – that 
(SUDs), emphasises the physiological disturbances due to persistent drug intake. 
The use of the word “addiction” was shunned for many years because of its 
negative societal connotations, but the term has come back into favour, especially 
among practitioners and scientists2. It refers to loss of control over the intense 
urges to take a drug despite its adverse consequences, and it highlights the 
struggles and distress these patients experience 3. 
 Extensive research has confirmed that addiction is a neurobiological 
disorder, the end result of a long-term interactive process involving a variety of 
genetic, psychological and social factors 4. Exposure to a psychoactive substance 
is an essential but by no means sufficient cause of addiction. Rather, addiction is 
a multicausal, chronic process, involving a host of promoting, mediating, and 
protective factors interacting with one another in the context of the developing 
individual. Most serious SUDs originate during adolescence, a crucial stage of 
life during which the individual starts to develop autonomy and explore new 
capacities and activities, including the use of psychoactive substances 5.
 A crucial point in the patient’s development is the moment of initial drug 
use. A host of contributing factors play a role in this process, including societal 
factors (e.g., customs , traditions, public opinion), environmental factors (e.g., 
availability of the drug), and individual factors (e.g., vulnerability, parental 
control) 6;7. Impulsivity has long been recognised as a risk factor for SUDs. It is an 
example of an individual pathological trait that contributes to the early onset of 
drug use 8-12. Initiation in drug use at an early age is a marker for psychopathol-
ogy in the child and/or its family, as well as the wider psychosocial environment; 
it also predicts SUDs in later life 11;13-16. During adolescence (especially between 
the ages of 10 and 15 years) the biological vulnerability of the developing brain 
to addictive pathology increases: early exposure to psychoactive substances is 
bound to have a negative effect on the development of precisely those controlling 
mechanisms necessary for constraining the intake of these substances. Addictive 
drugs, primarily by virtue of neuroplastic changes associated with dopamine 
activity most highly concentrated in the primary motivation circuitry of the 
brain, produce long-term motivational effects 5.
 Addiction is a chronic remitting and relapsing disorder that has great impact 
on the patient’s quality of life 17, but it also is treatable. Indeed, scientific interest 
in the biopsychosocial origins of SUDs has aided in the development of effective 
multimodular treatments for addiction18. 
2  In this dissertation, I treat these two terms more or less as synonymous.
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unitary nature of mental illness as well as vulnerability to addiction at both the 
neurological and clinical/behavioural levels. These models provide a scientific 
platform for exploring the theoretical concepts associated with psychiatric 
comorbidity 33. 
 The high incidenceof comorbidity consistently seen in patients with 
psychiatric disorders and SUDs suggests that many of the risk factors for psycho-
pathology are not disorder-specific. Indeed, the broad array of common 
psychiatric disorders can be explained more parsimoniously by a small number 
of underlying factors. In this way, single psychiatric symptoms can be considered 
diverse expressions of an underlying vulnerability to a spectrum of related 
disorders 34. This observation has led to broad groupings of internalising 
disorders (consisting of mood and anxiety disorders) and externalising disorders 
(the substance use disorders and antisocial personality disorders) 35. Patterns of 
genetic and environmental relationships among these disorders are also 
consistent with a common underlying predisposition 34;36;37. This approach 
implies that the relationship between externalising conduct disorders and 
addiction is complex and multifaceted from the start.
 In most cases the prognosis of patients with a dual diagnosis (psychiatric 
disorder plus SUD) will be compromised because treatment is less effective with 
dual diagnosis patients than with patients having single “pure” disorders, 
confirming a significant association between comorbidity and poor treatment 
response 32;38;39. This observation makes a strong argument for prevention and 
targeted intervention to diminish the increased risk for problematic substance 
use in psychiatric populations. Further study of the causal relationship between 
psychiatric and addictive disorders would not only offer a better understanding 
of the pathophysiology of both disorders, but also provide the possibility of 
identifying specific risk, protective, and mediating factors, thereby enhancing 
the potential for specific preventive interventions. 
3. The externalising disorder spectrum 
The complex relation between the different disorders in the externalising 
disorder spectrum, and especially the causal role of these disorders in the 
development of SUDs, can be illustrated by studying two specific members of 
this spectrum: Conduct Disorder (CD) and Attention Deficit/Hyperactivity 
Disorder (ADHD). Both originate in childhood, are characterised by a high 
prevalence of psychiatric comorbidity, and are strongly associated with SUDs in 
adult life. The childhood onset – before initiation of psychoactive substance use 
– and chronic course of both disorders allow us to study their temporal and 
underlie the domain of psychopathology, and determining how these factors 
combine to produce the range of clinically observed disorders” 26. 
 Several models have been developed to explain the complex associations 
between two psychiatric disorders. The simplest model explores different 
patterns of causality 27. In this model, one disorder can lead to the appearance of 
a second disorder. Another possibility is that both disorders are caused by a 
common etiological factor. Lastly, both disorders could develop in a mutual 
relationship, that is, each influences and aggravates the other. These pathways 
are expanded in the model of Neale and Kendler 28, where the different 
possibilities are: 
(i) alternate forms, where the two disorders have the same underlying continuum 
of liability; 
(ii) random multiformity, in which affection status on one disorder abruptly 
increases risk for the second; 
(iii) extreme multiformity, where only extreme cases have an abruptly increased 
risk for the second disorder; 
(iv) three independent disorders, in which excess comorbid cases are due to a 
separate, third disorder; 
(v) correlated liabilities, where the risk factors for the two disorders correlate; 
and
(vi) direct causal models, where the liability for one disorder is a cause of the 
other disorder. 
In most cases of psychiatric comorbidity, there is likely to be a complex, multi- 
causal relationship involving a combination of the pathways mentioned 
above.
Psychiatric comorbidity in substance use disorders
The concept of psychiatric comorbidity is particularly relevant for SUDs, not in 
the least because of the high co-occurrence of psychiatric disorders in addicted 
patients. Although SUDs can occur in isolation – smoking being an excellent 
example – the majority of cases are accompanied by other psychiatric symptoms 
and problems 29;30. On the other hand, SUDs are overrepresented among persons 
with mental illness, contributing significantly to premature death rates and the 
total public health burden 31. This immediately begs the question of causality. 
Indeed, most psychiatric disorders seem to be accompanied by an increased risk 
of addiction. Typically, mental disorders start at an earlier age than SUDs 32, 
suggesting a causal role for the (temporally primary) psychiatric disorder in the 
development of the (temporally secondary) SUD. As discussed above, a more 
complex and dynamic interaction between the two disorders is likely. Animal 
models of the psychiatric disorders studied in addiction paradigms suggest the 
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3.2. Attention-deficit/hyperactivity disorder
ADHD is characterized by the chronic presence of concentration problems and 
restlessness and/or impulsiveness in children. It has been given many other 
names in the medical literature, but it is labelled ADHD from the DSM-III onward 
48. ADHD is the most common psychiatric illness in children, with a prevalence 
between 3% and 12% 49;50;50. It is diagnosed two to four times more often in boys 
than in girls. 
 ADHD and CD frequently co-occur: the prevalence of CD in ADHD children 
is estimated at around 25% 51. Likewise, ADHD is present in up to 50% of CD 
patients. ADHD appears to have a negative influence on the course and prognosis 
of CD, suggesting a synergistic, interactive relationship between the two 
disorders 52-54. There are indications that the combination of CD and ADHD 
further increases the risk for adult psychopathology 55-58.
Adult manifestation
In the majority of cases, ADHD has a chronic course that persists far into 
adulthood. In 30% to 65% of cases, depending on the diagnostic criteria used, the 
complaints and symptoms do not remit after adolescence 59-61. Based on an 
overview of international publications, the worldwide prevalence of ADHD has 
been estimated at 3.4% (range 1.2% - 7.3%) in adults 62. A higher prevalence has 
been found in specific populations (e.g. forensic populations) and patient groups 
(psychiatric patients, patients with addiction problems) 63-66. It is striking that in 
the majority of adult ADHD cases, the illness had not been previously diagnosed 
or treated. A quite typical characteristic of adult ADHD is academic undera-
chievement 67: patients are commonly unable to perform at the level of their 
intellectual abilities 68. Owing to their often thoughtless, irresponsible, and 
unhealthy behaviour, this group is at greater risk of employment, financial, and 
health problems 69. 
 Psychiatric comorbidity is a marked clinical feature of childhood and adult 
ADHD 70;71. It has been estimated that up to 87% of adults with ADHD have one or 
more comorbid psychiatric disorders 72. The most frequently seen examples are 
mood disorder (depression, seasonal affective disorder, and bipolar disorder), 
anxiety disorder, addiction, and personality disorder. Many patients with an 
autism spectrum disorder also have ADHD characteristics 73.
ADHD and addiction
SUD is among the most frequently occurring problems in adults with ADHD. In 
some studies, the life-time prevalence of substance abuse and dependence is as 
high as 52% 74. ADHD has consistently been found in a substantial minority of 
addicted patients 75-78. Although higher prevalence was found in the early studies 79, 
developmental relationship with addictive behaviour. This perspective supports 
the dynamic interplay between genetic risk factors and environmental 
influences, both protective and aggravating, in the developing individual. It 
further stresses the importance of childhood and adolescent manifestations of 
psychiatric disorders, both as risk factors for later psychopathology and as a 
target of preventive interventions.
3.1. Conduct disorder
CD is one of the most serious psychiatric conditions in childhood and adolescence. 
Its essential characteristic is a repetitive and persistent pattern of behaviour in 
which the basic rights of others, as well as the major age-appropriate societal 
norms or rules, are repeatedly violated. This behaviour, which begins in 
childhood or adolescence, falls into four main categories: (1) aggressive behaviour 
that causes, or threatens to cause, harm to others; (2) nonaggressive property 
destruction; (3) covert, deceitful, aggressive behaviour (e.g., theft), and (4) rule 
violations 40. This severely disruptive and antisocial behaviour can lead to serious 
impairment of social, occupational, and academic functioning 40;41. Data from 
population-based studies of youngsters less than 18 years of age indicate CD 
prevalence ranging between 2 and 16% for boys and between 1.5 and 15.8% for 
girls, with most studies finding a higher probability for boys 40. 
Adult manifestations
Once established, conduct problems and antisocial behaviour are generally 
persistent, with 50 to 90% of youngsters meeting the diagnostic criteria after 4 
years. Current research suggests that about 40% of adolescents with CD will 
progress to antisocial personality disorder 40. Antisocial behaviour in childhood 
and adolescence (i.e., a history of CD) is a prerequisite for the diagnosis of 
antisocial personality disorder, according to DSM-IV-TR. 
 Prospective studies have shown that childhood CD leads to increased 
vulnerability for a variety of psychiatric disorders in adulthood 41. This vulnerability 
extends to externalising disorders such as substance use and antisocial personality 
disorders 42;43, but also anxiety and mood disorders 41, and somatic problems 44.
CD and addiction
CD has long been identified as the childhood psychiatric diagnosis with the 
highest risk of SUD in adulthood 29;45;46. Several pathogenic pathways are involved, 
including a shared hereditary component 47. The behavioural disturbances 
associated with childhood CD often lead to deviant peer associations and drug 
initiation during adolescence, and they carry an increased risk of SUD in 
adulthood. 
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negative results are somewhat surprising, because ADHD is considered to be 
eminently treatable in both children and adults, with robust effectiveness of 
pharmacotherapy demonstrated in placebo-controlled trials 100-102. 
 More research is needed to confirm the assumed causes of these negative 
results. First, one must consider the possible effect of psychiatric comorbidity, 
which is highly prevalent in both ADHD and addiction. This comorbidity can 
influence treatment results in both direct ways (e.g., decreased efficacy of 
medication) and indirect ways (e.g. decreased therapy compliance). Moreover, 
diagnostic inaccuracy is more likely to occur in patients with more complex 
problems. This issue pertains not only to difficulties in assessing ADHD in 
drug-using patients and to differences in screening and assessment methods, but 
more specifically in the prevalence of “atypical” ADHD patients, in whom ADHD 
symptoms can be caused or aggravated by other disorders (e.g., traumatic brain 
injury, persistent drug use). Diagnostic inaccuracy can also further decrease the 
effectiveness of medication. In addition, it is quite likely that the long-term use 
of psychoactive substances reduces the effectiveness of medication, because of its 
continuous interaction with the same neurotransmitter systems targeted by 
ADHD medication103. This observation implies that the effectiveness of ADHD 
treatment decreases the longer the SUD persists, and that the best results should 
be obtained by patients in the early phase of their addiction. The concurrent use 
of psychoactive drugs also influences the response to medication. In most of the 
outpatient studies mentioned above, abstinence was not maintained 104-106. 
Furthermore, inadequate medication dosages may have affected treatment 
outcome 107. Case reports provide evidence that some ADHD patients with an 
addiction need higher dosages as a result of their substance use. The type of 
addiction may also play a role: ADHD seems to respond better to medication in 
patients with alcohol use disorders than in drug-dependent patients 108. 
 In principle, we would expect effective treatment of ADHD to have a positive 
effect on the prognosis of the addiction. A number of case reports illustrate the 
impressive progress made by some addicted patients after effective treatment of 
their ADHD 109-111. However, very little research has been conducted on the effect 
of ADHD treatment on the prognosis of the addiction. The controlled trials on 
ADHD treatment in SUD patients have shown hardly any positive influence of 
active treatment on the course of the addiction 104-106;108 (table 1). However, even 
effective treatment of ADHD should not be expected to have a direct influence on 
the course of an addiction. This assumption is based on results achieved in other 
addicted patients with different comorbid psychiatric disorders (such as mood 
disturbances or anxiety disorders) 112;113. Active treatment alleviates the comorbid 
disorder but does not directly influence the SUD 39. This “classic” pattern in dual 
diagnosis treatment can be presumed to apply to ADHD as well. So far, clinical 
probably as a result of looser diagnostic criteria, a recent meta-analysis and me-
ta-regression analysis of 29 studies of a total of 6689 subjects estimated the 
overall prevalence of ADHD in the SUD patient population at 23.1% (95% C.I: 
19.4% – 27.2%) 80. Interestingly, this prevalence was not influenced by age, gender, 
or treatment setting. 
 ADHD in children has consistently been identified as a risk factor for the 
development of later SUDs 81-83. A characteristic of ADHD patients with SUDs is 
the early initiation of substance use 84. The increased prevalence of SUDs in 
ADHD patients can be seen as the product of a developmental interaction of the 
symptoms of ADHD (e.g. impulsivity, novelty seeking) with the consequences of 
ADHD (e.g., poor academic achievement). This interaction which  increases the 
risk of problematic substance use 85;86, is influenced by a variety of genetic and 
environmental factors. Both ADHD and addiction are highly heritable, and their 
tendency to occur together in the same families indicates a partly shared genetic 
basis 79;87. 
 Conduct disturbances in childhood have a strong influence on this process. 
Many adult patients with ADHD and SUD have a history of serious behavioural 
problems in childhood. In 40% to 93% of these patients, these childhood problems 
satisfy the diagnostic criteria for CD and/or oppositional-defiant disorder (ODD) 
78;88. In addition, many of these adult patients were found to have antisocial 
personality disorder (ASP): around 50% 78 compared to 25% in SUD patients 
without ADHD. Some authors maintain that the co-occurrence of CD and ADHD 
is the principal, if not the only explanation for the association between ADHD 
and addiction 89-91. Increasing evidence suggests that coexisting ADHD and CD 
pose the highest risk of all for SUD 45;92-94. However, ADHD has been shown to 
increase the risk for addiction independent of CD, with the more severe forms of 
the disorder involving the greatest risk 95. The risk seems to be more closely 
associated with hyperactive/impulsive symptoms than with concentration 
problems 95. Self-medication is often assumed to play a role in psychoactive 
substance use in ADHD. According to this explanatory model, patients with a 
psychiatric disorder use substances in an attempt to alleviate their psychiatric 
symptoms 96;97.
Treatment of ADHD in addiction
The course of an addiction seems to be more protracted, and treatment more 
difficult, in SUD patients with untreated ADHD than in SUD patients without 
ADHD 98;99;99. In addition, ADHD seems to be less treatable in addicted patients 
than in patients without an SUD. The few randomised trials of medication 
treatment of ADHD in SUD patients have failed to reproduce the positive effects 
obtained in ADHD children and adults without addiction (Table 1, p. 20). These 
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4. Synthesis - the developmental perspective 
The multicausal etiology of addiction, the interplay between individual and 
environmental factors and between  promoting and protective influences as well 
as addiction’s  association with psychiatric comorbidity, can best be understood 
from a developmental perspective 114.  As mentioned above, a crucial stage for 
increased  risk of SUDs is adolescence, a period characterised by continuous 
change and gradually decreasing instability. At  the same time, the developing 
control mechanisms struggle to keep novelty seeking and impulsivity in check 
115. This approach does justice to the dynamic and permanently-shifting evolution 
of problematic substance use in the context of the developing individual. This 
approach also reveals the inadequacies of the control mechanisms, which, if 
they fail, lead to increased substance use. 
 This developmental process can best be examined by prospective studies, 
which allow the influence of  promoting and protective factors for addiction  to 
be identified, predicted, and followed up. Unfortunately, due to their long 
duration, such studies are quite expensive and difficult to organise. Thus, our 
present knowledge is based mainly on retrospective studies of SUD patients. By 
studying the “end product” of this developmental interplay we hope to identify 
traces of the most relevant risk factors. 
 As previously discussed, the research literature offers clear but incomplete 
indications of the following factors: 
(1) More than ADHD, CD has been identified as a risk factor for addiction. 
These two disorders have been evaluated to a limited extent in adult SUD 
patients; the combination of both disorders has received even less 
attention.
(2)  The pathways by which these disorders influence SUD development have 
not yet been elucidated, partly due to the retrospective nature of most 
studies. Many questions remain about how these disorders contribute to 
the risk of addiction, and it is even unclear to what extent the pathways 
are similar for both disorders. 
(3)  The clinical implications of these disorders in SUD patients are not 
entirely clear. For example, poor response to the treatment of ADHD in 
this patient group, although repeatedly demonstrated, remains largely 
unexplained. 
 The research project reported in this dissertation was aimed at formulating 
more definite answers to these research questions  by systematically studying 
both SUD and ADHD in a selected group of SUD patients. 
trials seem to confirm this assumption. On the other hand, a positive effect on 
the course of the addiction is only to be expected if the ADHD is sufficiently well 
treated. As discussed above, the limited effectiveness of standard medication 
treatment of ADHD in addicted patients is likely to provide an additional 
explanation for the ineffectiveness of ADHD treatment in influencing addictive 
behaviour. 
Table 1   Randomised controlled trials of ADHD medication in adolescent  
(in italics) and adult SUD patients
Study, year sample
size
SUD
type
medication, dose effect
on 
ADHD*
effect
on SUD*
Schubiner  
et al., 2002 
48 cocaine methylphenidate  
3 x 30 mg
+ 0
Riggs et al., 2004 
(adolescents) 
69 various pemolide,  
75 – 112.5 mg
+ 0
Carpentier et.al., 
2005 
25 various methylphenidate,  
3 x 15 mg
0
Levin  
et al., 2006 
98 opioid (MMT**) methylphenidate,  
2 x 20-40 mg SR***
0 0
Levin  
et al., 2007
106 cocaine methylphenidate,  
40 + 20 mg SR***
0 0 (+)
Wilens  
et al., 2008 
80 alcohol atomoxetine,  
25 - 100 mg
++ +
Thurstone, 2010
(adolescents)
70 various atomoxetine,  
25 – 100 mg
0 0
Konstenius, 2010 24 amphetamine methylphenidate(OROS),   
72 mg
0 0
Riggs,2011
(adolescents)
303 various methylphenidate(OROS),   
72 mg
(+) (+)
* symbols used to indicate effectiveness:
 0 no significant difference
 + / ++ / +++ strength of the difference (with a positive effect of active treatment)
** MMT = methadone maintenance treatment
*** SR = slow release formulation (duration of action: 4-6 hours) 
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somatic complications. The high mortality rates are due mainly to accidental 
overdoses, suicide, violence, and somatic complications, especially infectious 
diseases 121;126;127. The primary reason for this negative prognosis is the complex 
and chronic nature of this severe addictive disorder, from which complete 
recovery remains more the exception than the rule. Long-term studies show 
high percentages of relapse after abstinence-oriented treatment. The frequent 
somatic complications, due mainly to unhealthy lifestyles, risky sexual 
behaviour, and unhygienic drug use procedures, further reduce life expectancy 
by causing infectious diseases such as HIV and Hepatitis C as well as pulmonary 
disorders 116. 
 Only in recent decades has the severe psychiatric pathology of these patients 
received systematic attention. Studies have shown that psychiatric comorbidity 
contributes to the limited efficacy of standard MMT and to the high prevalence 
of violent death and suicide in this patient population 121;126;127.
Purposes of the present study
Despite a respectable amount of research, opioid dependence remains a complex 
scientific puzzle and a clinical challenge. The severe problems and conduct 
disturbances in this patient group hinder their participation in research. Most 
research attention has been centred on specific characteristics of opioid addiction 
as well as on methadone and other substitution treatments. Only  a few studies 
have shed light on the diversity and complexity of psychiatric comorbidity. 
However, these studies were focused mainly on co-occurring psychopathology; 
the antecedents and origins of these psychiatric disorders, as well as their role in 
the development and prognosis of opioid dependence have received scant 
attention.
 This lack of systematic evaluation and treatment of comorbid psychopathol-
ogy has been an important cause of the disappointing treatment results for 
opioid dependence. By drawing attention to the extent and the consequences of 
psychiatric pathology in patients with a chronic SUD, this research project 
emphasises the serious need for competent psychiatric care. 
Research questions: the role of externalising disorders in 
addiction
The research reported in this dissertation was intended to confirm and expand 
existing knowledge of addiction by further examining the role of two childhood 
externalising disorders, CD and ADHD, in its development. Drawing on the 
literature reviewed in the previous pages, I expected to find a high prevalence of 
the two disorders and their consequences in a sample of patients with severe 
Study population: opioid-dependent patients in methadone 
maintenance treatment
The main part of the project was conducted with a group of patients with opioid 
dependence, a severe and chronic SUD. All 193 participants were in long-term 
methadone maintenance therapy (MMT), the standard treatment for this 
disorder.
Opioid dependence
Although opioids have been used for analgesic and other medicinal purposes for 
thousands of years, they also have a long history of misuse because of their 
psychoactive effects. Regular use of opioids quickly leads to tolerance and 
dependence. In developed countries, heroin is the opioid most frequently 
associated with abuse and dependence 116. It became widely available in the 
Netherlands starting in 1972, leading to a sharp increase in the number of users 
117. Nowadays, its street popularity is significantly less, and the Dutch population 
of mainly middle-aged heroin users has been shrinking every year. In 2009, the 
number of opioid dependent patients in the Netherlands was estimated at 
between 17.300 and 18.100, 70 to 73% of whom were in regular treatment 118. 
Methadone maintenance treatment
Thanks to the pioneering work of Vincent Dole and Mary Nyswander 119, a 
synthetic opioid called methadone has become the essential component of opioid 
dependence  treatment. By reducing the craving for heroin and blocking its 
euphoric effects, MMT effectively stabilizes opioid dependence and diminishes 
the negative, harmful consequences of addiction-related behaviour 120. Methadone 
substitution was first used as a convenient way to ease opioid detoxification, a 
first step towards complete abstinence. However, because of chronic relapses in 
opioid dependence, stabilization rather than abstinence has become the primary 
treatment goal; chronic maintenance treatment with methadone enables 
patients to focus on improving their daily functioning and facilitating social 
recovery 121. MMT has become the standard treatment for opioid dependent 
patients in the Netherlands; the extended experience and research with MMT 
has led to the formulation of standard-quality guidelines 122. These guidelines 
are currently applied in most addiction treatment centres in the Netherlands 123.
Treatment results 
Despite significant advances in the knowledge and treatment of opioid addiction, 
long-term prognosis remains grim and life expectancy is greatly reduced 124;125. 
The course of opioid dependence is characterised by severe psychiatric and 
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(5)  To what extent is the vulnerability to ADHD and SUD determined by shared genetic 
determinants?
Based on the concept of the externalising disorder spectrum, it was hypothesised 
that ADHD and SUD partly share the same genetic basis. This means that 
variations in some genes increase the risk for both disorders, whereas others 
code specifically for just one of the disorders. 
(6)  How effective is standard medication treatment of ADHD patients with comorbid SUD?
Based on the literature reviewed above illustrating the complex interaction 
between ADHD and addiction, which frequently involves CD, we hypothesised 
diminished efficacy of standard ADHD medication in patients with ADHD and 
SUD. 
Outline of this dissertation 
Chapter 2, Psychiatric Comorbidity Reduces Quality of Life in Chronic Methadone 
Maintained Patients, gives an extensive description of the psychosocial and 
psychiatric status of the study population, in particular the extensive psychiatric 
comorbidity and its influence on the quality of life.
 The next two chapters review the influence of two externalising disorders 
(CD and ADHD) in the population. Chapter 3, Influence of Attention Deficit 
Hyperactivity Disorder and Conduct Disorder on Opioid Dependence Severity and 
Psychiatric Comorbidity in Chronic Methadone-Maintained Patients, describes the 
prevalence and characteristics of ADHD. Chapter 4, Addiction from a Developmental 
Perspective: Influence of Conduct Disorder Severity, Subtype, and ADHD on problem Severity 
and Comorbidity in Adults with Opioid Dependence, deals with the prevalence and 
adult consequences of a history of CD. In both chapters, the influence of the two 
externalising disorders (singly and combined) on addiction severity and 
psychiatric comorbidity is discussed.
 Chapter 5, Shared and Unique Genetic Contributions to Attention Deficit/Hyperactivity 
Disorder and SUDs: Analysis of Six Candidate Genes, combines genetic data from the 
study population with data from other studies of adult ADHD patients and 
healthy controls. The prevalence of six genetic markers for ADHD and/or 
addiction is compared in different subgroups with ADHD and/or addiction. 
 Finally, Chapter 6, A Controlled Trial of Methylphenidate in Adults with Attention 
Deficit/Hyperactivity Disorder and SUDs, reports a double-blind, placebo-controlled, 
multiple- crossover trial of methylphenidate treatment in 25 adult patients with 
SUD and ADHD. It illustrates the limited efficacy of standard ADHD treatment 
for patients with severe addictions. 
SUD.  A comparison of the clinical and psychosocial characteristics of patients 
with and without these disorders was intended to indicate (1) how these disorders 
influence the development of SUD and (2) how they affect diagnostic and treatment 
policies. 
 A comparison of the prevalence of a small number of genetic markers in this 
patient population and in other populations with and without ADHD and SUD 
allowed us to explore the shared heredity of both disorders. A second study 
investigated to what extent ADHD can be treated in addicted patients. 
The project was intended to answer the following research questions:
(1)  What is the extent and diversity of psychiatric comorbidity in a sample population of 
SUD patients, and to what extent does this comorbidity influence these patients’ general 
functioning, problem severity, and quality of life? 
The hypothesis was that psychiatric comorbidity (both DSM-IV-TR Axis I and Axis 
II disorder) is highly prevalent in patients with an SUD. The study was aimed at 
confirming the relevance of this comorbid psychopathology by proving its 
significant influence on the level of dysfunction, problem severity, and quality of 
life. 
 (2)  How prevalent are CD and ADHD in a sample population of  SUD patients and what are 
their characteristics?
Previous studies suggest that a large percentage of participants should present 
with a history of CD in childhood or adolescence, and ADHD should be present 
in a significant minority of them. Also, the two disorders should frequently 
co-occur. 
 (3)  What is the influence of CD and ADHD on psychiatric comorbidity in a sample population 
of  SUD patients?
The hypothesis was that the presence of both ADHD and CD increases the 
prevalence of other psychiatric comorbid disorders, and contribute to more a 
more severe course of the addiction. 
(4)  What are the roles of CD and ADHD in the development of addiction?
The hypothesis was that both disorders, but CD more than ADHD, contribute to 
an increased risk of problematic substance use, leading to an earlier age of drug 
use initiation, and that the two disorders combined carry the highest risk. The 
study examined whether the influence patterns of the two disorders are similar. 
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De bult spreekt
Hier is de bult, de rammelkast,
de knobbelvent, de leuke gast,
de dwerg die ‘t hoofd omhoog moet steken
als hij zijn zonen toe wil spreken.
De knotwilg met den gekken stam,
waar boven op een reuzenzwam
genesteld is voor al mijn dagen
en die geen mensch er af kan jagen.
Hij huist daar reeds zoo lang mij heugt,
hij was de duivel mijner jeugd,
die ‘t al verpest heeft en bedorven
en glorie tot mijn schâ verworven.
Hij heeft mijn trouwdag meegevierd
en alles naar zijn zin bestierd,
mijn rok ontsierd, mijn bruid doen blozen
en gal gespuwd op hare rozen.
Zoo deed en doet hij moord op moord,
al zit hij stil en spreekt geen woord
en ziet noch hoort, noch maakt gebaren:
hij vreet mij op met huid en haren.
Gij die reeds alles hebt misdaan
wat doembaar is in één bestaan;
gij kerels met uw zwart geweten,
die slapen kunt noch rustig eten
en schichtig door het donker waart:
komt op, geeft hier wat u bezwaart,
ik zal het torsen zonder klagen
als gij zoo lang dat ding wilt dragen.
Willem Elsschot (1882 – 1960)
Psychiatric comorbidity reduces  
quality of life in chronic methadone 
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Introduction
Despite the established efficacy of methadone and similar opioid agonists for 
heroin substitution and maintenance treatment, opioid dependence remains a 
chronic and debilitating disorder with a diminished quality of life (Qol), severe 
psychiatric and somatic complications, and high mortality rates mainly due to 
accidental overdoses, suicides, violent incidents and somatic complications, 
especially infectious diseases 1-3. Via the reduction of craving and blockade of the 
euphoric effects of heroin, methadone maintenance therapy (MMT) offers an 
effective means to stabilize opioid dependence and diminish the negative and 
harmful consequences of addiction-related behavior 4. Nevertheless, the 
long-term outcomes of opioid addiction remain grim with a seriously diminished 
life expectancy 5. 
 In addition to the inconsistent and often insufficient quality of the MMT 
programs provided, a major factor in the negative long-term outcomes observed 
for opioid dependence may be the high rate of comorbid psychiatric pathology. 
Studies of larger populations of heroin users have consistently shown a high 
prevalence of DSM-IV Axis I psychiatric disorders and substance use disorders 
and Axis II personality disorders 6. Depending upon the methods used, between 
34% and more than 50% of patients have been found to have at least one comorbid 
psychiatric disorder 7-9. 
 The rates of depression are especially high, with 25% to over 50% of patients 
showing a current major depressive episode 10;11. Persistent depression is linked 
to worse treatment outcomes, worse physical health, and greater psychopathol-
ogy 12. Anxiety disorders occur frequently as well with two-thirds of the 
participants in one study meeting criteria for an anxiety disorder 13. Posttraumatic 
stress disorder is highly prevalent in women in particular with prevalences 
ranging from 11% to 42% 8;14. A sizable minority of patients (15%) has been found 
to suffer from psychotic symptoms 15. 
 In the majority of patients, especially those with comorbid psychiatric 
disorders, the addiction is not limited to opioids 9. Problematic use of several 
substances including most notably alcohol, cocaine, and benzodiazepines is 
common among such patients and clearly complicates their treatment prognosis 
16-20. Cocaine use is highly prevalent in MMT patient populations and has been 
linked to more severe psychopathology, more persistent opioid use, and higher 
treatment drop-out rates 16;17;19. About one third of opioid-dependent patients also 
abuses alcohol, which is also associated with the abuse of other drugs, greater 
treatment drop-out, and a reduced QoL 18;21. Cannabis use is frequent but seldom 
requires special attention 22. Special mention needs to be made of the high rate 
of benzodiazepine use in up to 50% of patients. Benzodiazepines are widely 
Abstract
Background
Despite the efficacy of methadone maintenance treatment (MMT), opioid 
dependence still involves severe impairment of functioning and low quality of 
life. This study examines the influence of the psychiatric comorbidity of MMT 
patients on their quality of life.
Methods
193 middle-aged patients in long-term MMT were assessed for current and 
life-time Axis I psychiatric disorders , substance use disorders, and personality 
disorders using the MINI, the CIDI-SAM, and the SIDP-IV. Quality of life (Qol) was 
assessed using the EQ-5D.
Results
Psychiatric comorbidity was documented in 78% of the patients. Mood disorders 
(60%) and anxiety disorders (46%) were the most common diagnoses. Additional 
substance use disorders were diagnosed in 70% of the MMT patients. While a 
probable personality disorder was documented for 65% of the patients, 66 of 
these patients actually showed an antisocial personality disorder. Qolwas 
severely diminished to a level comparable to that for patients with chronic 
psychiatric and/or somatic disorders. Multivariate analyses showed the 
occurrence of comorbid psychiatric disorders to explain about 32% of the 
variance in Qol. 
Conclusion
The quality of life for MMT patients is generally low. The present results showed 
a high rate of psychiatric comorbidity for this patient group with mood disorders, 
additional substance use disorders, and personality disorders occurring in 
particular. Such comorbid psychopathology substantially affects quality of life. 
The negative influence of comorbid psychopathology on quality of life is an 
important reason to provide additional mental health services for MMT patients. 
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The aim of the present study is to further examine the influence of psychiatric 
comorbidity (i.e., both DSM-IV-TR Axis I and II disorders) upon the Qol in patients 
with chronic opioid dependence. Via the assessment of current and life-time psy-
chopathology, additional substance use disorders, comorbid personality disorders, 
and the current Qol for a group of veteran MMT patients, it is attempted to 
confirm not only the high rates of psychiatric comorbidity among this patient 
population but also the negative impact of such comorbidity upon the Qol for 
such patients. The assumption is that lower Qol in these patients is associated 
with the presence of psychiatric disorders.  
Methods
Participants
All patients in a MMT program between March 1st and December 1st 2005 at the 
Kanaaldijk were invited to participate in the present study. Apart from methadone 
dispensing and a shelter service this low-threshold MMT facility of Novadic-Ken-
tron (Eindhoven) offers medical support by a nursing staff and a physician 
trained in addictive disorders. However, psychosocial support and outreaching 
interventions are limited. Participation was voluntary, but the patients were 
repeatedly encouraged to take part. Each patient was informed that the personal 
results of the study would be included in further treatment planning. A small 
financial reward of 5 EURO per session was also offered as an additional incentive 
to participate. As the study targeted the entire patient population, there were no 
formal exclusion criteria. However, the extensive interviews and rating scales 
included in the study required sufficient understanding of the Dutch language. 
Procedure
All of the participants provided their informed consent. In three to four sessions 
of 60 to 90 minutes, an extensive evaluation of psychiatric comorbidity was 
conducted. Each participant was given access to a written or oral report of his or 
her results and, with their permission, the results were passed on to the treating 
physician. The study was approved by the regional medical-ethical committee 
(METIGG zuid: protocol 5.114, 2005). 
Measures
Various standardized measurement instruments were administered to assess 
psychiatric comorbidity and Qol by two researchers who were training for their 
Master of Science in Mental Health at the time of the study (MvG and LK). The 
Mini International Neuropsychiatric Interview (MINI), which is a brief diagnostic 
prescribed despite the fact that this is not suggested by research evidence or 
guidelines 20;23. Benzodiazepine use has been linked to higher levels of psychopa-
thology, the presence of persistent depression and/or persistent anxiety, presence 
of antisocial personality disorder, and social dysfunction as well 24;25. 
 Previous studies have shown a high rate of personality disorders among 
MMT patients; between 66 % and 77% of patients meet the criteria for at least one 
personality disorder 26. The high incidence of the antisocial personality disorder 
is of major concern, not only because this disorder is associated with antisocial 
and criminal behavior but also due to the particularly negative influence of such 
a disorder on the therapeutic relationship and treatment outcomes 24;27.
 Many of the aforementioned psychiatric disorders and mainly those of an 
acute or episodic nature and can be seen to be a direct result of the patient’s 
addictive behavior and/or the long-term use of psycho-active drugs. These sub-
stance-induced psychiatric disorders have also been found to improve rapidly 
during MMT 28. Nevertheless, most of the disorders developed prior to or in 
conjunction with the opioid addiction and can therefore be considered an 
integral part of the problem 29. Severe psychiatric comorbidity clearly hampers 
the treatability of opioid-dependent patients and thus has serious negative 
consequences for their treatment prognosis 30-33. Those patients who have been 
found to benefit most from MMT are mainly those patients with limited 
psychiatric comorbidity while those patients with more severe and chronic 
psychiatric disorders show significantly less favorable treatment outcomes 32. 
Standard MMT treatment cannot meet the specific needs of these more severely 
impaired patients. Nonetheless, additional on-site mental health services have 
been shown to improve treatment retention and psychiatric symptomatology 9;34.
 In light of the above, it can be assumed that extensive psychiatric comorbidity 
and a failure to provide adequate mental health services constitute important 
reasons for the limited efficacy of MMT. These factors contribute to the low 
quality of life of opioid-dependent patients, an often neglected aspect in MMT 
research 35. Upon entry into a MMT program, heroin users generally perceive 
their health to be worse than the general population does and similar to 
individuals with major psychiatric disorders 2. However, the available studies 
offer no consensus with regard to which  factors may be most influential: 
personality disorders 36, poly-drug use 37, or excessive alcohol consumption 21. In 
a more extensive analysis, Millson et al. stated that no single factor may account 
for the variance in Qol although mental health problems appear to be a 
significant contributor 38. In other words, attending to the mental health 
problems of opiate-dependent patients may contribute significantly to not only 
improved treatment efficacy but also an improved QOL 39;39. 
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Data analysis
The various measurement scores were used to compute the prevalence of 
different disorders and specific psychiatric diagnoses. For each diagnostic 
category, the influence on the mean EQ-5D index was tested using t-test, ANOVA 
and/or simple regression analysis. Both forced entry and stepwise multiple 
regression analyses were then undertaken to single out the most influential 
factors. All of the statistical analyses were conducted using SPPS 16.0.2 (Chicago, 
Ill: SPSS Inc; 2008).
interview based upon the DSM-IV-TR criteria, was used to screen for psychiatric 
disorders 40;41. With the recording of current and life-time psychiatric symptoma-
tology, this instrument classifies a person’s psychiatric pathology in terms of the 
DSM-IV-TR. The MINI has been shown to have good psychometric properties and 
is reliable for the detection and classification of psychiatric comorbidity. 
Comorbid substance use was assessed using the Composite International 
Diagnostic Interview – Substance Abuse Module (CIDI-SAM), which is a fully-
structured interview to ascertain DSM-IV-TR diagnoses for the use of alcohol and 
nine classes of psychoactive drugs 42. The Social Conformism Scale (SCS), which 
is a screening instrument based upon the Structural Interview for Personality 
Disorders (SIDP-IV), was used to screen for personality disorders 43;44. A score 
above cut-off did not indicate a definite personality disorder but, rather, the 
possibility of a personality disorder. For all of the participants, however, the 
presence of an antisocial personality disorder was specifically assessed using the 
relevant section from the SIPD-IV 43. 
 Problem severity for seven life domains was evaluated using the Europ-ASI, 
which is the European version of the Addiction Severity Index 45. The scores can 
range from 0 (=no real problem) to 4-5 (=moderate problem, some treatment 
indicated) to 8- 9 (=extreme problem, treatment absolutely indicated). Regular 
lifetime and recent alcohol and drug use is assessed in the Alcohol & Drug section 
of this instrument.
 The EuroQol-5 (EQ-5D) was selected to measure the patient’s Qol or, more 
specifically, the patient’s health-related quality of life (HRQoL) . The EQ-5D is a 
simple self-report instrument developed by an international and interdisciplin-
ary group of researchers (EuroQol Group) to evaluate Qol and applicable to a wide 
range of health conditions and treatments 46. The EQ-5D assesses five different 
domains of general health and functioning (i.e., mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression) along a three-point scale (1 = 
no problems, 2 = some problems, 3 = extreme problems). The scores for the five 
domains are then converted to compose a single summary index using a formula 
that is based upon EQ-5D evaluations for the general population (the UK 
algorithm was used to calculate the index as it has been used in numerous 
international studies, including the field of mental health) 47. This EQ-5D index 
was chosen as our primary outcome measure: it spans a scale from -.594 (state 
“33333”) to 1.0 (perfect health) with ‘as bad as being dead’ by convention at zero. 
Therefore, all states with a negative value are considered as worse than dead.
 Mean EQ-5D data based on population surveys have been assembled for a large 
number of countries including the Netherlands 48; these reference scores are shown 
in figure 1. The EuroQol instrument also includes a Visual Analogue Scale (VAS) 
with a range of 0 to 100 for respondents to indicate their overall state of health. 
Figure 1   Percentage of participants reporting problems for each of the EQ-5D 
domains relative to the general population in the  Netherlands 48
Mobility Self-care Usual
Activities
Pain/
discomfort
Anxiety/
depression
0
10
0
No problems  
No problems  
Some/moderate problems  
Some/moderate/extreme problems 
Extreme problems  
Study population 
General population 
0
10
0
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participate. Eighteen patients did not complete the full assessment and were 
therefore excluded from the analyses for this study.
 The final population of 193 MMT patients consisted of 161 men (83.4%) and 32 
women (16.6%), most of whom were born in the Netherlands (table 1). The 
participants were predominantly middle-aged and single; most of them had only 
Results
Study population characteristics
During the study period, a total of 306 patients was enrolled in the relevant 
methadone maintenance treatment program: 49 women (16.0%) and 257 men 
(84.0%) (figure 2). A significant minority of these patients (24.5%) was of foreign 
birth. Twenty-one patients of mainly a non-European origin were excluded from 
the study due to language and communication problems. An additional 20 
patients left the treatment program and could not be traced. By the time of study 
start, two patients had died. And for various reasons, 52 patients refused to 
Figure 2   Overview of the MMT study population
EXCLUDED: 21
UNAVAILABLE: 22
REFUSED CONSENT: 52
DROP-OUT DURING STUDY: 18
PRIMARY
STUDY POPULATION
306 (M 257, F 49)
POSSIBLE
CANDIDATES
285
AVAILABLE
CANDIDATES
263
FINAL
STUDY POPULATION
211
STUDY
PARTICIPANTS
193 (M 161, F 32)
Table 1   Mean quality of life (EQ-5D index) according to gender, demographic 
characteristics, and treatment history for 193 MMT patients
N = 193 EQ-5D mean 
(s.d.) 
N (%) t F Sig.
Gender
   male 0.69 (0.29) 161 (83.4) 2.32 < 0.05
   female 0.53 (0.38) 32 (16.6)
Land of birth
   The Netherlands 0.66 (0.30) 161 (83.5) -0.57 0.57
   other 0.69 (0.33) 32 (16.5)
Nationality
   Dutch 0.66 (0.31) 183 (95.0) -1.15 0.25
   other 0.77 (0.34) 10 (5.0)
Marital status
   married / with partner 0.71 (0.31) 15 (7.8) 0.58 0.56
   single 0.66 (0.31) 178 (92.2)
Level of education
   primary education 0.66 (0.32) 123 (63.7) 0.18 0.84
   secondary education 0.68 (0.29) 54 (28.0)
   higher education 0.66 (0.34) 16 (8.3)
Work situation
   full-time employment 0.75(0.31) 33 (17.1) 2.26 0.08
   part-time employment 0.84 (0.16) 8 (4.1)
   jobless 0.64 (0.31) 105 (54.4)
   unfit for work 0.62 (0.30) 47 (24.4)
years (s.d.)
Mean age 40.3 (7.2)
N years heroin use 15.0 (7.9)
N years methadone use 11.7 (7.4)
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cannabis and pills (especially benzodiazepines). Nearly all participants reported 
use of several substances in the 30 days prior to their interview; 68.4% reported 
recent heroin use. 
 Compared to the general population, the opioid-dependent patients studied 
here reported a considerably lower QoL (figure 1). Relatively more problems were 
reported for all of the EQ-5D domains. The most problems were reported for the 
domains of pain/discomfort and anxiety/depression. Both the mean EQ-5D index 
and the VAS scores were low for the participants (table 2). 
Psychiatric comorbidity
In the MINI assessment for psychiatric disorders, 112 of the participants (58%) 
reported current psychiatric pathology (table 4). Depressive and anxiety disorders 
were reported most frequently. The majority of these participants (57%) had 
more than one psychiatric disorder (figure 3).  Depressive and anxiety disorders 
co-occurred most frequently. Psychotic disorders were seldom seen in isolation 
but mostly accompanied by depressive and anxiety symptoms. 
 A sizeable group of 53 participants (27.5%) reported a life-time hypomanic or 
manic episode. A small number of patients (10.0%) reported current psychotic 
symptomatology while a larger number (37.8%) reported having experienced 
a limited education. Less than 25% had gainful employment while 24.4% had 
been previously declared unfit for work. The participants typically had a long 
history of heroin addiction and methadone treatment (15.0 (± 7.9) and 11.7 (± 7.4) 
years, respectively). The group of 113 non-participants had a comparable age 
distribution (mean 40.4 (± 7.3) years) and gender ratio (female patients: 17 (15.0%)) 
as the group of participants; the main difference from the group of participants 
was the ethnic origin and nationality of the non-participants: 38.0% of the non-
participants was born outside the Netherlands as opposed to 16.5% of the 
participants. 
 The mean Europ-ASI (i.e., problem severity) scores for the participating MMT 
patients reflected a broad range of difficulties (table 2). Drug use was scored as 
the most important problem area, but employment status and psychiatric status 
also proved problematic. In addition but to a lesser extent, legal status and 
relationships were also reported to be problematic. Assessment of regular and 
recent alcohol and drug use showed a wide diversity in substances and amounts 
used (table 3). Most participants were regular users of several substances apart 
from heroin, starting at an early age : substances most used were alcohol, cocaine, 
Table 2   Mean problem severity (Europ-ASI) and self-reported quality of life 
(EQ-5D) scores for 193 MMT patients
Instruments mean (s.d.)
Europ-ASI
   Medical Status 2.7 (2.2)
   Employment/Support Status 4.5 (1.8)
   Alcohol Use 2.2 (2.2)
   Drug Use 5.2 (1.5)
   Legal Status 3.8 (2.3)
   Family/Social Relationships 3.7 (1.8)
   Psychiatric Status 4.2 (2.2)
EQ-5D
   Mobility 1.27 (0.47)
   Self-care 1.13 (0.35)
   Usual activities 1.46 (0.57)
   Pain/discomfort 1.71 (0.68)
   Anxiety/depression 1.69 (0.63)
   Index 0.66 (0.31)
   VAS 61 (21)
Table 3   Number of regular and recent alcohol and drug users with mean age 
of use, mean life-time years of regular use and mean recent days of 
recent use for 193 MMT patients (Europ-ASI).
psycho-active 
substance used
N regular 
users
(%)
mean age  
of first use
(s.d.)
mean N  
years of  
regular use
(s.d.)
N recent 
users
(%)
mean N days  
of use in past 30 
days (s.d.)
alcohol – any use 174  (90.2) 14.8 (4.6) 19.5 (11.0) 120 (62.2) 15.0 (11.9)
alcohol – over 
threshold  
(> 5 U/day)
123 (63.7) 20.4 (8.0) 11.1 (10.12) 63 (32.6) 19.2 (11.8)
heroin 193 (100,0) 21.6 (5.8) 15.0 (7.9) 132 (68.4)  15.4 (11.1)
medicine/pills 138 (71.5) 26.2 (8.2) 9.4 (7.8) 110 (57.0) 24.2 (9.8)
cocaine 163 (84.5) 23.3 (8.4) 11.1 (8.5) 113 (58.6) 11.8 (10.3)
amphetamines 77 (39.9) 20.4 (6.1) 4.8 (5.9) 11 (5.7) 10.4 (10.4)
cannabis 161 (83.4) 15.9 (4.2) 17.8 (10.6) 105 (54.4) 18.0 (12.0)
more than  
1 substance  
per day
189 (97.9) 21.2 (6.8) 16.2 (8.5) 165 (85.5) 22.8 (10.3)
44 45
C
h
ap
te
r 
2
P
sy
ch
ia
tr
ic
 C
om
or
b
id
it
y 
R
ed
u
ce
s 
Q
u
al
it
y 
of
 L
if
e 
in
 C
h
ro
n
ic
 M
et
h
ad
on
e 
M
ai
n
ta
in
ed
 P
at
ie
n
ts
T
ab
le
 4
   M
ea
n
 q
u
al
it
y 
of
 l
if
e 
(E
Q
-5
D
 i
n
d
ex
) i
n
 t
h
e 
p
re
se
n
ce
/a
b
se
n
ce
 o
f 
p
ar
ti
cu
la
r 
p
sy
ch
ia
tr
ic
 c
om
or
bi
d
it
y 
 
(A
x
is
 I
 p
sy
ch
ia
tr
ic
 d
is
or
d
er
s,
 c
om
or
bi
d
 s
u
b
st
an
ce
 u
se
 d
is
or
d
er
s,
 p
er
so
n
al
it
y 
d
is
or
d
er
s)
 f
or
 1
93
 M
M
T 
p
at
ie
n
ts
Pr
es
en
t
A
bs
en
t
St
at
is
ti
cs
EQ
-5
D
 m
ea
n 
(s
.d
.)
N
 (%
)
EQ
-5
D
 m
ea
n 
(s
.d
.)
N
 (%
)
t 
F
Si
g.
Ps
yc
hi
at
ri
c 
di
so
rd
er
 (M
IN
I)
Cu
rr
en
t p
re
va
le
nc
e
   
an
y 
ps
yc
hi
at
ric
 d
is
or
de
r
0.
56
 (0
.3
3)
11
2 
(5
8.
0)
0.
81
 (0
.2
0)
81
 (4
2.
0)
6.
75
< 
0.
00
1
   
m
oo
d 
di
so
rd
er
0.
51
 (0
.3
4)
89
 (4
6.
1)
0.
80
 (0
.2
0)
10
4 
(5
3.
9)
7.
16
< 
0.
00
1
   
an
xi
et
y 
di
so
rd
er
0.
52
 (0
.3
3)
81
 (4
2.
0)
0.
77
 (0
.2
4)
11
2 
(5
8.
0)
5.
60
< 
0.
00
1
   
ps
yc
ho
tic
 d
is
or
de
r
0.
42
 (0
.3
8)
19
 (1
0.
0)
0.
69
 (0
.2
9)
17
4 
(9
0.
0)
3.
01
< 
0.
01
   
1 
ps
yc
hi
at
ric
 d
is
or
de
r
0.
69
 (0
.2
6)
48
 (2
4.
9)
23
.6
< 
0.
00
1
   
2 
ps
yc
hi
at
ric
 d
is
or
de
rs
0.
50
 (0
.3
2)
51
 (2
6.
4)
   
3 
ps
yc
hi
at
ric
 d
is
or
de
rs
0.
30
 (0
.3
6)
13
 (6
.7
)
Li
fe
-t
im
e 
pr
ev
al
en
ce
   
an
y 
ps
yc
hi
at
ric
 d
is
or
de
r
0.
61
 (0
.3
1)
12
0 
(6
2.
2)
0.
75
 (0
.2
8)
73
 (3
7.
8)
3.
19
< 
0.
01
   
m
oo
d 
di
so
rd
er
0.
58
 (0
.3
2)
76
 (3
9.
4)
0.
72
 (0
.2
9)
11
7 
(6
0.
6)
3.
18
< 
0.
01
   
an
xi
et
y 
di
so
rd
er
0.
63
 (0
.3
1)
23
 (1
1.
9)
0.
67
 (0
.3
1)
17
0 
(8
8.
1)
0.
06
0
0.
55
   
ps
yc
ho
tic
 d
is
or
de
r
0.
61
 (0
.3
1)
73
 (3
7.
8)
0.
70
 (0
.3
0)
12
0 
(6
2.
2)
1.
83
0.
07
Co
m
or
bi
d 
Su
bs
ta
nc
e 
U
se
 D
is
or
de
r 
(C
ID
I-S
A
M
) 
   
an
y 
co
m
or
bi
d 
su
bs
ta
nc
e 
us
e 
di
so
rd
er
0.
63
 (0
.3
1)
13
5 
(7
0.
0)
0.
74
 (0
.2
8)
58
 (3
0.
0)
2.
39
< 
0.
05
   
al
co
ho
l d
ep
en
de
nc
e
0.
56
 (0
.3
5)
32
 (1
6.
6)
0.
68
 (0
.3
0)
16
1 
(8
3.
4)
2.
06
5
< 
0.
05
   
ca
nn
ab
is
 d
ep
en
de
nc
e
0.
67
 (0
.3
1)
10
0 
(1
00
.0
)
   
st
im
ul
an
t d
ep
en
de
nc
e
0.
37
 (0
.4
7)
8 
(4
.1
)
0.
68
 (0
.3
0)
18
5 
(9
5.
9)
1.
83
0.
11
   
se
da
tiv
e 
de
pe
nd
en
ce
0.
60
 (0
.3
4)
33
 (1
7.
1)
0.
68
 (0
.3
0)
16
0 
(8
2.
9)
1.
35
0.
18
   
co
ca
in
e 
de
pe
nd
en
ce
 
0.
57
 (0
.3
4)
53
 (2
7.
5)
0.
70
 (0
.2
9)
14
0 
(7
2.
5)
2.
61
< 
0.
05
   
de
pe
nd
en
ce
 o
f o
th
er
 d
ru
gs
0.
67
 (0
.4
2)
3 
(2
.0
)
0.
66
 (0
.3
0)
19
0 
(9
8.
0)
-0
.0
2
0.
98
   
al
co
ho
l a
bu
se
0.
66
 (0
.2
8)
35
 (1
8.
1)
0.
66
 (0
.3
2)
15
8 
(8
1.
9)
0.
11
0.
91
   
ca
nn
ab
is
 a
bu
se
0.
64
 (0
.3
2)
35
 (1
8.
1)
0.
67
 (0
.3
1)
15
8 
(8
1.
9)
0.
62
0.
54
   
st
im
ul
an
ts
 a
bu
se
0.
75
 (0
.0
7)
5 
(2
.6
)
0.
66
 (0
.3
1)
18
8 
(9
7.
4)
-2
.2
5
0.
05
   
se
da
tiv
es
 a
bu
se
0.
66
 (0
.2
0)
31
 (1
6.
1)
0.
66
 (0
.3
2)
16
2 
(8
3.
9)
0.
15
0.
88
   
co
ca
in
e 
ab
us
e
0.
72
 (0
.2
6)
36
 (1
8.
6)
0.
65
 (0
.3
2)
15
7 
(8
1.
4)
-1
.3
0
0.
19
   
ab
us
e 
of
 o
th
er
 d
ru
gs
0.
67
 (0
.4
5)
5 
(2
.6
)
0.
66
 (0
.3
1)
18
8 
(9
7.
4)
-0
.6
3
0.
95
Pr
es
en
t
A
bs
en
t
St
at
is
tic
s
EQ
-5
D
 m
ea
n 
(s
.d
.)
N
 (%
)
EQ
-5
D
 m
ea
n 
(s
.d
.)
N
 (%
)
t 
F
Si
g.
Co
m
or
bi
d 
Su
bs
ta
nc
e 
U
se
 D
is
or
de
r 
(C
ID
I-S
A
M
)
   
1 
co
m
or
bi
d 
su
bs
ta
nc
e 
us
e 
di
so
rd
er
0.
64
 (0
.3
2)
57
 (2
9.
5)
1.
70
0.
12
   
2 
co
m
or
bi
d 
su
bs
ta
nc
e 
us
e 
di
so
rd
er
s
0.
60
 (0
.3
2)
39
 (2
0.
2)
   
3 
or
 m
or
e 
co
m
or
bi
d 
su
bs
ta
nc
e 
us
e 
   
di
so
rd
er
s
0.
64
 (0
.3
1)
39
 (2
0.
2)
Pe
rs
on
al
it
y 
di
so
rd
er
 s
cr
ee
ni
ng
 
(S
CS
)
   
pr
ob
ab
le
 p
er
so
na
lit
y 
di
so
rd
er
0.
63
 (0
.3
1)
12
5 
(6
4.
8)
0.
72
 (0
.2
9)
68
 (3
5.
2)
1.
91
0.
06
A
nt
is
oc
ia
l P
er
so
na
lit
y 
D
is
or
de
r 
(S
IP
D
-IV
)
   
an
tis
oc
ia
l p
er
so
na
lit
y 
di
so
rd
er
0.
60
 (0
.3
2)
66
 (3
4.
2)
0.
70
 (0
.3
0)
12
7 
(6
5.
8)
1.
98
0.
05
Be
nz
od
ia
ze
pi
ne
 u
se
0.
64
 (0
.3
1)
12
6 
(6
5.
3)
0.
72
 (0
.3
0)
67
 (3
4.
7)
1.
74
0.
08
Su
ic
id
e 
ri
sk
 a
ss
es
sm
en
t (
M
IN
I)
   
an
y 
cu
rr
en
t s
ui
ci
de
 ri
sk
0.
54
 (0
.3
4)
10
0 
(5
1.
8)
0.
79
 (0
.2
0)
93
 (4
8.
2)
6.
25
< 
0.
00
1
   
lo
w
 c
ur
re
nt
 s
ui
ci
de
 ri
sk
0.
62
 (0
.3
0)
49
 (2
5.
4)
15
.2
0
< 
0.
00
1
   
m
od
er
at
e 
cu
rr
en
t s
ui
ci
de
 ri
sk
0.
43
 (0
.3
6)
10
 (5
.2
)
   
se
ve
re
 c
ur
re
nt
 s
ui
ci
de
 ri
sk
0.
48
 (0
.3
7)
41
 (2
1.
2)
46 47
C
h
ap
te
r 
2
P
sy
ch
ia
tr
ic
 C
om
or
b
id
it
y 
R
ed
u
ce
s 
Q
u
al
it
y 
of
 L
if
e 
in
 C
h
ro
n
ic
 M
et
h
ad
on
e 
M
ai
n
ta
in
ed
 P
at
ie
n
ts
In the forced entry multiple regression with the EQ-5D index (the QoL score) as 
criterion variable, psychiatric comorbidity accounted for 32.5% of the variation 
of the EQ-5D index (R2 = 0.325, Adjusted R2 = 0.288). The stepwise multiple 
regression analysis revealed a four-factor model (table 5) predicting 30% of the 
variation in QoL score (R2 = 0.300, Adjusted R2 = 0.285), resulting in the following 
equation:
EQ-5D index = 0.962 + (-0.362 × current mood disorder) + (-0.149 × current psychotic disorder) 
+ (-0.144 × female gender) + (-0.157 × current anxiety disorder).
The overall significance of this model that included current psychopathology 
and gender was confirmed in an ANOVA (F = 20.121, p < 0.0005). 
prior psychotic symptoms. There were no significant gender differences in the 
prevalences of these disorders. Only a minority of 43 of the participants (22.3%) 
failed to report actual or life-time psychopathology. 
 Of the 193 patients, only 58 (30.0%) had no comorbid substance use disorder 
(table 4). The substances most abused were alcohol, cocaine, and sedatives. Many 
of the patients reported several comorbid substance use disorders. Although a 
formal diagnosis of sedative dependence or abuse was limited to about a third of 
the participants, the majority of them (126; 65.3%) reported regular use of benzo-
diazepines. For 94 patients this medication was prescribed by the medical staff 
or their primary care physician. However, 62 patients admitted to unprescibed 
use, for 30 of them in addition to their prescribed dose. 
 The SCS screening revealed the possibility of a personality disorder for nearly 
two-thirds of the patients (125; 64.8%). About 50% of these patients or 66 
participants, which was about 35% of the study population, turned out to have 
an antisocial personality disorder. 
Quality of life
The mean EQ-5D index or QoL score was significantly lower in patients with 
comorbid Axis I psychopathology (table 4). This was most clearly visible for 
patients with a psychiatric disorder currently present and a psychotic disorder 
in particular. The EQ-5D index clearly declined when more symptoms of 
suicidality were reported. In patients with cocaine and alcohol dependence, the 
mean EQ-5D index was relatively lower but not as low as in patients with other 
comorbid Axis I disorders. The EQ-5D index was generally lower, almost reaching 
statistical significance, for those patients identified as possibly having a personality 
disorder. 
Quality-of-life correlations
A simple regression model with the various demographic factors showed only 
gender to have a statistically significant association with the EQ-5D index scores 
of the patients with the female patients showing substantially worse QoL scores 
than the male patients (table 1, p. 40). An important correlation with the duration 
of the opioid dependence could not be found.
 In a simple regression model that included the various psychiatric comorbidity 
factors, the presence of any psychiatric disorder was strongly associated with 
lower EQ-5D scores. The strength of the association increased as the number of 
current psychiatric diagnoses increased (regression coefficient -0.532, p < 0.01). 
The same held for the level of suicidality (regression coefficient -0.396, p < 0.05). 
Additional substance use disorders, personality disorders, and benzodiazepine 
use failed to show statistically significant impact. 
Table 5   Most relevant demographic and psychiatric factors for the prediction 
of quality of life (EQ-5D index) in a stepwise multiple regression*
Predictor variables Unstandardized 
Coefficients
Standardized
Coefficients
B Std.Error Beta t Sig.
Constant .962 .064 15.096 < 0.001
current mood disorder -.223 .044 -.362 -5.061 < 0.001
current psychotic disorder -.154 .066 -.149 -2.347 < 0.05
gender -.119 .051 -.144 -2.329 < 0.05
current anxiety disorder -.098 .045 -.157 -2.147 < 0.05 
*  Excluded variables (threshold: t < 0.05): suicide risk severity, alcohol dependence, cocaine dependence, positive 
personality disorder screening, antisocial personality disorder, benzodiazepine use
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Relative to the populations in other studies, which include mostly patients 
entering MMT treatment 7;8;38, the population of long-time MMT patients in the 
present study was substantially older. This reflects the aging of the MMT 
population in the Netherlands. An excess of male patients was found as in most 
studies of opioid dependant patients 6;8;9. There were no major differences relative 
to earlier Dutch studies 49-51 in the gender ratio, marital status, level of education, 
or employment status of the patients in the present study. With the exception of 
ethnic diversity, the study group can thus be regarded as representative of the 
current Dutch long-term MMT patient population and comparable to the chronic 
MMT patient populations in most other developed countries.
 Mean Europ-ASI scores were comparable to those found in previous studies 
49;50 and attest to the severity and extent of the addiction problems faced by these 
patients. On the basis of these scores, it is clear that a large group of the patients 
should be given treatment and help in several areas, including — in particular 
— employment and psychological functioning. The present results further show 
a low QoL for this patient population 38. The mean EQ-5D index was much lower 
than for the Dutch population in general 52 and even comparable to the QoL 
found for patients with chronic psychiatric disorders 53;54 and/or chronic somatic 
problems 55-57. 
 As expected, the study revealed extensive comorbid psychopathology in 
MMT patients. Only a minority of the patients (22%) failed to report any current 
or life-time psychiatric symptomatology. All of the major psychiatric disorders 
were found to be highly prevalent; most of the patients also reported several 
disorders. Mood and anxiety disorders were the most common current and 
life-time diagnoses although life-time psychotic symptomatology was certainly 
not rare. The reported prevalence rates are comparable to those in similar studies 
with MMT patients 13 but also to the prevalence rates in studies of heroin users 
upon treatment entry 6-8 and of untreated opiod abusers 9. Of particular concern 
is the high rate of reported suicidal ideation, an indication of the elevated levels 
of mortality for this patient group 58;59. 
 Systematic assessment of drug and alcohol use confirmed earlier reports of 
multiple drug use in this patient population; however, the amounts used by the 
participants varied considerably. The majority of participants were not abstinent 
from heroin during the study, indicating limited efficacy of the MMT program. 
Although quite extensive, the prevalence of comorbid substance use disorders in 
the present study is nevertheless lower than in comparable studies 7;9;18;60;61. This 
discrepancy probably reflects the difficulty of assessing the prevalence of 
additional substance use disorders in chronic opioid-dependent patients on the 
basis of patient reports only, as comprehensive urine drug testing was not part 
of the assessment process. As the participants reported a higher rate of regular 
Discussion
Some 63% of the original group of 306 chronic MMT patients agreed to participate 
in an extensive assessment of psychiatric comorbidity and QoL. In view of the 
severe dysfunction and distress documented on the part of these patients within 
the present study, such a high participation rate is extraordinary. However, 
study participation was significantly less among patients of a non-Dutch origin 
while such patients form a sizable subgroup in today’s Dutch MMT population. 
Only 42.7% of the 93 patients of a foreign birth from the original sample group 
participated in the study, compared to 70.0% of patients born in the Netherlands. 
To a large extent this difference can be attributed to the language demands of 
the measurement instruments, which effectively excluded the less well adapted 
of foreign-born patients. 
Figure 3   Current prevalence of single and multiple psychiatric disorders 
diagnosed with the MINI for 193 MMT patients
N mood disorders = 89 
N psychotic disorders = 19 
N anxiety disorders = 81 
27 
17 
4 
49 
0 
13 
2 
N no psychiatric disorder = 81 
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presence of Axis I disorders. The strong correlation between current psychopa-
thology and QoL was confirmed by the multiple regression results. Psychiatric 
comorbidity was found to have substantial predictive value and accounts for 
about a third of the variation in the QoL measure for the patients in the present 
study. 
 In highlighting the limitations of MMT, the results of the present study also 
have some important treatment implications. While numerous studies have 
attested to the effectiveness of MMT for the reduction of illicit (opioid and 
non-opioid) drug use, the reduction of criminality, and the improvement of 
social functioning 66-68, MMT alone is insufficient for the treatment of the 
psychiatric comorbidity that appears to be part and parcel of opioid dependence. 
Even taking in account that a lot of psychiatric comorbidity results from 
persistent drug and alcohol use and can be alleviated by a more strict control of 
abstinence, the fact remains that most low-threshold MMT services such as the 
one studied here are simply not equipped to tackle severe and chronic psychiatric 
disorders. Additional facilities and services are needed to provide the necessary 
psychiatric care. The prevalence and diversity of the psychiatric disorders, 
moreover, necessitates extensive psychiatric evaluation as part of the diagnostic 
assessment of treatment-seeking opioid dependent patients. Comorbid psychiatric 
disorders must be identified and treated accordingly. There is sufficient evidence 
that the provision of psychosocial support will alleviate the psychiatric 
symptomatology and improve the efficacy of MMT in the diminishment of drug 
use and retention in treatment 69;70. The present results further suggest that 
resolution of acute psychopathology can boost the patient’s QoL to a substantial 
extent. In addition, the use of a QoL instrument such as the EQ-5D provides a 
convenient means to monitor the general health of the relevant patient group. 
Systematic use of such an instrument can also provide vital information 
regarding health outcomes and MMT efficacy in addition to critical information 
for cost-utility analyses 71. 
 Because of design limitations another factor of substantial influence upon a 
patient’s QoL, namely physical health, was not assessed within the context of the 
present study. Due to many causes, including poor living standards and chronic 
infections (e.g., HIV, hepatitis C), the physical health of MMT patients is generally 
poor 72. This is reflected in the moderately elevated mean EQ-5D mobility score 
within the present study with 25% of the participants indicating problems in 
this area. More explicit assessment of the physical health of the participants 
would most likely have identified chronic physical problems with a similarly 
negative influence upon the patient’s QoL. 
 In conclusion, the extensive prevalence of psychiatric comorbidity in MMT 
patients was confirmed by the results of the present study. Varied and severe 
use (both life-time and recent use) of several substances, the rates of substance 
use disorders found should be assumed to be conservative estimates. The present 
assessment revealed a high rate of both prescribed an unprescribed benzodiazepine 
use among MMT patients; the results also suggest that the prescription of benzo-
diazepines may be due to the extensive prevalence of psychopathology among 
the patient population 20. The high rate of irregular use illustrates the risks 
involved in benzodiazepine prescription for opioid-dependent patients. 
 The screening for personality disorders further confirmed earlier reports of 
high rates of personality disorders 26, and the alarmingly high prevalence of 
antisocial personality disorder (about one third of the present sample) 24. 
 An important limitation of the study is that due to its cross-sectional design 
the temporal sequencing needed to determine causality is lacking; therefore, it 
remains unclear to what extent the psychiatric comorbidity results from chronic 
multi-substance use. The extensive life-time and recent use by the majority of 
participants certainly suggests that a substantial proportion of the psychiatric 
symptomatology is substance-induced. This is probably the case for the majority 
of life-time psychotic episodes in the absence of current psychotic symptomatology. 
However, the chronic course of both psychiatric and substance use disorders 
suggest a more complex and intertwined relationship 29;62;63; the scope of 
psychopathology and the prevalence rates found in the present study are quite 
similar to those of studies where the participants were assessed upon program 
entry 6-8 or psychopathology was identified prior to the initiation of treatment 9. 
Intervention studies have further documented a decrease of psychiatric 
symptoms after the start of MMT treatment 12;28;64. Nevertheless, the high 
comorbidity rates in the present study illustrate the persistence of psychiatric 
disorders and suggest only a limited effect of chronic MMT upon the course and 
remission of comorbid psychiatric disorders, especially in a group of chronic 
non-abstinent patients 65. 
 The direct influence of comorbid psychopathology and addiction on QoL, as 
measured by the EQ-5D, was confirmed by the results of the univariate analyses 
of variance, which showed current psychopathology to be the most influential 
factor. QoL also correlated relatively strongly with the level of suicidality, which 
is strongly associated with psychopathology. The presence of anxiety and 
depression items in the EQ-5D instrument may explain the strong influence of 
current mental state upon this QoL measure. Significant correlations with QoL 
were only found, moreover, for the more severe forms of comorbid substance use 
disorders, namely cocaine and alcohol dependence. Other clinically relevant 
factors, such as the presence of a personality disorder or benzodiazepine use, 
appeared to have much less impact. One possible explanation for this pattern of 
findings may be that the influence of these particular factors is mediated by the 
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a common, highly heritable, 
neurobehavioral disorder that begins in childhood but often persists into adult - 
hood. It is associated with significant impairment in psychosocial functioning 1. 
Worldwide prevalence of adult ADHD in the general population is estimated at 
3.4% (range 1.2 - 7.3%) 2. A much higher prevalence of ADHD has consistently been 
found in patients with substance use disorders (SUD) 3;4. More recent studies 
using strict DSM-IV criteria indicate a prevalence between 10 and 24% 5-8 in 
patients with different kinds of substance use disorders. Although ADHD and 
SUD are highly comorbid disorders, adults with both together have a greater risk 
for other psychiatric disorders than adults with either condition alone 9;10. A 
history of conduct disorder (CD) in these patients is common, with frequencies of 
up to 70% reported 6;11. Several studies have found higher rates of DSM-IV Axis I 
psychopathology (especially mood and anxiety disorders) in subjects with SUD + 
ADHD compared to patients with SUD or ADHD alone or controls 5;8;10;12. These 
differences have not been replicated in other studies 6. Personality disorders 
were also more frequent in SUD patients with ADHD 5;8;11. 
 The presence of ADHD in a substantial minority of SUD patients highlights 
its role as a risk factor for addiction. If untreated, children with ADHD have a 
higher risk than children without ADHD of developing problematic drug use. 
They also tend to start drug use at an earlier age, and they more rapidly transition 
to regular drug use, abuse, and dependence 11;13;14. ADHD in SUD patients has 
been linked to a more severe progression of substance abuse and a less favourable 
prognosis 15;16. It is still unclear whether ADHD is an independent risk factor for 
addiction and how much of this increased risk is mediated by comorbid 
externalising disorders. CD in childhood is a notorious risk factor for adult psy-
chopathology and substance use disorders 17, and comorbid CD has been found in 
30 to 50% of childhood ADHD cases 18;19. Most studies tend to agree that CD is the 
more dominant influence and that the contribution of ADHD is minimal or 
absent when the high overlap between ADHD and CD is taken into account 20-23. 
However a distinct influence of ADHD, and especially the hyperactive/impulsive 
symptomatology, on the development of addiction has been documented in a 
recent prospective study, using dimensional symptomatology scores 24. There is 
evidence that the interaction between ADHD and CD augments the risk even 
more than either disorder alone 22;25.
 Although there seems to be no specific relationship between ADHD and type 
of substance abuse 26, and ADHD is associated with both stimulant and depressant 
psycho-active drug use disorders 7, comparatively little is known about ADHD 
in opioid dependence. Of the few published studies nearly half focused on a 
Abstract
Background
Persistent ADHD and a history of Conduct Disorder (CD) are highly prevalent 
among patients with substance use disorders. We examined the influence of 
both diagnoses on problem severity, psychiatric comorbidity, and quality of life 
in methadone maintained patients. 
Methods
193 patients in long-term methadone maintenance treatment (MMT) were assessed 
for ADHD through a semi-structured interview. Psychiatric and substance use 
disorders were assessed with the MINI, the CIDI-SAM, and the SIDP-IV. 
Results
Childhood ADHD was diagnosed in 68 (35.2%) patients; 48 (24.9%) had persisting 
ADHD; a CD history was present in 116 (60.1%). Patients with adult ADHD had 
significantly higher problem severity scores, lower quality of life scores, more 
comorbid substance use disorders and more psychiatric comorbidity. Although 
both ADHD and CD contributed to problem severity, addictive pathology and 
psychopathology, ADHD was found to substantially increase the risk of 
psychiatric comorbidity, independent of CD. 
Conclusion
ADHD in MMT patients is characterised by greater addiction severity and more 
comorbid psychopathology, only partly explained by the influence of a co-existing 
conduct disorder. The presence of ADHD in a substantial minority of patients 
accentuates the need for early detection and treatment of this complicating 
disorder.
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retro spective diagnosis of childhood ADHD rather than its adult manifestations 
(Table 1). In the first of these studies, 22% of 157 opioid-addicted patients reported 
a childhood history of hyperactivity 27. Along with symptomatology suggestive of 
adult ADHD, greater mood pathology and a higher prevalence of antisocial 
personality disorder were observed in this subgroup. The most comprehensive 
and detailed study used an extensive psychiatric assessment and found a 16.7% 
prevalence of adult ADHD in a group of 125 patients entering methadone 
maintenance treatment (MMT) 8. The ADHD patients were characterised by 
greater psychiatric comorbidity and a greater number of personality disorders, 
especially antisocial personality disorders. However, ADHD had no effect on the 
number of substance use disorders or on treatment outcomes. This last finding 
was attributed to a strong psychiatric assessment and treatment focus in the 
treatment program studied. Studies with a more limited diagnostic assessment 
found a history of childhood ADHD in 11% and 29% of treatment-seeking opioid-
dependent patients 28;29. ADHD has also been associated with more frequent 
antisocial behaviour 29 and negative treatment outcomes 30. A recent study of 
1761 patients with a diagnosis of lifetime cocaine and/or opioid dependence 
found a relatively low lifetime ADHD prevalence of 5.2% 12; after controlling for 
the influence of a conduct disorder, the ADHD group showed an earlier age of 
first drug use and a greater number of substance-dependence and psychiatric 
disorders than the non-ADHD group. In all these studies, most patients with 
ADHD had never been previously diagnosed with ADHD nor treated for this 
disorder specifically. 
 These studies suggest that ADHD is present in a substantial minority of opi-
oid-dependent patients and is associated with more severe expressions of 
substance use and psychiatric disorders 10;12 as well as antisocial personality 
disorders. However, the small number of studies, the varied and often limited 
ways in which ADHD was assessed, and the influence of a CD history preclude 
drawing formal conclusions (Table 1). The present study was designed to address 
these limitations by using an extensive and systematic psychiatric assessment to 
investigate ADHD and comorbid psychiatric disorders in a clinical population of 
opioid-dependent patients. By assessing both ADHD and a history of conduct 
disorder we aimed to determine the influence of both disorders on psychiatric 
comorbidity and substance use disorder severity. The high prevalence of 
psychiatric comorbidity in opioid dependence 31-33 contributes to the low quality 
of life typical for these patients 34, as was demonstrated in our previous work 35. 
In an extention of this study we were interested to find out if the increased 
psychiatric comorbidity associated with ADHD would be reflected in a lower 
quality of life in these patients. In contrast to the studies mentioned above, 
participants in the present study had been in long-term MMT. T
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observation of each participant mitigated the influence of any drug use. The 
ADHD diagnoses were based on information obtained with the Semi-structured 
Interview for ADHD in adults, developed by J.J.S. Kooij 36-38. This instrument, available 
only in Dutch, is based on the DSM-IV definition of ADHD, and assesses both 
childhood and current presence of three symptom groups (inattention, 
restlessness, and impulsivity) and the resulting dysfunction. The instrument 
was developed primarily for clinical practice and its psychometric qualities have 
not been systematically validated. The resulting diagnosis is based primarily on 
information regarding lifetime and current symptom presence and functioning, 
and not on clinical symptom presentation. If possible, and only with the 
permission of the participants, their partners or relatives were contacted to 
confirm the information. A diagnosis of definite ADHD was given only when the 
information from the interview consistently confirmed the presence of 
invalidating ADHD symptoms from childhood to the present. Confirmation by 
other sources (partner, relatives) was considered as additional evidence, but not 
as necessary for the diagnosis. If the information was suggestive but inconsistent, 
a diagnosis of possible ADHD was made. If ADHD symptoms that were clear in 
childhood were no longer present or troublesome at the time of evaluation, a 
diagnosis of childhood ADHD was made. The choice for assessing ADHD in this 
way was based on the investigators’ experience with the patient group in 
question. The level of dysfunction necessary for an ADHD diagnosis was better 
reflected by the semi-structured interview responses than they would have been 
by responses to symptom items on a rating scale. Thus, in our opinion the 
interview procedure we used allowed for a reliable diagnosis of ADHD in this 
specific patient population. For retrospective diagnoses of CD, the relevant 
section of the Diagnostic Interview Schedule (DIS-N) was used 39. 
 Problem severity for seven life domains (general health, employment and 
income, alcohol and drug use, legal problems, family and social relationships, 
psychiatric problems) was evaluated using the Europ-ASI, the European version 
of the Addiction Severity Index 40. ASI scores, indicating the level of dysfunction 
in each domain, can range from 0 (no real problem) to 4-5 (moderate problem, 
some treatment indicated) to 8- 9 (extreme problem, treatment absolutely 
indicated). The general section of this instrument provided the sociodemograph-
ic characteristics of the participants. 
 The EuroQol-5 (EQ-5D) was selected to measure patients’ health-related 
quality of life 41. The EQ-5D assesses five different domains of general health and 
functioning (i.e. mobility, self-care, daily activities, presence of pain or 
discomfort, and presence of anxious or depressed mood) using a three-point 
scale (1 = ‘no problems’, 2 = ‘some problems’, 3 = ‘extreme problems’). The scores 
for the five domains are summed to create a single index, using a formula based 
 We proposed the following hypotheses: (a) ADHD would be diagnosed in a sizable 
subgroup of MMT patients; (b) the presence of ADHD would be associated with (i) 
a more severe course of addiction, (ii) greater frequency of co-occurring 
problematic substance use, (iii) a greater number of comorbid psychiatric 
disorders, (iv) a higher level of dysfunctionality, and (v) a lower quality of life; 
and (c) ADHD would be associated with more severe psychopathology even when 
the influence of a CD history is taken into account. 
Methods
Participants
The present study is part of a larger research project, the first results of which 
have been published elsewhere 35. All patients who registered in the MMT 
program at the Kanaaldijk, a low-threshold facility of the Novadic-Kentron in 
Eindhoven, The Netherlands, between March 1st and December 1st 2005 were 
invited to participate. Participation was voluntary, but the patients were 
repeatedly encouraged to take part. All patients were informed that their 
personal data would be used for planning their further treatment. A small 
reward of € 5 per session was offered as an additional incentive to participate. As 
the study targeted the entire patient population, there were no formal exclusion 
criteria. However, the extensive interviews and rating scales included in the 
study required sufficient understanding of the Dutch language by the 
participants. 
Procedure
All participants gave their informed consent. In three or four sessions, each 
lasting 60 to 90 minutes, an extensive evaluation of psychiatric comorbidity was 
conducted. The participants were each given access to a written or oral report of 
their results and, with their permission, the results were passed on to the 
treating physician. The study was approved by the regional medical-ethical 
committee (METIGG zuid: protocol 5.114, 2005). 
Measures
To assess ADHD, psychiatric comorbidity, and problem severity, various 
instruments were administered by two researchers (MvG and LK), who at the 
time of the study were training for their Master of Science in Mental Health, and 
by a nurse researcher (C.A.G. Verbrugge), who were supervised by the principal 
investigator (PJC). For this extensive examination of at least three sessions of 
more than 60 minutes participants had to be sufficiently sober and alert. Multiple 
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Results
From a total of 306 eligible patients, 193 (161 men and 32 women) volunteered to 
participate in the present study. Patient recruitment and participation have 
been described more extensively in a previous article 35. 
Prevalence of ADHD and conduct disorder history
All 193 participants were assessed for the presence of ADHD. For 19 participants, 
the partner provided additional information on current symptomatology and 
functioning. For 50 participants, a family member supplied information on 
childhood symptomatology. A definite diagnosis of childhood ADHD was made 
for 68 participants (57 men, 11 women: 35.2% of the sample); 48 of them (38 men, 
10 women: 24.9%) had persistent ADHD, whereas 19 no longer had significant 
ADHD symptomatology at the time of assessment (Figure 1). Most of the adult 
ADHD patients (89.6%) endorsed both inattentiveness and hyperactive/impulsive 
symptoms; only a few patients mentioned inattentiveness (2.1%) or hyperactive/
impulsive symptoms (8.3%) alone. For 14 patients, the information was suggestive 
on EQ-5D evaluations for the general population 42. Scores on this summary 
EQ-5D index can range from -.594 (a score of 3 for all domains) to 1.0 (perfect 
health). The EQ-5D also employs a visual analogue scale (VAS) on which 
respondents can indicate their overall state of health. The possible scores range 
from 0 to 100. 
 The Mini International Neuropsychiatric Interview (MINI), a brief diagnostic 
interview protocol based on DSM-IV-TR criteria, was used to screen for co-existing 
psychiatric disorders 43. Recording current and past psychiatric symptomatology, 
this instrument classifies psychiatric pathology in general DSM-IV-TR categories. 
Problematic substance use was examined in both a qualitative and a quantitative 
way. Comorbid substance use disorders in addition to the opioid dependence 
were assessed using the Composite International Diagnostic Interview – 
Substance Abuse Module (CIDI-SAM), a fully-structured interview protocol aimed 
at ascertaining DSM-IV-TR diagnoses representing problematic use of alcohol 
and five classes of psychoactive drugs (cannabis, stimulants, sedatives, cocaine, 
and other drugs) 44. To provide more quantitative information about the use of 
these substances, independent of any diagnosis, age at first use, years of regular 
use and current use (number of days of substance use in the past 30 days) was 
assessed with the Alcohol & Drug section of the Europ-ASI.
 The Social Conformism Scale (SCS), a screening instrument based on the 
Structural Interview for Personality Disorders (SIDP-IV), was used to screen for 
personality disorders 45;46. A score above the cut-off point does not indicate a 
definite personality disorder but, rather, the possibility of a personality disorder. 
Antisocial personality disorder was assessed using the relevant section of the 
SIPD-IV 45.
Data analysis
The ADHD patients were compared with the non-ADHD patients on psychiatric 
comorbidity and dysfunction, using t-tests for continuous variables and €2-tests 
for categorical variables (degrees of freedom = N – 1). Patients diagnosed as only 
possibly having ADHD or who had ADHD only in childhood were excluded from 
these analyses. To differentiate the influence of ADHD and CD, linear and binary 
logistic regressions were carried out with ADHD and CD as the independent 
variables. The corresponding standardised Beta coefficients and odds ratios were 
estimated. To compensate for the large number of analyses, a conservative alpha 
level of p < .01, two-tailed, was adopted. All the statistical computations were 
performed using the Statistical Package for the Social Sciences (SPPS) 15.0.1 
(Chicago, Ill: SPSS Inc; 2006).
Figure 1   Prevalence of childhood and adult ADHD in the study population 
(N = 193)
All participants were assessed for the presence of childhood and adult ADHD. Of 68 participants with childhood 
ADHD, 48 continued to have disabling ADHD symptoms at the time of assessment, one had questionable 
symptomatology, and 19 had remitted. For 14 participants, the history was suspect for childhood ADHD but the 
information was inconclusive; 10 of them continued to have some symptoms, but the symptoms were insufficient 
for a clear diagnosis of ADHD; the remaining 4 mentioned no current ADHD symptoms. 
ADHD
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but inconclusive for childhood ADHD, so they were given a diagnosis of possible 
childhood ADHD. Ten continued to have some ADHD symptomatology in 
adulthood, but it was not severe enough to warrant a definite diagnosis. For the 
majority of patients, the ADHD diagnosis had not been made earlier; only 5 were 
currently being treated for ADHD.
 A history of conduct disorder was confirmed in 116 participants (102 men, 14 
women: 60.1%). For a majority of them (82 participants; 70.7%), CD symptomatology 
started only after the age of 10 years, whereas in 34 participants (29.3%) there 
was a history of childhood-onset CD. ADHD and CD frequently occurred together: 
51 participants with a history of CD had childhood ADHD (44.0%), whereas 37 
(31.9%) had persistent ADHD. The prevalence of ADHD in the 77 participants 
without a CD history was much lower: only 16 (20.8%) had childhood ADHD, and 
11 (14.3%) had persistent ADHD.
Sociodemographic characteristics
The 48 participants with definite ADHD were compared to the 111 participants 
without ADHD (Figure 1). Fifteen participants with an unclear diagnosis and 19 
patients with only childhood ADHD were excluded from the analysis. The soci-
odemographic and opioid-dependence characteristics of both groups are listed 
in Table 2. The ADHD subgroup was significantly younger than the non-ADHD 
group, resulting in a significantly shorter mean duration of heroin use, but there 
were no differences between the subgroups in age of first heroin and methadone 
use.   
Gender, nationality, level of education, and work situation were similar in both 
groups. A marginal (p < 0.10) difference was found for land of birth, with fewer 
ADHD diagnoses for foreign-born participants. 
Problem severity and quality of life
The ADHD participants had a significantly higher mean Europ-ASI score than 
the non-ADHD participants, reflecting increased problem severity in terms of 
Legal Status, Relationships, and Psychiatric Status (Table 3). Differences in 
Relationships and Psychiatric Status remained significant after controlling for 
CD, whereas CD explained most of the variance in Legal Status. The ADHD 
participants had higher problem scores for Usual Activities and Anxiety/
Depression on the EuroQol-5. This resulted in a significantly lower index score 
for the combined measures, reflecting a lower quality of life (Table 3). The ADHD 
group also rated their general health as significantly poorer than the non-ADHD 
group on the VAS. Adding CD as an independent variable in the regression model 
had little influence on these differences. 
Table 2   Opioid dependence and sociodemographic characteristics of 48 MMT 
patients with ADHD compared to 111 MMT patients without ADHD
ADHD
N = 48
Non-ADHD
N = 111
t  * Sig.
mean age (s.d.) 37.8 (6.5) 41.8 (7.0) -3.37 0.001
age first heroin use (s.d.) 21.7 (5.6) 21.9 (5.6) -0.21 0.84
N years heroin use (s.d.) 12.1 (7.4) 16.1 (7.6) -3.08 0.002
age first methadone use (s.d.) 24.8 (5.8) 26.8 (6.9) -1.67 0.10
N years methadone use (s.d.) 10.8 (7.1) 12.4 (7.4) -1.26 0.21
N (%) N (%) χ2 * Sig.
Gender 0.31 0.66
   male 38 (79.1%) 92 (82.9%)
   female 10 (20.9%) 19 (17.1%)
Land of birth 4.08 0.07
   The Netherlands 44 (91.7%) 87 (78.4%)
   other 4 (8.3%) 24 (21.6%)
Nationality 1.25 0.44
   Dutch 47 (97.9%) 104 (93.7%)
   other 1 (2.1%) 7 (6.3%)
Marital status 0.21  0.74
   married 4 (8.3) 7 (6.3)
   unmarried 44 (91.7) 104 (93.7)
Level of education 1.48 0.48
   primary education 32 (66.7%) 69 (62.2%)
   secondary education 14 (29.2%) 31 (27.9%)
   higher education 2 (4.1%) 11 (9.9%)
Work situation 0.66 0.88
   full-time employment 8 (16.7%) 19 (17.1%)
   part-time employment 1 (2.1%) 5 (4.5%)
   jobless 28 (58.3%) 60 (54.0%)
   unfit for work 11 (22.9%) 27 (24.3%)
* d.f. = N-1 = 158
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Substance use disorders
The mean number of substance use disorders assessed by the CIDI-SAM was 
significantly greater in participants with ADHD than in those without ADHD 
(Table 4). A nearly significant difference between these groups (p < 0.05) emerged 
for the numbers of diagnoses of substance dependence and substance abuse. To a 
large extent, these differences are attributable to a co-occurring CD history; 
however, ADHD still has a comparable and significant influence when CD was 
controlled for. There were no significant differences in the prevalence of the 
individual substance use disorders, with the exception of cannabis abuse (31.3% 
of the ADHD group vs 14.4% of the non-ADHD group). 
 Amphetamine use as measured with the Europ-ASI was similar in the two 
groups: 23 patients (47.9%) in the ADHD group and 40 patients (36.0%) in the 
non-ADHD group had been regular users (€2 = 0.22), but only 6 in the ADHD group 
and 3 in the non-ADHD group were current users. In general, the ADHD group 
started their use of psychoactive substances at an earlier age than the non-ADHD 
patients. However, this age difference was significant only for heavy alcohol users 
(18.3 vs 22.0 years) and those who consumed different drugs each day (19.1 vs. 22.0 
years); this difference was marginally significant for cocaine use (21.0 vs 24.0 
years; p < 0.10). The ADHD group included a higher percentage of (prescribed and 
unprescribed) benzodiazepine users than the non-ADHD group (79.2% vs 61.3%). 
Psychiatric comorbidity
A higher percentage of ADHD participants reported current psychiatric disorders 
on the MINI (Table 5). Mood and anxiety disorders, but not psychotic disorders, 
were found more frequently in ADHD patients, as was Posttraumatic Stress 
Disorder (PTSD). ADHD patients were more likely to have more than one current 
DSM-IV-TR Axis I psychiatric disorder than non-ADHD patients. Lifetime 
prevalence of psychiatric disorders was also higher in ADHD patients, but a 
specific difference in lifetime occurrence was found only for mood disorders. An 
ADHD diagnosis carried an increased likelihood of psychiatric comorbidity (not 
including psychotic disorders). This increased risk was only slightly reduced 
after a history of CD was taken into account. 
Conduct disorders and personality disorders 
A history of CD was significantly more frequent in ADHD patients than in 
non-ADHD patients (77.1% vs. 46.8%; p < 0.001) (Table 5). There was no significant 
difference in CD subtype between the two groups. The SCS screening instrument 
revealed a very high percentage of probable personality disorders in the ADHD 
group, with nearly all patients in this group scoring positive. The diagnosis of 
antisocial personality disorder was also more frequent in the ADHD group. The T
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a history of CD (present in 77.1% of ADHD patients). Indeed, most of the differences 
between the ADHD and non-ADHD patients (in functioning and quality of life, in 
substance use disorder prevalence and in psychiatric Axis I and Axis II 
comorbidity) remained significant when the influence of CD was controlled for. 
Although the cross-sectional and retrospective design of the study limits the 
conclusions that can be drawn about a possible causal link between ADHD and 
addiction, the high prevalence of ADHD in childhood and the increased 
psychiatric comorbidity in adulthood suggest that ADHD is an influential factor 
in the origin and development of substance use disorders, especially in 
conjunction with CD 23.
 Although both ADHD and CD contributed to the severity of the addiction, as 
reflected in the number of diagnoses of substance use disorder, the additional 
results suggest that these influences are mediated through different pathways. 
In the present study a CD history explained most of the variance in social 
dysfunctioning. On the other hand, ADHD was associated with a much higher 
prevalence of Axis I psychiatric comorbidity and personality disorders. This 
findings suggests that, while CD is the more influential risk factor, ADHD has a 
unique contribution to the development and severity of substance use disorders, 
possibly mediated through an increased risk for comorbid psychiatric pathology 
10;12;24. This influence of ADHD only becomes more apparent retrospectively when 
psychiatric comorbidity is taken into account 8;31; this may help to explain why 
the influence of ADHD was not detected in earlier studies focusing on the 
development of addiction, as CD remains the more influential risk factor. 
Moreover the increase in psychiatric comorbidity contributes to the negative 
prognosis associated with ADHD in substance use disorder patients 15;16. This 
could result in an accumulation of this combination of disorders among 
chronically addicted patients, offering a possible explanation for the somewhat 
higher prevalence in the present sample of long-term MMT patients . In contrast 
the study of King e.a. failed to identify any negative influence of an ADHD 
diagnosis on treatment outcome 8; this discrepancy with the present findings 
could be resulting from both a difference in study population and treatment 
setting and the somewhat smaller sample size of the King e.a. study. Lastly the 
psychiatric comorbidity adds to the decrease of quality of life of ADHD patients 
in our study group. 
 The repeated occurrence of  a CD history in the total sample attests to the 
importance of this childhood diagnosis as a risk factor for and precursor of adult 
psychopathology 17. In this respect, the presence of a substantial subgroup with 
childhood-onset CD, which is known to be associated with a poor prognosis for 
adult psychopathology, cannot be considered a coincidence 6;49. The frequent 
co-occurrence of ADHD and CD in this sample of MMT patients confirms that the 
presence of a personality disorder was much more likely to be influenced by 
ADHD than by a CD history (OR 19.44 vs. 3.17).
Childhood ADHD 
Nineteen participants with clear childhood ADHD but without significant ADHD 
symptomatology at the time of their assessment were identified (Figure 1). 
A comparison between this childhood ADHD group and the non-ADHD group 
(N= 111) revealed only a few significant differences. A history of CD was more 
frequent in the childhood ADHD patients than in the non-ADHD patients (73.7% 
vs. 46.8%). There also was a greater likelihood of personality disorders (78.9% vs 
48.6%; p < 0.05) and antisocial personality disorders (42.1% vs 19.8%; p < 0.05) in 
the childhood ADHD group. 
Discussion
A substantial presence of childhood and adult ADHD was found in this sample of 
MMT patients. The prevalence of ADHD is generally higher than that found in 
less extensive studies 12;27-29 but comparable to that found in recent studies of 
patients having other substance use disorders 5-7. The best documented study to 
date in a similar group of American patients with opioid dependence entering 
treatment found a somewhat lower but still comparable prevalence 8; this 
dissimilarity can probably be attributed to methodological and assessment 
differences. 
 Nearly all our results confirmed our hypotheses that MMT patients with 
ADHD have a more serious addiction, more comorbid substance use disorders, 
greater severity of current problems and a diminished quality of life than MMT 
patients without ADHD. These findings are consistent with a growing body of 
literature showing that ADHD is associated with more severe expressions of 
substance use and psychiatric disorders 10;12. As in previous studies 12;13;24 our 
ADHD participants generally began using drugs at an earlier age than our 
non-ADHD participants. As expected, psychiatric comorbidity (both DSM-IV-TR 
Axis I and II) was significantly more prevalent in the ADHD patients. Particularly 
noteworthy is the increased prevalence of PTSD in the ADHD patients, indicating 
a more specific association between these two disorders 47;48. The greater 
benzodiazepine use in the ADHD group, compared to the non-ADHD group, can 
be attributed both to the higher prevalence of psychiatric comorbidity and a 
more specific influence of benzodiazepines on ADHD symptoms.
 The increase in problem severity and psychiatric comorbidity found in the 
ADHD patients can be explained only partially by the frequent co-occurrence of 
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quality of life 59. The prevalence found in this study makes systematic screening 
for ADHD worthwhile and relevant in this patient group 60.  
 In conclusion, the present findings confirm the high prevalence of ADHD in 
substance use disorder patients. They also support the hypothesis that by 
influencing the expression of co-occurring psychopathology ADHD contributes 
to a more severe disorder in which the individual initiates substance use at an 
early age and later experiences more severe addiction with more comorbid psy-
chopathology 12. The present study confirms the relevance of ADHD for opioid 
dependent patients in methadone maintenance treatment, and it emphasises the 
need for ADHD assessment and treatment in this patient group. 
 
combination of disorders carries the greatest risk for the development of severe 
psychopathology and addiction 25;50-52. Opioid dependence in patients with both 
ADHD and CD can be considered the adult expression of a chronic psychiatric 
disorder starting in childhood 28;53;54. More effort should be made to prevent this 
negative prognosis by developing and implementing specific therapeutic 
strategies for children with this combination of disorders. The fact that ADHD 
can be detected and treated early in life offers a possible strategy for reducing 
the risk for substance use disorders in later life 55-57.
 No greater problem severity and comorbidity was found in the small group 
of patients with childhood ADHD only compared to the other MMT patients 
without ADHD. This result may be due to the small size of this subgroup. Another 
possible explanation is that the risk of increasing psychopathology from ADHD 
diminishes as the severity of the ADHD lessens during adolescence and young 
adulthood. The increased personality pathology in the childhood ADHD group is 
probably accounted for by the high co-occurrence of a conduct disorder.
 A strength of the present study is that a large group of MMT patients, frequently 
considered the ones with the most complex and difficult substance use disorders, 
participated in an extensive assessment protocol, allowing us to confirm the 
substantial prevalence of ADHD, and to illustrate its sizable influence in comorbid 
psychopathology, problem severity and quality of life. A limitation of the study 
is that the assessment of ADHD was not carried out with an internationally 
validated instrument. Furthermore, collateral information could be obtained for 
only a minority of the participants, illustrating the impoverished social relationships 
of this patient group. In our opinion, the assessment procedure yielded sufficient 
information allowing reliable diagnoses in accordance with the DSM-IV-TR diagnostic 
criteria. 
 A further limitation of the present study is that the influence of an ADHD 
diagnosis on treatment efficacy was not explored. In view of the higher psychiatric 
comorbidity and problem severity reported here, as well as in previous studies, a 
diagnosis of ADHD would seem to carry a negative prognosis. However, as in 
earlier studies, most of our participants had never been diagnosed or treated for 
ADHD before, so the treatment options were not fully explored. ADHD treatment 
is less successful in patients with substance use disorders than in ADHD adults 
without comorbidities [4]. Treatment of ADHD in MMT patients has rarely been 
investigated, and results in the few studies that have been reported have been 
disappointing 58. Standard ADHD treatment will probably be ineffective for this 
patient group due to the complexity of their psychopathology. On the other 
hand, a regimen integrating treatment for opioid dependence and for psychiatric 
comorbidity with ADHD treatment can potentially make a significant 
contribution to the restoration of psychiatric stability and to an improved 
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Introduction 
Conduct disorder (CD) is one of the most serious psychiatric conditions in childhood 
and adolescence. Characterised by severely disruptive and antisocial behaviour, 
it can lead to serious impairment in social, occupational and academic functioning 1;2. 
CD has been identified as a strong predictor of adult psychopathology 3, including 
antisocial personality disorder 4;5, anxiety and mood disorders 6 and somatic 
problems 7. The age of onset of CD is a key differentiating factor determining the 
heterogeneity of outcomes 8.The relatively infrequent DSM-IV-TR childhood- 
onset type of CD (co-CD), occurring predominantly in boys, is considered to be 
the most severe and persistent expression of the disorder, and to have the 
strongest genetic component interacting with poor parenting and carrying the 
more negative prognosis 9;10. In the more common adolescent-onset type (ao-CD) 
environmental factors seem to be more influential, especially affiliation with 
deviant peers 11. 
 Conduct disorder has long been identified as the psychiatric diagnosis with 
the highest risk of comorbid substance use disorder 12-14. The National Comorbidity 
Survey Replication found that the odds of developing alcohol or drug dependence 
increased five-fold in the presence of CD and 10- to 14-fold if both CD and 
antisocial behaviour were present 15. Several pathogenetic pathways are involved, 
including a shared hereditary component 16: the behavioral disturbances of CD 
in youth leading to deviant peer association and earlier drug initiation during 
adolescence carry an increased risk of later substance use disorder 17;18.
 Attention-deficit hyperactivity disorder (ADHD), a rather persistent neuro-
psychiatric disorder that also begins in childhood, accompanies CD in up to 50% 
of cases. There are indications that the combination of CD and ADHD further 
augments the risk for adult psychopathology 19-21, suggestive of a synergistic 
interactive relationship between these two disorders 22;23. Conduct Disorder has 
long been recognised as the most influential factor in the development of 
substance use disorders 24;25. However ADHD, and especially its hyperactive/
impulsive symptomatology, has been shown to increase the risk for addiction 
independent of CD 26. Increasing evidence suggests that coexisting ADHD and CD 
poses the highest risk of all for substance use disorders 25;27;28. 
 The influence of these childhood disorders has not yet been systematically 
evaluated in opioid dependence, one of the most severe substance use disorders, 
characterised by a high prevalence of psychiatric comorbidity and comorbid 
substance use disorders, resulting in many chronic and complex psychosocial 
problems and poor overall functioning 29-32. The few published CD studies have 
confirmed a prevalence of between 39% and 68% in this patient population 33-35. 
Antisocial personality disorder, which is preceded by CD according to its DSM-IV-TR 
Abstract
Objective
This retrospective cross-sectional study examines whether conduct disorder (CD) 
and 
ADHD are associated with problem severity and psychiatric comorbidity in 193 
middle-aged
opioid-dependent patients.
Methods
CD history, ADHD, psychiatric comorbidity and problem severity were assessed 
by structured interviews and validated instruments.
Results
A CD history was confirmed in 116/193 participants (60.1%). CD Patients had 
significantly higher problem severity scores, more frequent comorbid substance 
use disorders and more severe psychiatric comorbidity. ADHD was found to 
increase the risk for psychiatric comorbidity.
Conclusions
Conduct disorder persistence is a useful model for elucidating complex 
psychiatric comorbidity of opioid-dependent patients.  
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extensive interviews and rating scales included in the study required sufficient 
understanding of the Dutch language. 
 A total of 306 patients were eligible for participation. Twenty-one patients of 
mainly non-European origin were excluded due to language and communication 
problems. An additional 22 patients left the treatment program and could not be 
traced. And for various reasons, 52 other patients refused to participate. Finally, 
18 patients dropped out during the course of the study; 193 patients completed 
the full assessment (63.1%).
Measures
Various instruments to assess the current presence of ADHD, a history of CD, 
co-existing psychiatric disorders, and level of impairment in global functioning 
were administered by two researchers (MvG and LK), who at the time of the study 
were completing their training for their Master of Science in Mental Health, and 
by a nurse researcher (C.A.G. Verbrugge). All were supervised by the principal 
investigator (PJC). 
 The relevant section of the Diagnostic Interview Schedule (DIS-O) was used to 
provide a retrospective diagnosis of CD, based on DSM-IV-TR criteria 46. The Social 
Conformism Scale (SCS), a screening instrument based on the Structural 
Interview for Personality Disorders (SIDP-IV), was used to screen for personality 
disorders 47;48. A score above the cut-off point indicates only the possibility of a 
personality disorder. Antisocial personality disorder was assessed in all 
participants using the relevant section of the SIPD-IV 49.
 Problem severity for seven life domains (medical status, employment/support 
status, alcohol  use, drug use, legal status, family/social relationships, psychiatric 
status) was evaluated using the Europ-ASI, the European version of the Addiction 
Severity Index 50. ASI scores indicating the level of dysfunction in each domain can 
range from 0 (“no real problem”) to 4-5 (“moderate problem, some treatment indicated”) 
to 8- 9 (“extreme problem, treatment absolutely indicated”). The general section of this 
instrument was used to measure the sociodemographic characteristics of the 
participants. The Alcohol & Drug sections of the instrument yielded information on 
substance use initiation and duration, as well as treatment characteristics. 
 The Mini International Neuropsychiatric Interview (MINI), a brief diagnostic 
interview protocol based on DSM-IV-TR criteria, was used to screen for current 
and past co-existing psychiatric disorders 51. Substance use disorders comorbid 
with the opioid dependence were assessed using the Composite International 
Diagnostic Interview – Substance Abuse Module (CIDI-SAM), a fully-structured 
interview protocol checking the DSM-IV-TR diagnoses representing the problematic 
use of alcohol and five classes of psychoactive drugs (cannabis, stimulants, sedatives, 
cocaine, other drugs) 52.
definition, has been studied more extensively in these patients: a significant 
increase of 25% to 72% from the general population prevalence of 2% to 4% has 
consistently been found 36-39. An increase in the prevalence of ADHD from 10% to 
24%, has been found in samples of substance use disorder patients 40-42, a finding 
that has been confirmed with opioid dependent patients 34;43;44. 
 In the present study we sought to confirm and expand current knowledge on 
the role of CD, especially in conjunction with ADHD, in the development and 
course of opioid dependence in a sample of chronic opioid-dependent patients in 
methadone maintenance treatment. We expected that illustrating this role of 
CD would confirm the relevance of early psychopathology to the development of 
severe addiction and highlight CD as a model for explaining the complex and 
chronic psychiatric comorbidity found in patients with severe addiction.
 We tested the following hypotheses: 
1.  Patients with opioid dependence will more frequently have a prior history 
of CD, in particular childhood-onset CD, than a control sample from the 
normal population.
2.  The severity of prior CD will correlate positively with the severity of 
 psychopathology, addiction and functional impairment in adulthood.
3.  A combination of ADHD and CD will lead to more severe pathology than 
either disorder separately.
Method
The study was entirely funded by Novadic-Kentron, the regional addiction 
services institute, and approved by the regional medical-ethical committee 
(METIGG zuid: protocol 5.114, 2005). All participants gave their informed consent.
Participants
This retrospective cross-sectional study is part of a larger research project, the 
first results of which have been published elsewhere 45. The study sample can be 
considered representative of the Dutch MMT patient population. All patients 
who were registered in the MMT program at the Kanaaldijk, a low-threshold 
facility of Novadic-Kentron in Eindhoven, The Netherlands, between 1 March 
and 1 December 2005 were invited to participate in this cross-sectional study. 
Participation was voluntary, but the patients were repeatedly encouraged to take 
part. All patients were informed that their personal data would be used for 
planning their further treatment. A small reward of € 5 (about $ 6.50) per session 
was offered as an additional incentive to participate. As the study targeted all 
the registered patients, there were no formal exclusion criteria. However, the 
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Results
The sociodemographic characteristics of the study population (193 participants; 
161 men and 32 women), showing limited education and employment in general 
and rare lasting relationships, are compatible with their long-term methadone 
maintenance status (Table 1). 
CD prevalence groups
A history of CD was confirmed in 116 patients (60.1% of the study population; 
87.9% male). These patients formed the CD group, with the remaining 77 patients 
(76.6% male) forming the non-CD group. In 35 of the patients in the CD group 
(30.2% of the CD group; 88.6% male) CD symptoms were present before the age of 
10 years, defining the co-CD subgroup. The remaining 81 CD patients (87.7%) 
were included in the ao-CD subgroup. 
Sociodemographic characteristics
As shown in table 1, within our predominantly male sample a gender difference 
was found in the distribution of the CD diagnosis, with more males than females 
reporting a CD history to a nearly significant degree (P < 0.05). The patients with 
a CD diagnosis were younger on average than the non-CD patients, which helps 
explain their (statistically insignificant) shorter duration of heroin and 
methadone use. A CD diagnosis was found significantly less frequently in patients 
born outside the Netherlands. Although the whole sample was poorly schooled, 
the CD patients fared worst of all, with more than two thirds having only a 
primary school education. Comparison between the co-CD and ao-CD subtype 
groups revealed no significant differences, including gender differences.
Problem severity 
The CD participants had significantly higher mean Europ-ASI scores than the 
non-CD participants on Legal Status, Relationships and Psychiatric Status, 
reflecting greater problem severity in these domains (Table 2). Comparing the 
CD subtypes, the patients reporting childhood-onset CD showed a tendency 
towards higher scores (i.e. more severe problems) in most life domains, to a 
significant degree only on Relationships and Medical Status. In the linear 
regression analysis, the greater the CD severity, the significantly higher the 
severity scores were for Legal Status, Relationships and Psychiatric Status. This 
relationship was only suggestive for Employment/Support Status and Drug Use (P 
= 0.01). The presence of an ADHD diagnosis significantly influenced only 
Relationships and Psychiatric Status severity scores. 
 The ADHD diagnoses were based on information obtained using the Semi-
structured Interview for ADHD in Adults, developed by J.J.S. Kooij 53-55. This instrument, 
which is based on the DSM-IV definition of ADHD and is available only in Dutch, 
assesses both the childhood and current presence of three symptom groups 
(inattention, restlessness, impulsivity) and the resulting impairment of functioning. 
The instrument was developed primarily for clinical practice and its psychometric 
qualities have not been systematically validated. The resulting diagnosis is based 
primarily on information regarding lifetime and current symptom presence and 
functioning, rather than on clinical symptom presentation. If possible, and only 
with the permission of the participants, partners or relatives were contacted to 
confirm the information. If ADHD symptoms that were clear in childhood were 
no longer present or troublesome at the time of evaluation, a diagnosis of childhood 
ADHD was made. 
Procedure
In three or four sessions, each lasting 60 to 90 minutes (depending on the amount 
of information retrieved and the varying cooperation of the participants), an 
extensive evaluation of functional impairment and psychiatric comorbidity was 
conducted, using the instruments mentioned above. The participants were each 
given access to a written or oral report of their results and, with their permission, 
the results were passed on to the treating physician. 
Data analysis
The CD patients were compared with the non-CD patients on sociodemographic 
characteristics, as well as general functioning, psychiatric comorbidity and 
substance use disorders, using t-tests for continuous variables and €2-tests for 
categorical variables. A similar comparison was made between the childhood 
onset (co-CD) and adolescent-onset (ao-CD) subgroups of the CD group. 
 The influence of CD on these measures of impairment, psychopathology and 
addiction was assessed by means of linear and binary logistic regression, using 
the number of positive DSM-IV-TR CD criteria (as a measure of disorder severity) and 
the presence of an ADHD diagnosis as independent variables. The corresponding 
standardised Beta coefficients and odds ratios were estimated. To compensate for 
the large number of analyses, a conservative alpha level of P < 0.01, two-tailed, 
was adopted. All statistical computations were performed using the Statistical 
Package for the Social Sciences (SPSS) 15.0.1 (Chicago, Ill: SPSS Inc; 2006).
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The left of the table shows the prevalence of psychiatric diagnoses by Conduct 
Disorder diagnosis and by Conduct Disorder subtype.  In the hierarchical logistic 
regression on the right the number of positive DSM-IV-TR Conduct Disorder 
criteria and the presence of an ADHD diagnosis are used as independent variables; 
prevalence of psychiatric comorbidity is the dependent variable. 
 MINI: Mini International Neuropsychiatric Interview. SCS: Social Conformism 
Scale. SIPD-IV: Structured Interview for DSM-IV-TR Personality Disorders. ADHD: 
attention-deficit hyperactivity disorder. N-conduct disorder: number of positive 
DSM-IV-TR Conduct Disorder criteria.
Psychiatric comorbidity, including personality disorders
As shown in Table 3, persistent ADHD was found significantly more frequently 
in CD than in non-CD patients (31.9% vs. 14.3%; P < 0.01). There was no significant 
difference between the co-CD and ao-CD subgroups in the presence of ADHD ( 
42.9% vs. 27.2%; p = 0.13). Current psychiatric comorbidity, as assessed by the 
MINI, was significantly more frequent in the CD patients than in the non-CD 
patients; the prevalence of comorbidity was higher in co-CD patients than in 
ao-CD patients, but these differences did not reach statistical significance. 
Personality disorder screening revealed a significantly higher prevalence of 
possible personality disorder in the CD group than in the non-CD group, with 
similar distributions in both CD subgroups.  
 The absence of antisocial personality disorder in the non-CD participants 
was to be expected, given that a CD history is a prerequisite for the diagnosis 
according to the DSM-IV-TR criteria. Logistic regression revealed a positive 
relation between CD severity and risk of co-existing psychiatric disorders and of 
(antisocial) personality disorder; the presence of an ADHD diagnosis increased 
this risk even further. 
 The subgroup of patients with both CD and ADHD (37 participants; 19.2% of 
the study sample) had particularly high scores on problem severity, especially on 
the Europ-ASI domains of Relationships and Psychiatric Status (4.8 (s.d. 1.5) and 
5.6 (s.d. 1.5), respectively). This subgroup was characterised by the most frequent 
presence of co-existing psychiatric disorders; 31 participants (83.8% of the CD + 
ADHD subgroup) indicated a current psychiatric disorder on the MINI. All the CD 
+ ADHD participants had positive scores on the personality disorder screening; 
73% of them had an antisocial personality disorder.
Substance use disorders
As shown in Table 4, the mean number of substance use disorder diagnoses, as 
measured by the CIDI-SAM, was significantly larger in the CD group than in the 
non-CD group. The prevalence of specific substance use disorders however was T
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Table 2   Influence of Conduct Disorder diagnosis and severity on  
Europ-ASI addiction problem severity.
Step I :   
N CD-criteria
Step II :   
ADHD
Beta (P) in full model Prop.  
variance
explainedCD
n = 116
non-CD
n = 77
P
(t)
co -CD
n = 35
ao-CD
n = 81
P
(t)
R Square 
change
F change  
(P)
R Square 
change
F change  
(P)
N-CD ADHD
Medical Status 2.6 (2.2) 3.0 (2.1) 0.21 2.7 (2.3) 2.5 (2.2) 0.58 0.001 0.14 (0.71) 0.016 3.09 (0.08) -.06 (0.45) .13 (0.081) 0.017
Employment/ Support Status 4.7 (1.7) 4.3 (1.8) 0.09 5.1 (1.5) 4.5 (1.8) 0.14 0.034 6.76 (0.01) 0.007 1.37 (0.24) .17 (0.024) 0.085 (0.24) 0.041
Alcohol Use 2.3 (2.3) 2.0 (2.2) 0.40 2.1 (2.1) 2.3 (2.3) 0.70 0.002 0.30 (0.58) 0.008 1.46 (0.23) .02 (0.79) .09 (0.23) 0.009
Drug Use 5.3 (1.6) 5.0 (1.4) 0.10 5.6 (1.4) 5.2 (1.6) 0.14 0.035 6.85 (0.01) 0.000 0.02 (0.90) .18 (0.013) .009 (0.90) 0.035
Legal Status 4.5 (2.1) 2.7 (2.1) 0.000 4.9 (2.1) 4.4 (2.1) 0.22 0.22 52.24 (0.000) 0.005 1.17 (0.28) .45(0.000) .07 (0.28) 0.22
Family/ Social Relationships 4.1 (1.6) 3.1 (1.9) 0.000 4.8 (1.5) 3.8 (1.6) 0.003 0.12 23.18 (0.000) 0.046 10.57 (0.001) .30 (0.000) .22 (0.001) 0.167
Psychiatric Status 4.5 (2.1) 3.6 (2.2) 0.003 5.3 (1.9) 4.2 (2.1) 0.007 0.070 14.28 (0.000) 0.088 19.90 (0.000) .20 (0.005) .30 (0.000) 0.158
The left of the table shows a comparison of Europ-ASI problem severity by Conduct Disorder diagnosis and  
by subtype.  The right half shows the results of a hierarchical linear regression using the number of positive  
DSM-IV- Conduct Disorder criteria and the ADHD diagnosis as independent variables and the Europ-ASI scores  
as the dependent variable. 
SD: Standard Deviation. N- Conduct Disorder: number of positive DSM-IV-TR Conduct Disorder criteria.
Table 3   Influence of Conduct Disorder diagnosis and severity on  
the prevalence of psychiatric comorbidity
Step I  : N CD Step II : N CD Step II : ADHD Prop.
variance
explained
CD
n = 116
non-CD
n = 77
P co-CD
n = 35
ao-CD
n = 81
P OR 95%
CI
Adj
OR
95%
CI
Adj
OR
95%
CI
ADHD prevalence
Childhood ADHD 15 (12.9%) 5 (6.5%) 0.23 2 (5.7%) 13 (16.0%) 0.23 1.12 0.97 – 1.30 0.024
Persistent ADHD 37 (31.9%) 11 (14.3%) 0.006 15 (42.9%) 22 (27.2%) 0.13 1.18 1.06 – 1.32 0.072
Current psychiatric comorbidity 
(MINI)
Any psychiatric disorder 76 (65.5%) 36 (46.8%) 0.012 29 (82.9%) 47 (58.0%) 0.011 1.16 1.05 – 1.29 1.13 1.02 – 1.25 3.12 1.42 – 6.84 0.118
Mood disorder 64 (55.2%) 25 (32.5%) 0.002 24 (68.6%) 40 (49.4%) 0.069 1.21 1.09 – 1.34 1.18 1.06 – 1.31 2.52 1.24 – 5.13 0.140
Anxiety disorder 55 (47.4%) 26 (33.8%) 0.074 22 (62.9%) 33 (40.7%) 0.042 1.15 1.04 – 1.27 1.12 1.01 – 1.24 3.41 1.68 – 6.92 0.135
Psychotic disorder 16 (13.8%) 3 (3.9%) 0.027 10 (28.6%) 6 (7.4%) 0.006 1.17 1.01 – 1.36 1.14 0.97 – 1.33 2.60 0.96 – 7.03 0.081
The left of the table compares different addiction characteristics of the patient groups with and without a  
Conduct Disorder diagnosis. This is followed by a hierarchical linear regression using the number of positive  
DSM-IV-TR CD criteria and the presence of an ADHD diagnosis as independent variables and the addiction  
characteristics as the dependent variable.
SD: Standard deviation. N-CD: number of positive DSM-IV-TR CD criteria.
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Table 3   Continued
Step I  : N CD Step II : N CD Step II : ADHD Prop.
variance
explained
CD
n = 116
non-CD
n = 77
P co-CD
n = 35
ao-CD
n = 81
P OR 95%
CI
Adj
OR
95%
CI
Adj
OR
95%
CI
Personality disorder screening 
(SCS)
Probable personality disorder 90 (77.6%) 35 (45.5%) 0.000 29 (82.9%) 61 (75.3%) 0.47 1.44 1.26 – 1.65 1.39 1.21 – 1.60 15.44 3.5 – 67.83 0.373
Antisocial Personality Disorder 
(SIPD-IV)
Antisocial personality disorder 66 (56.9%) 0 (0.0%) 0.000 21 (60.0%) 45 (55.6%) 0.69 1.72 1.47 – 2.01 1.71 1.46 – 2.01 2.73 1.19 – 6.24 0.472
The left of the table compares different addiction characteristics of the patient groups with and without a  
Conduct Disorder diagnosis. This is followed by a hierarchical linear regression using the number of positive  
DSM-IV-TR CD criteria and the presence of an ADHD diagnosis as independent variables and the addiction  
characteristics as the dependent variable.
SD: Standard deviation. N-CD: number of positive DSM-IV-TR CD criteria.
Table 4   Influence of Conduct Disorder diagnosis and severity on addiction  
characteristics and severity
Step I :  N CD-criteria Step II :  ADHD Beta (P) in full model Prop. 
variance
explained
CD
n = 116
non-CD
n = 77
sig
(t)
R Square 
change
F change 
(P)
R Square 
change
F change  
(P)
N-CD ADHD
N substance use disorders 1.4 (1.4) 1.0 (1.2) 0.000 0.083 17.23 (0.000) 0.03 6.46 (0.012) .25 (0.001) .18 (0.012) 0.113
N substance dependence disorders 0.8 (1.0) 0.4 (0.7) 0.003 0.094 19.91 (0.000) 0.012 2.56 (0.11) .28 (0.000) .11 (0.11) 0.097
N substance abuse disorders 0.9 (1.1) 0.6 (0.9) 0.029 0.013 2.43 (0.12) 0.017 3.34 (0.069) .08 (0.27) .13 (0.069) 0.030
Age of first alcohol use 14.3 (4.1) 15.6 (5.3) 0.086 0.046 8.40 (0.004) 0.001 0.14 (0.71) -.21 (0.007) -.03 (0.71) 0.036
Age of first cannabis use 15.3 (3.4) 16.9 (5.1) 0.014 0.080 14.82 (0.000) 0.002 0.41 (0.52) -.30 (0.000) .05 (0.52) 0.076
Age of first alcohol > 5E use 18.8 (6.8) 23.6 (9.1) 0.001 0.111 15.18 (0.000) 0.006 0.86 (0.35) -.31 (0.000) -.08 (0.35) 0.100
Age of first amphetamine use 19.8 (6.1) 21.0 (7.0) 0.43 0.009 0.72 (0.40) 0.004 0.33 (0.57) .11 (0.34) -.07 (0.57) 0.014
Age of first several drugs use 20.2 (6.8) 22.8 (6.6) 0.009 0.041 7.98 (0.005) 0.019 3.77 (0.054) -.17 (0.022) -.14 (0.054) 0.060
Age of first heroine use 21.0 (5.8) 22.5 (5.6) 0.081 0.054 10.88 (0.001) 0.004 0.87 (0.35) -.25 (0.001) .07 (0.35) 0.058
Age of first cocaine use 21.4 (7.6) 27.0 (8.8) 0.000 0.120 22.74 (0.000) 0.007 1.23 (0.27) -.33 (0.000) -.08 (0.27) 0.130
Age of first medicine use 24.9 (7.9) 28.3 (7.7) 0.016 0.082 12.09 (0.001) 0.001 0.14 (0.71) -.28 (0.001) -.03 (0.71) 0.083
Age of first methadone use 25.6 (6.7) 27.2 (7.0) 0.13 0.024 4.73 (0.031) 0.007 1.30 (0.26) -.14 (0.068) -.08 (0.26) 0.031
N drug overdoses 0.84 (1.79) 0.25 (0.75) 0.007 0.078 16.14 (0.000) 0.003 0.64 (0.12) .29 (0.000) -.06 (0.42) 0.081
N outpatient detoxifications 0.49 (1.45) 1.68 (4.62) 0.01 0.027 5.37 (0.022) 0.002 0.32 (0.57) -.18 (0.018) .04 (0.57) 0.029
N residential detoxifications 2.91 (4.44) 1.80 (2.51) 0.049 0.058 11.63 (0.001) 0.001 0.11 (0.74) .24 (0.001) .02 (0.74) 0.058
Longest period of abstinence (months) 12.8 (20.9) 14.8 (19.4) 0.57 0.016 2.52 (0.11) 0.000 0.000 (0.99) -.12 (0.13) .001 (0.99) 0.016
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patient group is their increased problem severity, which prompted them to seek 
treatment at an early age. 
 A sizable subgroup (30%) of the CD participants in this patient population 
with a severe and chronic substance use disorder had their CD begin in 
childhood, confirming that the childhood-onset subtype of CD is associated with 
a much worse prognosis than the adolescent-onset subtype.  That the co-CD 
subtype can be regarded as the more severe is reflected in the generally higher 
problem scores of this subgroup on the Europ-ASI, and especially in their higher 
rate of psychiatric comorbidity. However, the CD diagnosis was assessed retro-
spectively; the fact that participants were unable to accurately report onset age, 
might have affected group membership, and might explain why most differences 
between co-CD and ao-CD subgroups failed to reach statistical significance.
 The present results also confirm the increased risk of more severe and more 
complex addictive pathology in patients with the combination of CD and ADHD, 
compared to patients with either disorder alone 56;57. Prospective studies have 
documented developmental differences in the adult outcomes of CD and ADHD, 
identifying CD as the more relevant risk factor for the development of substance 
use disorders 58-60. These previous results are confirmed by the present findings of 
significant correlations between CD severity and most of the indicators of 
addiction severity. However, the combination of CD with ADHD seems to add 
another level of complexity by increasing psychiatric comorbidity 61, in 
accordance with our hypothesis of a synergistic relationship between the two 
disorders 62. This synergy seems to hold particularly for personality pathology, 
lending support to an early theory, predicting that patients with both CD and 
ADHD are particularly at risk for antisocial personality disorder 63. 
 Consistent with other studies 64, we found a significant overlap among these 
externalising disorders, with three quarters of the ADHD patients also having 
CD. The fact that the dominant presentation of ADHD in patients with substance 
use disorders is in combination with CD could be an important explanation for 
the disappointing results of standard ADHD pharmacotherapy in this patient 
population 65-69; not only the effects of substance use, but also the influence of 
complex psychopathology interferes with the response to treatment. 
 Our findings show that opioid dependence in the study group was clearly 
linked to childhood psychopathology. Replication of these results in patient 
populations with other substance use disorders is necessary to confirm a causal 
association between childhood psychopathology and adult mental disorders and 
addictions. However the present results are in accordance with recent constructs 
describing the development of adult psychopathology and addiction, especially 
the concept of graded and continuous liability to externalising spectrum 
disorders 70-72, but also with the concepts of (both homotypic and heterotypic) 
similar in the two groups: only cocaine dependence was more prevalent in the 
CD group (37.9% vs. 11.7%; P < 0.001). No difference between the co-CD and ao-CD 
subgroups in the prevalence of substance use disorders was found. For nearly all 
the substances assessed the CD group reported an earlier mean age of first use 
than the non-CD group, in several instances approaching or reaching statistical 
significance, again with no difference between the CD subgroups. 
 Likewise, the number of drug overdoses and inpatient detoxifications was 
significantly higher in the CD group than in non-CD group, with the means 
similar in the CD subgroups. However, no difference was found for the longest 
period of abstinence.  Linear regression showed a positive relation of CD severity 
with the prevalence of substance use disorders and with the severity of substance 
abuse, as well as a negative relation between CD severity and the age of first 
substance use; in these relations the presence of an ADHD diagnosis had hardly 
any influence. 
Discussion
The increased CD prevalence in the MMT study population, and the correlation 
of CD severity with the severity of current psychopathology, addiction and 
impairment point to the crucial role of this childhood disorder in the 
development of complex adult psychiatric disorders beyond addictive and 
antisocial pathology. For nearly all the tested parameters of social and relational 
functioning, a positive correlation was found between the retrospective 
assessment of CD severity and current problem scores. Participants with a CD 
history began substance use at an earlier age, had a more serious addictive illness 
characterised by more drug overdoses and more inpatient detoxifications, and 
higher rates of currently co-existing psychiatric disorders, comorbid substance 
use disorders, and personality disorders. 
 In view of the complex psychopathology and severe dysfunction documented 
in this study population, a participation rate of nearly 63% can be considered as 
a positive achievement. Nevertheless, information on more than one third of the 
target group is lacking. The general impression is that these excluded patients 
did not function substantially different from the study participants (the unsub-
stantiated suspicion is that they fared worse); in this respect the results reported 
here can be considered as conservative estimates. The high CD prevalence in the 
present sample is in accordance with previous studies. We have no clear 
explanation of why a CD history was found predominantly in participants born 
in the Netherlands; a lack of cultural sensitivity in the diagnostic instrument 
may play a role. A possible explanation for the younger mean age of the CD 
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A further limitation of the present study is the lack of information on environmental 
conditions or stress factors during childhood, due to the small amount of data 
collected on childhood behaviour, as well as the absence of data on neurocognitive 
functioning. A more complex model incorporating both constitutional/genetic 
and environmental factors might highlight even more clearly the relevance of a 
CD diagnosis for future psychopathology, as unconstrained and more stressful 
environments amplify the genetic risk for externalising behaviour 76. Nevertheless, 
the numerous significant results from the present study demonstrate that this 
simple model has made a useful contribution to an understanding of the causes, 
development and comorbidity of chronic addiction, from both a research and a 
clinical point of view. 
continuity of psychopathology 73;74. A focus on childhood psychopathology as the 
starting point can also help us explain the extensive psychiatric comorbidity in 
this patient group. From a developmental perspective, the comorbid psychiatric 
symptomatology can be seen both as a developmental extension and as a 
complication of a chronic disorder that originates in childhood, starting with 
conduct disturbances, leading up to early substance use and abuse. 
 This approach has important clinical implications as well. The most impressive 
finding from this study, albeit a retrospective one, is that 60% of participants 
could have been identified as high risk patients from an early age. Juvenile 
conduct disorder especially is considered a primary target of preventive strategies 
aimed at reducing psychiatric disorders in the adult population 75. In future 
prospective research it will be quite interesting to see if early interventions for 
conduct disturbances in childhood are able to influence prognosis and lead to a 
decrease in psychopathology (especially addiction) in later life. 
 From a clinical and therapeutic perspective, a categorical distinction between 
addictive and psychiatric disorders is no longer tenable, especially for patients 
with chronic and severe addictions such as opioid dependence. The term 
“psychiatric comorbidity” as used in the addiction literature belies the inherent 
psychiatric nature of this chronic and often complex disorder. This understanding 
should also be reflected in treatment services, which up to now have been 
focused mainly on problematic substance use. These services are in need of more 
psychiatric expertise, so that the treatment of these patients can become more 
in accordance with current standards.
 The limited size of the study sample and its selective composition (mainly 
male middle-aged patients with chronic opioid dependence) preclude a simple 
generalisation of these conclusions.The present study of a severely dysfunctional 
patient population of chronic MMT patients illustrates mainly the most negative 
course of development of conduct disturbances in childhood. Further studies 
should examine whether an association with childhood psychopathology also 
applies to patient populations with other and less severe substance use disorders. 
We would expect to find similar results, confirming the association between 
conduct disorder severity and adult psychopathology. However, more than one 
third of the participants did not have a conduct disorder history. Despite the fact 
that they generally fared better in adulthood, these non-CD participants still had 
a complex and highly comorbid substance use disorder, illustrating that other 
developmental pathways for complex addictive pathology should be considered. 
This might be especially true for women, which would explain the lower prevalence 
of CD diagnoses in the female participants. As women were underrepresented 
both in the CD subgroups and in the total sample, the present findings mainly 
apply to men, although they are still in accordance with the general literature. 
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Introduction
Both attention deficit/hyperactivity disorder (ADHD) and substance use disorders 
(SUDs) are quite prevalent, with estimated prevalences in the adult population of 
3.4% and 9.2% respectively 1;2. These disorders are highly heritable and are 
accompanied by substantial rates of psychiatric comorbidity. Moreover, they 
frequently coexist 3. Although there are clear indications that the psychiatric 
symptoms and conduct disturbances associated with ADHD have a causative role 
in the development of problematic drug use and addiction 4;5, there are also 
indications of a genetic basis for the overlap 6;7. ADHD is more prevalent in 
families of probands with SUDs 8-11, and SUDs are more frequent among family 
members of ADHD patients 12-14. Indeed, a study assessing both ADHD and SUDs 
in families of ADHD probands revealed evidence for a shared familiality of ADHD 
and drug use disorders with variable expression 15.
 The genetic risk factors common to ADHD and SUDs have not yet been 
identified, mostly because the etiologies of the two disorders are still largely 
unknown. The most attention has been focused on neurotransmitter systems 
involved in the pathophysiology of the two disorders, especially the dopaminergic 
system; dopamine is the primary neurotransmitter of the central motivation 
system, which plays a crucial role in addiction 16;17. Dopamine is also implicated 
in ADHD, mainly due to the therapeutic effects of stimulant medication, which 
inhibits the reuptake of dopamine 18;19. Serotonin dysregulation is also 
hypothesized to play a causal role in ADHD and addiction 20-22. Genetic 
determinants of variability in these neurotransmitter systems have been studied 
in both disorders, with controversial results 23-25. In cases where particular 
variants conveying an increased risk were described, the results have proven 
difficult to reproduce. This is because the impact of each variant is quite small, 
attesting to the polygenic nature of the two disorders 26;27. 
 Direct comparison studies of risk genotypes in different patient populations 
are rather scarce. A recent assembly of both clinical and genetic data from 
different populations allowed us to explore the role of a limited number of 
genetic polymorphisms in the proposed shared predisposition to ADHD and 
SUDs. Due to the limited size of the project, a pragmatic choice was made to 
study six well-documented polymorphisms of the genes DRD4, DRD5, HTR1B, DBH, 
COMT, and OPRM1, previously used in association studies of ADHD and/or SUDs. It 
is important to point out that most family studies on the genetics of ADHD 
(indeed, most of the studies mentioned below) were carried out in child and 
adolescent populations. However the available scientific information indicates 
that the heritability of clinically diagnosed childhood and adult ADHD  is quite 
similar. Moreover results of candidate gene as well as genome-wide molecular 
Abstract
Objectives
The shared genetic basis of attention deficit/hyperactivity disorder (ADHD) and 
substance use disorders (SUDs) was explored by investigating the association of 
candidate risk factors in neurotransmitter genes with both disorders. 
Methods
One hundred seven methadone maintenance treatment patients, 36 having an 
ADHD diagnosis, 176 adult patients with ADHD without SUDs, and 500 healthy 
controls were genotyped for variants in the DRD4 (exon 3 VNTR), DRD5 (upstream 
VNTR), HTR1B (rs6296), DBH (rs2519152), COMT (rs4680; Val158Met), and OPRM1 
(rs1799971; 118A>G) genes. Association with disease was tested using logistic 
regression models. This pilot study was adequately powered to detect larger 
genetic effects (OR ≥ 2) of risk alleles with a low frequency. 
Results
Compared to controls, ADHD patients (with and without SUDs) showed 
significantly increased frequency of the DBH (rs2519152: OR 1.73; CI 1.15 – 2.59; P 
= 0.008) and the OPRM1 risk genotypes (rs1799971: OR 1.71; CI 1.17 – 2.50; P = 
0.006). The DBH risk genotype was associated with ADHD diagnosis, with the 
association strongest in the pure ADHD group. The OPRM1 risk genotype increased 
the risk for the combined ADHD and SUD phenotype. 
Discussion
The present study strengthens the evidence for a shared genetic basis for ADHD 
and addiction. The association of OPRM1 with the ADHD and SUD combination 
could help to explain the contradictory results of previous studies. The power 
limitations of the study restrict the significance of these findings: replication in 
larger samples is warranted. 
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the frontal lobe, where it plays an important role in regulating synaptic 
dopamine levels. The most studied polymorphism of COMT is a functional SNP 
that generates a valine to methionine substitution (Val158Met), which results in 
decreased enzymatic activity and increased dopamine in the prefrontal cortex 
50. Studies of this variation in ADHD have yielded equivocal results, and a recent 
meta-analysis indicates no association of this polymorphism with the disorder 51. 
However, the Val allele of the Val158Met polymorphism has been linked with 
aggressiveness and conduct disorder symptoms; this association with conduct 
disorder has been replicated in ADHD patients 52-54. Among all the childhood 
psychiatric disorders, conduct disorder carries the highest risk of later SUD 
development 4. In the present study the Val allele was considered the risk allele. 
 The OPRM1 gene codes for the μ-opioid receptor, which is the molecular target 
for endogenous opioid peptides as well as for morphine and other opioids. Due to 
this receptor’s crucial role in opioid tolerance and dependence, variations in its 
genetic code receptor have been implicated not only in opioid dependence but 
also in other SUDs. As our risk variant we took one of the most studied variants 
of the receptor genome is the 118A>G (rs1799971) SNP, which alters the amino 
acid sequence of the receptor. Although some studies have found a significant 
association of this SNP with opioid dependence 55-57 and other SUDs 58, a recent 
meta-analysis found no significant evidence for either a dominant or additive 
effect of this polymorphism on the risk of opioid dependence 59. Although there 
have been no investigations of this variant in ADHD, recent research suggests a 
role for the opioid system in impulse control disorders 60. 
 Starting from the hypothesis of a shared genetic basis for ADHD and SUDs, 
we proposed that some risk genotypes are associated with one of them alone, 
whereas others are associated with their combination. We tested this hypothesis 
in an exploratory study using genetic material from three previous studies. 
However, not enlarging our study samples and using only available material 
restricted the possibility to sufficiently power the study for optimal significance. 
Materials and Methods
Study populations (Table I)
In the present analysis genetic material from three different study samples was 
used: 
1)  Methadone maintenance patients (n = 107, 81.3% men, mean age 41.2 
years, age range 24–59). An extensive assessment was recently performed 
of the psychiatric comorbidity (including ADHD) of 197 opioid-dependent 
patients in long-term methadone maintenance treatment 61-63. ADHD 
genetic studies in adult ADHD samples implicate some of the same genes involved 
in ADHD in children, although in some cases different alleles and different 
genes may be responsible for adult versus childhood ADHD 28. 
 The dopamine D4 and D5 receptors are well represented in the frontal-sub-
cortical networks implicated in the pathophysiology of ADHD, as shown by 
neuroimaging and neuropsychological studies 29;30. Most molecular genetic 
studies of DRD4 in ADHD have focused on a variable number of tandem repeat 
polymorphisms (VNTRs), which consist of a 48 base-pair (bp) repeat unit that 
codes an amino-acid sequence located in the third cytoplasmic loop of the 
receptor. This sequence is thought to be involved in G-protein coupling 31. The 
association of the 7-repeat allele with ADHD has been confirmed in three 
meta-analyses 32-34, and was used as the risk allele in this study. The DRD4 
polymorphism has not been studied extensively in substance use disorders, 
except for a Hungarian study of addicted patients which failed to reveal a 
significant association with addiction 35. The most widely studied polymorphism, 
our choice for this study, of the dopamine D5 receptor (DRD5) is a dinucleotide 
repeat that maps approximately 18.5 kb upstream of the transcription start site 
36. The common 148-bp repeat allele is clearly associated with ADHD 37-40. No 
significant association of this allele with SUDs has yet been identified 41.
 Serotonin dysregulation has been related to impulsive behaviour 42 and thus 
hypothesized to play a causal role in ADHD. A modest but significant association 
between ADHD and a G>C transition at nucleotide position 861 (861G>C; rs6296) 
of the serotonin 1b receptor (HTR1B; 5-HT1B) gene has been confirmed in a recent 
meta-analysis 43;44 and was selected for the current study. Because the serotonin 
system is also involved in drug and alcohol dependence, the role of this same 
single nucleotide polymorphism (SNP) has been studied in addiction, and its 
association with a history of substance use disorder has been reported in three 
studies 45. However, no association with the rs6296 SNP was found in a study of 
heroin addiction, although nominally significant associations of heroin 
dependence with other polymorphisms in the HTR1B genome were identified 46. 
Dopamine beta-hydroxylase (DBH) is the primary enzyme responsible for the 
conversion of dopamine to norepinephrine. A significant association of ADHD 
with a SNP in intron 5 of the DBH gene, which results in the creation of a TaqI 
restriction enzyme site sequence (rs2519152), was first reported by Daly 47. A 
recent meta-analysis of attempted replications of this finding failed to reach 
statistical significance, indicating a trend towards an association of rs2519152 
with ADHD 48;  we took this variant as our risk polymorphism. There have been 
few studies of SUD associations and these have yielded inconsistent results 49.
 Catechol-O-methyl-transferase (COMT) is responsible for the degradation of 
the catecholamines dopamine and norepinephrine. This enzyme is very active in 
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Screening for SUDs was part of the clinical evaluation.
3)  Healthly control subjects (n = 500, 49.4% men, mean age 59.4 years , age 
range 22–92). Controls of Caucasian origin were recruited as part of the 
Nijmegen Biomedical Study 69, a population-based survey conducted by 
the Department of Epidemiology and Biostatistics and the Department of 
Clinical Chemistry of the Radboud University Nijmegen Medical Centre. 
A random sample of 21,756 residents of the municipality of Nijmegen, 
stratified by age and sex, received an invitation to fill out a postal 
questionnaire on lifestyle and medical history. Forty-three percent of the 
sample (N=9350) returned valid questionnaires; 69% of participants 
(N=6468) also donated a blood sample. The subjects were asked to 
complete the adult ADHD DSM-IV-TR Rating Scale for current symptoms 
70. All those reporting four or more positive symptoms on this screening 
list were excluded from the analyses. The control group was not 
specifically screened for SUDs. 
For all three samples, the approval of the study design and proceduce by the 
appropriate ethics committee and the informed consent procedure are 
documented in the original study reports 63;71;72. Groups and subgroups based on 
ADHD and SUD status were formed from the two patient samples (Table I). The 
ADHD_all group included all patients with ADHD (both with and without SUDs). 
The ADHD_pure subgroup was restricted to patients with ADHD only. The 
ADHD&SUD_pure subgroup consisted of patients with both disorders. Patients 
with SUDs only formed the SUD_pure subgroup. Finally, the SUD_all group 
included all patients with SUDs. 
Laboratory methods
Genotyping was performed on DNA isolated from blood or saliva using standard 
protocols. Generally, 5% blanks as well as duplicates in and between plates were 
included as quality controls during genotyping. All genetic analyses were 
performed at a CCKL-certified laboratory at the Department of Human Genetics 
in Nijmegen.
 Genotyping of DRD4 (exon 3 VNTR) and DRD5 (upstream VNTR) was performed 
using Fragment Length Analysis. The PCR reaction of the DRD4 was assessed 
using 50 ng of genomic DNA, 1.25 μM of the fluorescent-labelled forward primer 
5’-Vic-GCGACTACGTGGTCTACTCG-3’, 1.25 μM of the reverse primer with PIG tail 
(5’-AGGACCCTCATGGCCTTG-3’), 0.4 mM dNTPs, TaKaRa 1x GCI Buffer TaKaRa 
(2x), 0.5 U TaKaRa LA Taq™ polymerase (Lucron Bioproducts B.V, Gennep, the 
Netherlands), and 1M Betaine. Amplification was initiated by a denaturation step 
diagnoses were based on information obtained from semi-structured 
interviews. The interview protocol, which is based on the DSM-IV 
definition of ADHD, assesses both the childhood and current presence of 
three symptom classes (inattention, restlessness, and impulsivity) and 
the resulting dysfunction 64-66. If possible, partners or relatives were 
contacted to confirm the information. During this study a majority of 
participants agreed to provide a blood or saliva sample for genetic 
analysis. Patients of non-Caucasian origin were excluded from the 
analyses reported here, as were patients with an insufficiently 
substantiated ADHD diagnosis. This left us with a final selection of 107 
samples, from 36 patients diagnosed as having ADHD and 71 patients 
diagnosed as not having ADHD respectively. 
2)  Adult ADHD patients (n = 176, 47.7% men, mean age 37.1 years, age range 
18–65).
 Adult patients with persistent ADHD were recruited as part of the 
International Multicentre Persistent ADHD CollaboraTion (IMpACT) 67 
from two treatment centres in The Netherlands. All patients were 
evaluated by experienced psychiatrists; the diagnosis of persistent ADHD 
was based on DSM-IV criteria 68. All the patients were ethnic Caucasian. 
Table I   Gender distribution in the study populations, and formation of 
comparison groups and subgroups based on ADHD and SUD status 
from two patient samples (MMT patients: N = 107; ADHD patients:  
N = 176)
N N  
Male (%)
n
ADHD  
all
n
ADHD 
pure
n 
ADHD&SUD
_pure
n
SUD  
pure
n
SUD  
all
N 212 176 36 71 107
N Male (%) 52.4 47.7 75.0 84.5 81.3
N MMT patients
with ADHD
36 27 (75.0) 36 36 36
N MMT patients
without ADHD
71 60 (84.5) 71 71
N ADHD 
patients
176 84 (47.7) 176 176
Controls 500 247 (49.4)
MMT: methadone maintenance treatment
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3.875 μl of water, on a 7500 Fast Real-Time PCR System. The genotypes were 
scored using the algorithm and software supplied by the manufacturer (Applied 
Biosystems).
 The OPRM1 polymorphism (rs1799971) was genotyped again using Taqman 
analysis (assay ID: Taqman assay: C___8950074_1_; reporter 1: VIC-A-allele, 
forward assay; Applied Biosystems), in a 10 μl solution consisting of 10 ng of 
genomic DNA, 5 ul of Taqman Mastermix (2x; Applied Biosytems), 0.25 ul of the 
Taqman assay, and 3.75 ul of water, and performed on a 7500 Fast Real-Time PCR 
System. The genotypes were scored using the algorithm and software supplied 
by the manufacturer (Applied Biosystems).
Statistical analysis
We determined allelic frequencies in all three samples. Starting from a dominant 
model of inheritance for each risk allele, we calculated the frequency of the risk 
allele carriers (both homozygous and heterozygous) in the different groups and 
subgroups. For each risk polymorphism we defined the risk group/genotype as 
comprising both the homozygous and heterozygous carriers of the minor allele 
(in case of HTR1B and OPRM1), the major allele for DBH, the Val-allele for COMT, the 
7-repeat allele for DRD4 and the 148-bp repeat allele for DRD5. 
 Hardy–Weinberg equilibrium (HWE) was assessed for each genetic variant 
tested using standard methods and using a p-value cut-off of 0.05. To analyse the 
association between the selected genetic variants and the risk of ADHD, a logistic 
regression was performed comparing the ADHD_all group and the control group 
with gender as the covariate. To account for multiple analyses, the significance 
level was adjusted using a Bonferroni correction (P/n: significance level divided 
by number of tests). If a risk genotype showed a significant increase in the odds 
ratio (OR), a post hoc logistic regression was carried out for this genotype in each 
patient group and subgroup compared to the control group, again with gender 
as a covariate. As the subgroup analysis explored the basis of the associations 
found in the entire group, an additional Bonferroni adjustment was deemed to 
be an overcorrection, and the same corrected significance level was used. All 
statistical analyses were performed using Statistical Package for the Social 
Sciences 15.0.1, 2006 (SPSS Inc., Chicago, Ill., USA).
 Performing a power analysis using the ‘Genetic Power Calculator’ (http://
pngu.mgh.harvard.edu/~purcell/gpc/) we found that at a power level of 0.80, 
assuming a dominant model of inheritance and perfect linkage desequilibrium 
between the causal variant and the markers used, the study is adequately 
powered to detect in the total group (ADHD patients: N=283) larger genetic 
effects (OR ≥2) of risk alleles with a moderate (=0.25) to low (≤0.10) frequency.
at 94°C for 1 minute, followed by 35 cycles of 30 seconds at 94°C, 30 seconds at 
58°C, 1 minute at 72°C, and a final step of 5 minutes at 72°C. The DRD5 upstream 
VNTR was amplified using 50 ng of genomic DNA , 1 μM of the fluorescent-la-
belled forward primer (5’-FAM-GCTCATGAGAAGAATGGAGTG-3’), 1 μM of the 
reverse primer with PIG tail (5’-CGTGTATGATCCCTGCAG-3’), 0.25 mM of dNTPs, 
2.5 mM of MgCl
2
, 1x PCR buffer II (10x; Applied Biosystems, Nieuwerkerk aan de 
Ijssel, The Netherlands), and 0.4 U of AmpliTaq Gold Polymerase (Applied 
Biosystems). The PCR reaction was obtained through an initial denaturation step 
of 12 minutes at 92°C, followed by 35 cycles of 30 seconds at 92°C, 30 seconds at 
55°C, 1 minute at 72°C, and finally 10 minutes at 72°C. The PCR-products of DRD4 
and DRD5 were combined by diluting the DRD4 product 100 times and the DRD5 
product 10 times. One μl of the result, combined with 9.7 μl of formamide and 0.3 
μl of Genescan-600 LIZ Size Standard (Applied Biosystems), was analyzed using a 
3730 Genetic Analyzer (Applied Biosystems) according to the protocol of the 
manufacturer. 
 The HTR1B polymorphism rs6296 was genotyped using a Taqman analysis 
(assay ID: Taqman assay: C___2523534_20 Applied Biosystems). Genotyping was 
performed in a 10 μl solution containing 10 ng of genomic DNA, 5 μl of Taqman 
Mastermix (2x; Applied Biosytems), 0.125 μl of the Taqman assay, and 3.875 μl of 
water, using a 7500 Fast Real-Time PCR System. The genotypes were scored using 
the algorithm and software supplied by the manufacturer (Applied Biosystems).
The DBH polymorphism rs2519152 was genotyped using a restriction-fragment 
length polymorphism (RFLP) analysis. PCR was performed on 50 ng of genomic 
DNA using 0.4 μM of the forward primer 5’- AGGCATTTTACTACCCAGAGG-3’, 0.4 
μM of the reverse primer 5’- CTGTATTTGGAACTTGGCATC-3’, 0.25 mM of dNTPs, 
and 0.5 U of Taq DNA polymerase (Invitrogen, Breda , The Netherlands) in a PCR 
buffer containing 10 mM of Tris-HCL pH 8.0, 50 mM of KCl, 0.1% Triton X-100 (v/v), 
0.015% gelatin (w/v), 5% DMSO (v/v), and 1.5 mM of MgCl
2
. The cycling conditions 
were 5 minutes at 92 °C, followed by 35 cycles of 1 minute at 92°C, 1 minute at 
61°C, 1 minute at 72°C, and lastly 10 minutes at 72°C. To purify the PCR-product, 
NucleoFast96 plates (Macherey-Nagel, Düren, Germany) were used. An enzyme 
restriction reaction was subsequently produced in a 15 μl solution consisting of 
10 μl of purified PCR-product, 5 U of TaqI restriction enzyme, 1x NEBuffer 3, and 
1x bovine serum albumin. Digestion was produced at 65°C for 4 hours, which 
resulted in two fragments of 297 bp and 167 bp for the homozygous T genotype; 
the homozygous C variant remained uncut (464 bp). 
 The COMT polymorphism (rs4680) was genotyped using Taqman analysis 
(assay ID: Taqman assay: C__25746809_50; reporter 1: VIC-A-allele, reverse assay; 
Applied Biosystems), in a 10 μl solution consisting of 10 ng of genomic DNA, 5 μl 
of Taqman Mastermix (2x; Applied Biosytems), 0.125 μl of the Taqman assay, and 
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The prevalence of the six risk allele carriers in the different groups and subgroups 
is listed in Table II. Table III shows the ORs for the risk allele carriers in the 
ADHD_all group compared to the control group. After the Bonferroni correction, 
a significant association with disease was found for the DBH (OR 1.73; CI 1.15 – 
2.59; P = 0.008) and the OPRM1 (OR 1.71; CI 1.17 – 2.50; P = 0.006) risk genotypes 
(Table III). The covariate Gender had no significant effect.
 A more detailed analysis of these two risk allele carriers in the different 
patient groups revealed clearly divergent patterns (Table IV). The DBH risk 
genotype (comprising homozygous and heterozygous expressions of the DBH- 
intron5-C>T allele) was specifically associated with ADHD diagnosis, with the 
highest OR in the ADHD_pure subgroup (ADHD but not SUD: OR 1.97; CI 1.25 – 3.10; 
Table II   Frequency of six risk allele carriers (both homozygous and 
heterozygous individuals) in different subgroups of patients with 
ADHD and/or SUD
ADHD 
all
ADHD 
pure
ADHD&SUD 
pure
SUD  
pure
SUD  
all
Controls
N 212 176 36 71 107 500
% Male 52.4 47.7 75.0 84.5 81.3 49.4
DRD4 VNTR-48bpVNTR
risk group (7R-carriers)
30.4 29.9 33.3 32.9 33.0 36.0
DRD5 VNTR- 2bpVNTR
risk group (148-bp 
carriers)
66.5 66.9 64.7 79.7 74.8 73.7
HTR1B 861G>C (rs6296)
risk group (C-carriers)
44.8 47.2 32.4 45.1 41.0 46.4
DBH-intron5-C>T 
(rs2519152) risk group 
(C-carriers)
78.8 80.8 69.7 72.9 71.8 68.2
COMT-VALMET-G>A 
(rs4680) risk group  
(G -> Val-carriers) 
69.3 70.8 62.9 66.2 65.1 69.1
OPRM1 118A>G 
(rs1799971)
risk group (G-carriers)
27.0 25.0 37.1 14.3 21.9 17.8
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The OPRM1 findings are interesting, as the association of OPRM1 118A>G with the 
ADHD and SUD combination has not been previously documented. In this study 
the increased prevalence of the risk genotype in SUD groups was primarily due 
to a concentration of the risk genotype in patients with both SUD and ADHD, 
while the prevalence in patients with only SUD was strikingly low (Table II). 
Interestingly, this specific association can help explain the contradictory 
findings for this gene in previous studies of patients with SUD 78;79; in these 
studies, the influence of comorbid ADHD was not taken into account. As the 
endogenous opioid system has not yet been implicated in the neurobiology of 
ADHD, the connection between ADHD and the risk genotype addressed in the 
present study remains unclear, as it has not been examined in previous studies. 
However, it is relevant to note that the opioid system could be involved in the 
disturbances of reward and reinforcement regulation, observed in ADHD, 
particularly the impaired signalling of delayed rewards arising from disturbances 
in motivational processes 80. The same polymorphism of the μ-opioid receptor 
gene (OPRM1) has been associated with dispositional and neural sensitivity to 
social rejection 81 and parent-child relations 82, implicating the opioid (reward) 
system in the regulation of social relations and behaviour. The present findings 
suggest a specific pathophysiological role for the opioid system in the increased 
vulnerability to both behaviour disturbance (ADHD) and problematic substance 
use. 
 Despite its small size, the present study confirms the value of recognizing 
the shared heritability of ADHD and addiction, and it demonstrates that taking 
comorbidity into account can help us understand the association of psychiatric 
disorders with specific genes. Further study of the genetic basis of addiction in 
ADHD patients could allow us to determine whether these genes exert their 
influence primarily at the neurobiological, behavioural, or social/emotional 
level, thereby helping us elucidate the pathophysiology and the link between the 
two disorders.
 As the genetics of ADHD remain largely undetermined, assessing comorbidity 
in ADHD patients could be a productive way to identify reliable subtypes of 
ADHD and create more homogeneous study samples, thereby enabling a more 
specific association of ADHD with genetic risk factors 83;84. The present findings 
also have implications for patient care. Their replication could lead to the 
identification of the ADHD and SUD combination as a specific genetic subtype of 
ADHD. Such identification would be in accordance with the observation that the 
risk for problematic substance use is not evenly distributed among ADHD 
patients. Indeed, the majority of ADHD patients do not show problematic 
substance use. From both the therapeutic and preventive perspectives, it is 
important to know in what respects ADHD patients with increased SUD risk 
P = 0.003). For the OPRM1 risk genotype (the homozygous and heterozygous OPRM1 
118A>G genotypes), the largest OR was found in the ADHD&SUD_pure subgroup 
(combined ADHD and SUDs: OR 2.75; CI 1.35 – 5.72; P = 0.007). The covariate Gender 
appeared to have an important effect in the SUD subgroups (Table IV); this was 
due to the important gender disparity in the SUD patient group.
Discussion
The results of this exploratory investigation confirm our hypothesis that specific 
genotypes increase the risk for ADHD only, whereas others convey an increased 
risk for the combination of ADHD and SUD. The findings for the DBH risk 
genotype are in accordance with the literature: up to now, only the association 
of this genotype with ADHD, but not with SUD, has been replicated 73;74. The 
present findings suggest that the inconsistent results in SUD patients could 
result from the significant prevalence of (undiagnosed) ADHD in these patient 
populations 75-77. 
Table IV   Odds ratios of DBH and OPRM1 risk allele carriers (homozygous and 
heterozygous individuals) in different subgroups of patients with 
ADHD and SUD compared to the control group
genotype sex
Adj
OR
95%
CI
p Adj
OR
95%
CI
p
DBH-intron5-C>T (rs2519152) risk group (C-carriers)
ADHD_all 1.73 1.15 – 2.59 0.008 1.13 0.80 – 1.60 0.48
ADHD-pure 1.97 1.25 – 3.10 0.003 0.94 0.65 – 1.37 0.75
ADHD&SUD_pure 1.05 0.49 – 2.28 0.89 2.76 1.26 – 6.07 0.011
SUD_pure 1.22 0.69 – 2.17 0.49 5.55 2.84 – 10.81 < 0.001
SUD_all 1.15 0.71 – 1.86 0.57 4.29 2.55 – 7.21 < 0.001
OPRM1 118A>G (rs1799971) risk group (G-carriers)
ADHD_all 1.71 1.17 – 2.50 0.006 1.12 0.81 – 1.54 0.50
ADHD-pure 1.54 1.02 – 2.32 0.040 0.94 0.67- 1.33 0.73
ADHD&SUD_pure 2.75 1.32 – 5.72 0.007 2.98 1.36 – 6.51 0.006
SUD_pure 0.80 0.39 – 1.66 0.56 5.47 2.81 – 10.67 < 0.001
SUD_all 1.35 0.79 – 2.30 0.28 4.38 2.61 – 7.35 < 0.001 
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differ from ADHD patients with no addiction and how much of this increased 
risk is determined by genetic factors. 
 Confirmation of the genetic vulnerability to SUD offers the possibility of 
early identification and targeted preventive interventions for ADHD patients at 
genetically increased risk for addiction. Treatment of children with ADHD with 
stimulant medication has shown some promise in diminishing but not 
eliminating the risk for later addiction 85;86. A better understanding of the genetic 
underpinnings of addiction could help us identify which patients would benefit 
most from ADHD medication and which patients would be better served by other 
interventions. 
 We are very fortunate that this pilot study, using material from previous 
studies, yielded interesting results, meriting further investigation. However, in 
view of its limitations a cautious interpretation of the relevance of its results is 
warranted. The present study was executed with small study samples, leading to 
even smaller subgroups, restricting both the power to detect gene variants of 
lesser effect and the statistical significance of the present findings. This is 
particularly true for risk alleles with higher frequency, such as the DBH risk 
genotype used. The ORs we have found are most likely inflated and suffering 
from the winner’s curse. The fact that the surprisingly large OR of 2.75 for the 
OPRM1 risk genotype was found in the smallest subgroup of the study (N=36) 
raises even the possibility a false positive result due to the small sample size. 
Moreover the study was performed without the availability of a replication 
sample, and comparable studies are lacking in the present literature. This means 
that the present findings should be regarded as assumptions, needing replication 
in independent samples. Future comparable studies should optimally include at 
least 500 cases per group.The intriguing results of this study indicate that 
further genetic research on the intersection of ADHD and addiction could well 
prove to be fruitful by elucidating the genetic basis and pathophysiology of both 
disorders. 
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Introduction
Attention Deficit/Hyperactivity Disorder (ADHD) is a frequent diagnosis among 
patients with Substance Use Disorders (SUD), most often in combination with 
serious conduct disorders in youth and antisocial personality disorder 1. In 
various populations of patients with SUD, the prevalence of ADHD was 10 – 30% 2.
The clinical relevance of ADHD in addiction is still poorly understood. There is 
growing evidence that ADHD plays an important role in the etiology and 
pathogenesis of substance abuse 3. Recent studies have shown that treatment for 
ADHD in children has a beneficial effect on preventing addiction problems in 
later life 4. It is unclear whether in adults with addiction problems, ADHD 
treatment influences the course of their substance abuse. Case reports on ADHD 
treatment showed a positive effect on the SUD prognosis 5. However, this positive 
effect has yet to be demonstrated in controlled trials.
 Very few controlled studies assessed the efficacy of pharmacological 
treatment for ADHD in substance abusers 6. Psychostimulants (methylphenidate 
(MPH) and dextroamphetamine) are still the treatment of choice for ADHD in 
children and adults 7. Several controlled studies found that MPH had a positive 
effect on ADHD in adults, although the effect was less robust than in children 8;9. 
As these studies involved mostly ADHD patients without psychiatric comorbidity 
and substance abuse was generally a reason for exclusion, it is unknown whether 
MPH is as effective in patients with comorbid substance abuse disorders. 
Furthermore,  psychostimulants are often considered to be contraindicated in 
substance abusers, because of concerns regarding abuse of the medication and 
increased risk of relapse 10-12. Despite these concerns, a few case reports have 
illustrated the efficacy of stimulant medication in patients with substance use 
disorders. These uncontrolled trials suggested that psychostimulants may be 
both safe and effective 13-15. Up to now only one placebo-controlled study has been 
conducted on the efficacy of stimulant medication (MPH) in adult cocaine abusers 
with ADHD 16. ADHD symptom relief was greater in the group treated actively 
(although not statistically significant), but there was no influence on substance 
use (abstinence was not a prerequisite for participation in that study). 
 The present small-scale pilot study was designed to gain experience in the 
use of MPH as trial medication in patients with ADHD and substance use 
disorders, and to compare its short-term efficacy on ADHD symptomatology in 
this patient group with study results in adult ADHD patients with less psychiatric 
comorbidity. Most studies and case reports in this field are of US origin, including 
a few controlled studies on stimulants in adult ADHD patients. There is a need 
for replication of these data in Europe to investigate similarities and differences 
in populations and treatment outcomes and to validate the diagnosis of ADHD in 
Abstract 
Aims: Attention deficit/hyperactivity disorder (ADHD) is common among adult 
patients with substance use disorders. The benefits of treating ADHD in these 
patients are uncertain and the prescription of psychostimulants is disputed, 
because of the risk of abuse. This study examined the short-term effectiveness of 
methylphenidate treatment for ADHD in adults with substance use disorders.
Design: Double-blind, placebo-controlled, multiple cross-over (A-B-A-B design) 
comparative trial of methylphenidate versus placebo.
Setting: Inpatient addiction treatment facility.
Participants: Twenty-five patients with ADHD  who were receiving inpatient 
treatment for various substance use disorders. 
Intervention: During the course of 8 weeks, each participant completed 2 phases 
of placebo and 2 phases of active medication treatment, in a fixed low dosage 
schedule (up to 0.6 mg/kg/day). Abstinence was maintained during the study.
Measurements: The outcome measure was ADHD symptomatology, as measured 
with the ADHD Rating Scale-IV. The results were compared using MANOVA 
repeated measures.
Findings: Nineteen out of the 25 patients completed the trial. A significant 
reduction in ADHD symptoms was observed in the first week in both conditions. 
The positive response to active treatment (9 patients; 36%) was not significantly 
higher than that to placebo (5 patients; 20%).
Conclusions: In this small pilot study, the effect of low-dose methylphenidate in 
adult ADHD patients with concomitant substance use disorders is limited. ADHD 
symptoms in adults were susceptible to a distinct short-term placebo response.
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All the patients were put on a fixed dosage schedule of 3 doses a day (Table 1) . 
The maximum daily dose for all the participants was 45 mg MPH. This design 
enabled us not only to compare the group results of MPH and placebo, but also to 
obtain a clear result regarding the effectiveness of the trial medication in each 
individual. If MPH was found to have a positive effect,  the patient was advised to 
continue with the medication. However, the limited scale of the study precluded 
any definitive verdict regarding MPH efficacy in this patient group. 
 Patients were examined by the same investigator (CV) once a week during 
the 8 weeks of the trial, i.e. twice in each treatment phase. Improvement in 
ADHD symptoms was used as the primary outcome measure. These symptoms 
were measured on 3 different scales. The first and most detailed was the Dutch 
version of the ADHD Rating Scale-IV, based on the 18 DSM-IV items for ADHD 19. 
Additional information was gathered using a Clinical Observation Scale, based 
on a follow-up information form by Barkley 20 and the Clinical Global Impression 
Scale, adapted for the ADHD symptoms 21. As an indication of robust effectiveness, 
a positive response was defined as improvement of at least 30% on all 3 treatment 
scales.  The nursing staff monitored medication compliance. To check for 
abstinence (e.g. during weekend leave), urine samples were tested weekly for all 
the major drugs of abuse. 
 After clustering individual ratings into two study groups (A-B-A-B and 
B-A-B-A), baseline and weekly measurements were compared  using a  2-tailed 
paired t-test. In addition,  MANOVA was used, in which repeated measures 
controlled for baseline (Greenhouse-Geisser). 
adults. To our knowledge, this is the first European study that compared methyl-
phenidate to placebo in a sample of adult substance abusers diagnosed with 
ADHD.
 The present study did not aim to investigate the effect of adequate ADHD 
treatment on the course and severity of the substance use disorder. Practical 
considerations, as well as the clinical setting and the limited scale and time of 
the study, played important roles in this decision.
Methods
Twenty-five participants were recruited from a group of inpatients at an open 
addiction treatment facility; they remained on clinical rehabilitation treatment 
throughout the study. A positive diagnosis of ADHD was the primary inclusion 
criterion;  newly diagnosed patients, as well as patients with a negative 
therapeutic response to  alternative medication were eligible for participation. 
As the study aimed to reflect clinical practice, psychiatric comorbidity was not a 
reason for exclusion, unless its severity prevented compliance with the 
requirements of the trial or necessitated urgent treatment. Participants had to 
remain abstinent for the total duration of the study: if detoxification was 
necessary, the study was started 3 weeks at the earliest after achieving abstinence. 
Participants had to stop all psychotropic medication before entering the trial. 
Subjects gave written informed consent after receiving a complete description of 
the study.
 The diagnosis of ADHD was made during psychiatric evaluation in the course 
of clinical treatment and confirmed if the patient met at least 6 of the DSM-IV 
criteria for inattention and/or hyperactivity/ impulsivity in their present 
functioning and in childhood. No standardised diagnostic instruments were 
used. If available, the psychiatric history was confirmed by interviewing the 
parents or relatives. Substance use disorders and psychiatric disorders were 
diagnosed with the use of the DSM-IV criteria, according to the International 
Diagnostic Checklist for DSM-IV 17. The severity of the substance use disorders 
was evaluated with the Dutch version of the Addiction Severity Index 18.
 A double-blind, placebo-controlled, multiple cross-over design was used that 
lasted 8 weeks (4 treatment phases of 2 weeks each). Each patient completed 2 
phases of placebo (A) and 2 phases of active medication (B). They were randomised 
independently by a clinical pharmacologist to follow the A-B-A-B or B-A-B-A 
schedule. Owing to study limitations, there was no chance to titrate the 
medication dosage for each participant. 
Table 1   Trial medication dosage schedule
day doses MPH daily dosage
1 – 3 1 tablet tid 15 mg
4 - 7 2 tablets tid 30 mg
8 – 14 3 tablets tid 45 mg
tid = 3 doses a day (8 – 12 – 16 hours). One tablet = 5 mg MPH or placebo
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Table 2   Characteristics of the study population
Characteristic
 N
Age, mean (SD) (yrs) 31.9 (5.8) 25
Sex, % male 88.0 25
Country of birth, %
Europe 100
25
Relationship, %
Married
Never married
Divorced/widow
8.3
83.3
8.3
24
Employed full time, % 56 25
Education, %
Lower
Secondary
Higher
68
28
4
25
Type of substance dependence, %
  Alcohol dependence
  Drug dependence
52.0
92.0
25
Years of drug use, mean (SD) (yrs) 13.4 (6.5)
Years of alcohol use, mean (SD) (yrs) 7.9 (6.9)
Primary substance use disorder, % 25
  Alcohol 28  7
  Cannabis 4  1
  Cocaine 32  8
  Alcohol and cocaine 8  2
  Poly-drug use (i.e. heroine and cocaine) 16  4
  Other 12  3
Europ-ASI severity scores, mean (SD)*
Physical health 1.76 (1.6) 25
Work, education and income 2.9 (2.1) 25
Alcohol 2.79 (2.9) 24
Drugs 4.67 (2.2) 24
Justice/Police 2.0 (2.3) 25
Family/Social relations 3.83 (2.4) 24
Psychological/Emotional problems 4.63 (2.2) 24
ADHD, % 25
* Europ-ASI score range 0-9
Table 2   Continued
Characteristic
N
  Combined Type 76.0 19
  Predominantly Inattentive Type 20.0  5
  Predominantly Hyperactive-Impulsive Type 4.0  1
Further DSM-IV Axis I diagnoses, % 25
  None 44.0 11
  Posttraumatic Stress SYNDROME  4.0  1
  Oppositional Defiant Disorder 16.0  4
  Conduct disorder 36.0  9
DSM-IV Axis II diagnoses, % 25
  None 36.0  9
  Borderline Personality Disorder 4.0  1
  Antisocial Personality Disorder 8.0  2
  Personality Disorder NAO 52.0  13
* Europ-ASI score range 0-9
Figure 1   Baseline and treatment phase (1-4) scores on the ADHD Rating Scale 
(Figure 1a) and on the Clinical Observation Scale (Figure 1b) and  
the Clinical Global Impression Scale-ADHD (Figure 1c). Participants 
received either MPH or placebo, in an alternating schedule (A-B-A-B 
or B-A-B-A)
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Results
The participants were predominantly male (88%); their mean age was 31.9 years. 
The majority of patients had combined-type ADHD. In 13 patients, the presence 
of ADHD symptoms in childhood was confirmed by family members. In most 
cases, the diagnosis was made during the present clinical trial; these patients 
had never tried any ADHD medication. Six patients had used other medication 
for ADHD, with insufficient response: 5 had tried tricyclic antidepressants, 1 
venlafaxin. This medication was stopped before entering the trial; 1 patient was 
allowed to continue his medication (amytryptilin), because of a partial response. 
He was accepted as a participant, because he still showed clinically significant 
ADHD symptoms. 
 The abused substances included all major drugs and alcohol (Table 2). A high 
proportion had  psychiatric comorbidity, more particularly histories of childhood 
conduct disorders (Oppositional Defiant Disorder: 52%; Conduct Disorder: 36 %) 
and personality disorders (Borderline Personality Disorder: 4%; Antisocial 
Personality Disorder: 8%; other Personality Disorders: 52%).  One patient had a 
Post-Traumatic Stress Disorder, but other major psychopathology was notably 
absent in our population.
Four patients had to stop the benzodiazepine use they had started during 
detoxification. One patient completed the trial while still on methadone; in his 
case, the trial was aimed to reduce his ADHD symptomatology, not to ensure his 
abstinence.
 Twenty-five patients entered the study and nineteen completed the entire 
trial. Three participants had to be withdrawn from the trial, because their 
clinical treatment was abruptly terminated for reasons outside the trial. Three 
other participants decided to terminate the trial, one because of the lack of 
effect, one because of the stress of the trial and the other because of side-effects 
(while on placebo).
 A statistically significant reduction in symptoms was found with the ADHD 
Rating Scale (t=4.84, df=21, p<0.01), the Clinical Observation Scale (t=4.64, df= 
22, p<0.01) and the Clinical Global Impression Scale (t=4.34, df=22, p<0.01) in the 
first week of treatment compared to baseline with both placebo and methylphe-
nidate. Similarly, each week of treatment showed significant symptom reduction 
(p<0.01) compared to baseline (Figure 1). MANOVA failed to show any significant 
difference between MPH and placebo on the ADHD Rating Scale, the Clinical 
Observation Scale and the Clinical Global Impression Scale, even when the 
periods with the highest dosage were used as independent variables.  
Figure 1   Continued
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diagnosis had been made fairly recently, which reflects the current interest in 
ADHD in this population. 
 Apart from the comorbid psychiatric disorders mentioned above, most of the 
participants did not show any other major psychopathology. Probable 
explanations are the stabilising influence of longer-term abstinence (weeks to 
months) and the in-patient treatment setting. This also helps to explain the 
limited use of psychotropic medication prior to the trial. Consequently, the 
prerequisite to stop all psychotropic medication before entering the trial was 
seldom a problem; most patients were not using any medication, while a minority 
were using temporary medication (benzodiazepines) to help them through 
detoxification. A few of the patients had used other ADHD medication with 
limited results, which was the reason for entering the trial. This medication 
could be stopped in almost all cases. Only one participant kept on using 
methadone during the trial, because in his case, abstinence was not recommended.
Twenty-four per cent of the participants were unable to complete the trial; 
partial explanations for this high drop-out rate might be the serious psychiatric 
problems in this patient population and the considerable demands made by an 
8-week placebo-controlled trial.
 The effectiveness of MPH treatment in this study was limited: only 9 out of 
the 25 patients (36%) showed a clear-cut positive response. This is much lower 
than the positive response of 50% or more found in other studies on ADHD adults 
8;23. A number of factors may account for this modest response rate. Probably the 
most important factor was the subtherapeutic medication dosage. Due to study 
limitations, it was not feasible to perform individual dosage titration of the 
study medication. Although prior studies have shown more definite responses 
with higher doses of MPH (of up to 1.0 mg/kg/day) 7, lack of experience with the 
medication in this patient population led us to use a cautious fixed dosage 
schedule with fairly low doses (with a maximum of about 0.6 mg/kg/day). Thus, 
higher dosages may have led to a more robust response. Interestingly, the present 
results are comparable with those of older studies, in which  similar psycho-
stimulant doses were used with equally unimpressive results 24;25.
 The limited number of positive responses could be attributed to too stringent 
response criteria (30% improvement in all 3 treatment scales). However, the 
number of positive responses per scale did not vary widely (see Table 4). A 
carry-over effect was not expected, given the short half-life of MPH. Analysis of 
only the first cross-over (A-B) showed indeed similar modest results. 
 The high psychiatric comorbidity rate in the study sample may also have 
limited the effect of the medication. As was to be expected in this population, 
most of the patients had antecedents of childhood conduct disorders and 
personality disorders. Other psychopathology was notably absent. 
Direct comparison between the mean results for MPH and placebo treatment 
showed no significant difference (Table 3). However, methylphenidate showed 
significantly more side-effects than placebo (F=4.30, df=1.87, p=0.03). 
The study design permitted conclusive analysis of individual results. These 
showed a positive response (a 30% improvement in all 3 treatment scales) in nine 
patients while they were on MPH and a positive response in five patients while 
they were on placebo. No clear response was observed in five patients (Table 4). 
Discussion
In this study, a representative sample of adults with ADHD and substance abuse 
disorders participated in a double-blind medication trial. Patterns of drug abuse 
and dependence varied, which confirmed earlier observations that these patients 
have no preference for any specific drug of abuse 22. In most cases, the ADHD 
Table 3   Mean result for each treatment scale (paired t-test; 95 % interval, 
N=19, df=18)
Outcome measure T0
mean (SD)
placebo
mean (SD)
MPH
mean (SD)
paired
t-test
sign.
ADHD Rating Scale 46.9  (7.6) 31.8  (12.7) 27.6  (15.3) t= -0.955 (p=0.352)
Clinical 
Observation Scale
27.3  (6.7) 17.8  (8.1) 14.0  (9.2) t= 1.298 (p=0.211)
Clinical Global 
Impression Scale
11.8  (2.6) 8.3  (3.9) 6.5  (4.3) t= 1.381 (p=0.184)
Table 4   Number of positive responses for each treatment scale, and for all 3 
treatment scales combined
N responders* N non-responders N placebo-responders
ADHD rating scale 9 (47.4%) 5 (26.3%) 5 (26.3%)
Cl. Observation scale 11 (57.9%) 2 (10.5%) 6 (31.6%)
C.G.I. scale 11 (57.9%) 2 (10.5%) 6 (31.6%)
All 3 scales 9 (47.4%) 5 (26.3 %) 5 (26.3%)
* positive response = symptom reduction of at least 30%
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this manuscript, the Novadic-Kentron Institute who funded the study and Drs. R. 
Kempen, clinical pharmacologist, who prepared the study medication and 
carried out the independent randomisation procedure.
Although it is unlikely that drug withdrawal had any influence on the results, it 
remains unclear whether previous drug abuse influenced the effectiveness of 
MPH on the ADHD symptoms. Further research is needed to identify clinical 
determinants that can predict a positive response.
 The difference in effect with the active treatment condition was further 
diminished by the distinct positive responses to placebo in 20% of our subjects. 
It is generally considered that the placebo response of adults with ADHD 
symptoms is more substantial than in children, but limited and only short-lived, 
especially compared to the high placebo response rates of patients with other 
psychiatric disorders, such as depression 26;27. However, a similar placebo response 
(between 10 and 20%) has been found in recent controlled studies on ADHD 
medication in adults 9;28.
 In the present study, the patient population and the clinical setting could be 
contributing factors to the strong placebo response. Most of the patients were 
eager to participate and had high expectations of recovering from their addiction 
as a result of treatment with MPH. This was clearly reflected in the trail scores: 
all the symptom scores improved in the first week of the trial, regardless of the 
treatment condition. A placebo lead-in phase may diminish this effect. 
 In summary,  in agreement with the other controlled study on adult patients 
with ADHD and  concurrent substance abuse disorders 16, this (underpowered) 
placebo-controlled pilot study failed to show any definite effect of MPH. In the 
interpretation of the relevance of these findings, the limitations of the study and 
the small sample size should be taken into account. The study underscores the 
importance of adequate psychostimulant dosage for the treatment of ADHD. 
Nevertheless, the significant improvement in a minority of patients (9 out of 25) 
while on MPH illustrates that psychostimulant medication can indeed be an 
effective medication for some of them. This is an important argument against 
excluding these patients from psychostimulant therapy. Further studies are 
recommended on the effectiveness and safety of long-term use of psychostimu-
lant medication in this patient group. 
 A treatment trial with an individualized placebo-controlled A-B-A-B design 
can identify ADHD patients who may benefit from long-term psychostimulant 
treatment. In view of the uncertainties and risks associated with MPH use in 
ADHD patients with SUD and the impending chance of a placebo response,  such 
a treatment trial (preferably with a placebo lead-in) is a relevant option in this 
patient group.
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General discussion
First, I come back to the original research questions of this dissertation and 
discuss to what extent they have been answered in the preceding chapters. Then 
I will focus on the relevance of the study results and their consequences for 
clinical practice and future research. 
Answers to research questions
(1) What is the extent and diversity of psychiatric comorbidity in a sample population of 
SUD patients, and to what extent does this comorbidity influence these patients’ general 
functioning, problem severity, and quality of life? 
The results confirmed the presence of extensive psychiatric comorbidity in a 
middle-aged MMT patient sample.  Psychiatric assessments revealed a wide range 
of current and life-long psychopathology in nearly all the participants. The 
profound influence of this wide-ranging psychiatric comorbidity on quality of 
life in this patient group is in accordance with findings from other studies 1;2. 
These results indicate the extent to which co-occurring psychiatric pathology 
determines the prognosis and treatability of opioid dependence; treatment of 
chronic addiction is ineffective unless these comorbid conditions are addressed 3. 
On the other hand, systematic evaluation and treatment of psychiatric comorbidity 
has the potential to drastically improve the quality of life of such patients, 
offering the prospect of better therapeutic compliance and prognosis. 
 As noted above, an important limitation of this cross-sectional study is that 
the exact temporal sequence of the various psychiatric disorders could not be 
established with certainty. Such temporal sequences are essential for the 
determination of causal relationships. The chronic course of both psychiatric 
disorders and SUDs, as illustrated by the high prevalence of life-long psychopa-
thology, suggests a complex bi-directional relationship between psychiatric 
and addictive disorders. Psychiatric pathology is an inherent aspect of opioid 
dependence. It can be both a risk factor for drug dependence and a consequence 
of it. A better understanding of this complex relationship can offer clues for both 
treatment and prevention of this kind of severe SUD. One way to tackle this 
scientific problem is to study specific examples from the spectrum of externalising 
disorders, as shown in the subsequent chapters. 
(2)  How prevalent are CD and ADHD in a sample population of SUD patients and what are 
their characteristics? 
A CD history was found in the majority of participants (60.1%). Persistent ADHD, 
which had not been previously diagnosed in the vast majority of participants, 
144 145
C
h
ap
te
r 
7
Su
m
m
ar
y 
an
d
 D
is
cu
ss
io
n
whereas ADHD is associated with susceptibility to a variety of internalising and 
externalising psychiatric disorders. These results suggest that it is especially this 
association with the internalising disorders spectrum which distinguishes the 
influence of ADHD from that of CD, once more confirming ADHD as a risk factor 
for addiction in its own right. 
 The results also confirm that the risk of severe and complex addictive 
pathology is greater in patients with both CD and ADHD than in patients with 
either disorder alone 12;13. The combination of CD with ADHD seems to add 
another level of complexity by increasing psychiatric comorbidity, as predicted 
by the hypothesis of a synergistic relationship between the two disorders 14. This 
synergy seems to hold particularly well for personality pathology, lending 
support to the observation that patients with both CD and ADHD are particularly 
at risk for antisocial personality disorder 15. 
(4)  What is the role of CD and ADHD in the development of addiction?
The results confirm that participants with a CD history (1) began substance use 
at an earlier age and (2) had a more serious addictive illness (characterised by 
more drug overdoses, more inpatient detoxification, and higher rates of comorbid 
SUD) than participants without a CD history. ADHD had a similar but much 
more limited influence on the course and severity of the SUD. 
 These findings clearly indicate that opioid dependence in adulthood is 
inseparably linked to childhood psychopathology. From a developmental perspective, 
both addictive disorders and comorbid psychiatric symptomatology can be seen as 
both developmental extensions and complications of chronic disorders that 
originated in childhood, starting with CD and graduating to early substance use 
and abuse. The present results confirm earlier findings that CD (diagnosed in 60.1% 
of our participants) increases the risk of addiction problems, with ADHD being a 
secondary risk factor 16;17. For example, only about a quarter of the ADHD patients in 
the study (22.9%) did not have a history of comorbid CD, implying that ADHD alone 
is much less liable than CD to lead to severe addiction. In fact, what the present 
results mainly illustrate is the strong association between these two disorders in the 
development of severe addictive pathology. In several ways, the combination of the 
two disorders increases the risk of severe adult pathology, not only because of their 
different pathogenetic influences, but also because of the complex developmental 
interaction between their various manifestations and consequences. Their combined 
presence leads not only to an increase in maladaptive and antisocial behaviour, but 
also to increased vulnerability to psychiatric comorbidity. If untreated, this complex 
psychopathological mix diminishes the likelihood of developing healthy coping 
mechanisms and adequate problem-solving skills, while increasing the risk of 
problematic substance use. 
was diagnosed in nearly a quarter of them. These results are in accordance with 
previous estimates, both from the limited number of studies in patients with 
opioid dependence 4-6 and studies of patients with other types of SUD 7-9. The high 
prevalence of both these externalising disorders testifies to their important 
etiological role in the development of serious SUD. The fact that severe psychiatric 
disturbances such as CD, and to a lesser extent ADHD, were present in the 
majority of patients points to the role of the psychiatric problems that preceded 
the addiction. In this way, the externalising disorders can be seen as an etiological 
model for cases where a psychiatric disorder originating in childhood is the 
major risk factor, as well as the developmental pathway, for problematic 
substance use, leading to addiction. The extensive psychiatric history and 
symptomatology of these complex patients illustrates first and foremost the 
psychiatric nature of SUDs.
 Consistent with the concept of externalising disorders, a significant overlap 
between ADHD and CD was found, with three quarters of the ADHD patients 
also having a CD history. The co-occurrence of CD and ADHD was not 
systematically checked in most previous studies of ADHD prevalence in SUD 
populations, with two exceptions 6;8. In combination with these two studies, the 
present results suggest that ADHD in SUD patients is more closely linked to 
other conduct disturbances in childhood, and that the combination with CD is 
the predominant presentation of ADHD in patients with severe SUD. This fact 
implies that from the outset ADHD in SUD patient populations is a more complex 
disorder than is “simple” ADHD in adults without comorbid SUD. This observation 
can explain the propensity for addiction in SUD patients, as well as their more 
complex psychopathology, and hence the diminished effectiveness of standard 
ADHD pharmacotherapy 10;11. 
(3)  What is the influence of CD and ADHD on psychiatric comorbidity in a sample population 
of SUD patients? 
The results confirmed that patients with either ADHD or CD had a higher 
prevalence of psychiatric comorbidity, more severe addiction and dysfunction 
and a diminished quality of life compared to patients without these disorders. 
Specifically, patients with both CD and ADHD had the highest problem scores.
Although both disorders contributed to increased psychiatric comorbidity, the 
results suggest both similar and distinct pathogenetic mechanisms. The presence 
of an ADHD diagnosis in participants was associated with a higher rate of Axis I 
psychiatric comorbidity and personality disorders than with a CD history, 
whereas the antecedents of CD explained most of the variance in social 
dysfunction. This pattern seems to indicate that CD is the primary, but not the 
exclusive, predisposition to antisocial behaviour and personality disorders, 
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illustrated by the marked improvement in all the symptom scores in the 
first week of the study, irrespective of treatment condition. Adding a 
placebo lead-in phase to the research design would go a long way toward 
solving this problem in future studies. 
Whereas the clinical setting probably contributed to this placebo effect, it also 
had the advantage of better securing participant abstinence, a recurring problem 
in outpatient studies. Nevertheless, methylphenidate was effective in a minority 
of our ADHD participants, as one would expect from clinical experience and the 
results of earlier studies. 
Generalisability of the results
In view of the complex psychopathology and severe dysfunction exhibited by the 
study sample, the participation rate of nearly 63% must be considered a 
substantial achievement, mainly due to the impressive efforts of the research 
assistants. Nevertheless, information on more than one third of the target group 
was lacking. A small number of patients were excluded because of language 
barriers; a larger number refused to participate or could not be reached. Our 
general impression is that these excluded patients do not function substantially 
differently from the study participants; our unsubstantiated suspicion is that 
they fare worse. In this respect, the conclusions reported in this dissertation 
should be considered conservative. 
 As mentioned above, patients of non-Dutch origin were underrepresented. On 
the other hand, the predominance of middle-aged participants was quite 
representative of the current Dutch MMT population; a similar composition is to be 
expected in other West-European countries. In this respect, our sample was quite 
representative of chronic MMT populations in most parts of Western Europe. Studies 
focusing on patients entering treatment differ mainly on demographic characteris-
tics. Differences in demography, as well as local differences in drug use and 
availability, variations in treatment facilities, and differences in legislation impede 
the generalisability of the results to other countries. 
 Due to its specific characteristics, especially the severity of the addiction and 
the negative long-term prognosis, opioid dependence is not immediately 
comparable to other SUDs. On the other hand, because our MMT sample can be 
considered representative of patients with severe and chronic addiction, our 
results can be generalised to this broader patient population. Given the 
dimensional nature of the disorders and risk factors studied, it will be interesting 
to see if similar patterns (of lesser severity) will be found in patients with less 
severe addictions. 
(5) To what extent is the vulnerability to ADHD and SUD determined by shared genetic 
determinants? 
Despite its relatively small scale and the limited number of risk genotypes 
studied, this exploratory investigation into the shared genetic basis of ADHD 
and SUD yielded interesting results. The frequency of the DBH and OPRM1 risk 
genotypes was increased in ADHD patients compared to controls. However, the 
DBH genotype was associated with the ADHD diagnosis and the OPRM1 genotype 
was associated with the combined ADHD and SUD phenotype. These results are 
consistent with the concept of the externalising disorders spectrum, implying 
that genetic risk factors are shared by the different disorders in the spectrum. 
These findings also suggest that it is possible to differentiate shared genotypes, 
conveying a risk for both disorders, from more specific genotypes, increasing the 
risk for one disorder only. 
 These results imply that the increased vulnerability to problematic 
psychoactive substance use in ADHD patients is partly mediated by genetic 
mechanisms. Identification of these genetic risk factors could lead to a better 
understanding of the pathogenetic mechanisms involved in the development of 
the addiction. Clinical characteristics such as CD and ADHD symptomatology, 
can be used to identify risk for addiction at an early age; the combination with 
genetic risk factors would help us to further differentiate the vulnerabilities and 
deficiencies involved and could provide indications for the development of more 
effective interventions.
 (6)  How effective is standard medication treatment of ADHD patients with comorbid SUD?
With the increase in our knowledge and experience since the execution of this 
pilot study, the reasons for the ineffectiveness of methylphenidate treatment in 
SUD patients have become more apparent: 
-  Whereas all the participants in our small patient group were in inpatient 
therapy, reflecting a severe addictive disorder, psychiatric comorbidity 
was not systematically assessed and documented. This makes it impossible 
to discuss the role of psychiatric comorbidity – which was probably more 
extensive than originally indicated – in the negative treatment results. 
-  The main limitation of the study design was the use of a fixed medication 
dosage regimen with an end dosage that we now know is suboptimal or 
even ineffective for ADHD patients with comorbid SUDs 18;19. Clinical 
experience and a number of case reports suggest that ADHD patients 
with a history of addiction need on average higher dosages of psycho-
stimulant medications for optimal effect 20.
-  A considerable placebo effect made it even more difficult to demonstrate 
a positive effect of the active medication. This placebo effect is clearly 
148 149
C
h
ap
te
r 
7
Su
m
m
ar
y 
an
d
 D
is
cu
ss
io
n
treatment of these comorbid disorders. An adequate assessment of the 
co-occurring psychiatric disorders in addicted patients can increase our 
understanding of their role in the development and persistence of the addiction, 
and it can provide vital clues for improving further treatment of both the SUD 
and the comorbid psychopathology. This observation is particularly relevant in 
view of the compromised prognosis of patients with dual diagnoses, as well as 
the diminished efficacy of standard treatment in this patient group 21;22. This 
implies that psychiatric expertise is essential for effective addiction treatment. 
This expertise is sadly lacking in major segments of the addiction field. The 
traditional categorical division of mental health care has led to improved 
standards of care for SUD patients in specialised addiction treatment services. 
However, these improvements have also caused many psychiatric patients 
(including the participants in our study) to remain without state-of-the-art 
psychiatric care simply because it is unavailable at addiction treatment centres. 
In comparison to regular mental health institutions far too few psychiatrists 
work in addiction service centres. Their expertise in psychiatric assessment and 
their integration of modern psychiatric and psychosocial treatment methods is 
sorely missed. This shortage of expertise is sadly illustrated by the fact that the 
MMT team in our study did not include a psychiatrist.
 Unfortunately, the problem does not end there. Despite progress in our 
scientific understanding of addiction as a brain disease, and despite all efforts to 
convey this knowledge to health professionals, research continues to show, even 
now, that addicted patients have to cope with stigmatisation, negative 
perceptions, and sub-standard treatment. This is true not only in primary care, 
but also in psychiatric services 23-26. It is a sobering fact that moral prejudices still 
prevail in the age of evidence-based medicine. 
 Only a concerted effort by all the parties involved can remedy this situation. 
The history of change in our perception of neurosyphilitic patients following the 
introduction of effective treatment (i.e. malaria fever therapy) shows that advances 
in knowledge and access to effective treatment are potent tools for changing 
attitudes and perceptions of health care providers 27. In a similar way working in 
the addiction field can be made more interesting and inspiring for psychiatrists. 
This study illustrates not only the high prevalence of psychiatric problems and 
disorders in addicted patients and the relevance of adequate psychiatric treatment, 
but also the vast possibilities for carrying out interesting and relevant research. Of 
course, initiatives to improve psychiatric care and expertise must be funded, and 
that will be quite hard to accomplish - even more so now, as psychiatric patients can 
count on little sympathy from the political system. 
 What the adequate treatment of ADHD could contribute to the prognosis of 
addicted patients remains unanswered, both in this dissertation and in the 
The above assumptions are corroborated by previous studies, the results of which 
are comparable to ours with respect to the prevalence of psychiatric comorbid 
disorders and externalising disorders in samples from populations similar to the 
one we sampled. 
Consequences for clinical practice 
The present results confirm the relevance of externalising disorders to the 
development of severe addiction. It is nearly impossible to determine whether CD 
and ADHD should be considered a precursor of, a risk factor for, or a cause of 
addiction. Using the externalising disorders spectrum as our framework, we can 
see that CD and ADHD are childhood precursors of adult SUD. However, we need 
to explain why the majority of ADHD and CD patients – fortunately – do not 
develop the full spectrum of disorders and are able to remain free of problematic 
substance use in their adult lives. Differentiating a cause from a risk factor is a 
challenge both linguistically and scientifically: given the multifaceted etiology 
of addiction, evidence for direct causality would be very hard to find. The life 
history of some of our participants can be seen as evidence that CD (and to a 
lesser extent ADHD) were the direct causes of their addictive pathology. However, 
other participants had severe SUDs without a history of childhood CDs, implying 
that other causal factors were involved. Given the heterogeneity of these disorders 
and their dynamic interaction with environmental factors, all these different 
aspects come into play during the development of SUDs. This interactive 
developmental approach makes it easy to understand why the combination of 
ADHD and CD carries such a high risk for future pathology and SUDs. In our 
study, this subgroup invariably had the highest problem and severity scores.
 This study highlights the fact that adult SUDs are chronic disorders by 
definition, that in most cases they begin in adolescence, and that the 
accompanying psychiatric comorbidity is predominantly chronic. The study 
sample displayed one of the more negative developmental trajectories, with 
severe conduct disturbances at a young age, followed by a protracted history of 
addiction with al kinds of negative personal and social consequences. It is not 
hard to imagine a similar developmental pattern in less severe SUD cases, where 
psychiatric disorders, from their onset, contribute to the appearance and 
development of problematic substance use.
Psychiatric assessment and treatment
Comorbid psychiatric pathology is part and parcel of any severe and chronic 
SUD. Treatment of the addiction will be ineffective without concomitant 
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remain unclear, it is quite possible to identify genetic risk factors shared by both 
disorders.This point clearly illustrates the need to evaluate the presence of SUD 
when doing genetic research on ADHD patients. Not only would such an evaluation 
help identify more shared risk genotypes, but it also would test the reliability of 
combined ADHD and SUD as a subtype of ADHD. The validity of this subtype would 
contribute to the delineation of more homogeneous study samples, thereby 
improving our understanding of the genetic basis of both disorders 29;30. 
 The methylphenidate trial was a valuable learning experience, and it 
highlighted the difficulties in carrying out randomised placebo-controlled trials 
with SUD patients. The negative results were due not only to design deficiencies, 
but also to the lack of an effective medication regimen for treating ADHD in 
addicted patients. It is little consolation that these negative results also appeared 
in more extensive and better-quality studies than the present endeavour 10;31;32. 
The evidence from previous trials suggests that even a more meticulously 
designed study (with systematic psychiatric assessment of the study population) 
would only confirm the limited efficacy of standard ADHD medication in this 
patient population. The question is whether further research should be 
conducted given what seems to be a foregone conclusion.
 Of course, it remains relevant to demonstrate that ADHD can be treated 
effectively in SUD patients, something which according to its harshest critics 
has not yet been proven unequivocally. However, given that most double-blind 
placebo-controlled trials with ADHD and SUD patients have been carried out 
with methylphenidate, a likely explanation for the negative and unconvincing 
results is simply that for this particular patient population this medication is 
ineffective. One way to confirm this conclusion would be to conduct similar 
trials with a different medication; one good candidate is dexamphetamine (Wim 
van den Brink, personal communication). 
 Another, perhaps more clinically meaningful, possibility would be to 
conduct a prospective longitudinal study comparable to the cohort studies used 
to assess other psychiatric disorders, such as mood disorders. A population of 
SUD patients with ADHD would be assessed and treated in a systematic way, 
using a research and medication protocol that provides for an individually-tai-
lored and optimised medication scheme for each patient. Patients’ ADHD 
symptomatology, abstinence, and general functioning would then be followed 
up for a longer period. While not as robust as a randomised controlled trial, such 
a research protocol would demonstrate the treatability of ADHD in SUD patients 
while documenting the interaction between effective ADHD treatment and 
abstinence. At the same time, the protocol would be rigorously tested, yielding 
valuable information on the efficacy of different medications. Most 
importantly,the results would have immediate relevance for clinical practice. 
scientific literature. One thing the dissertation has accomplished is to highlight 
why ADHD is so much harder to treat in middle-aged addicted patients and to 
help us understand the associated problems. To repeat, the only adequate 
treatment for ADHD is psychiatric treatment; the whole range of psychiatric and 
psychosocial problems must be taken into account in the context of an integrated 
treatment program. The heterogeneity of the ADHD patient population and its 
complex comorbidity necessitate individually- tailored medication schedules. It 
has become clear that prolonged abstinence offers the best hope for effective 
ADHD treatment. Conversely, the fact that effective treatment of ADHD 
symptomatology can contribute to stable abstinence suggests that treatment of 
more severe cases of both ADHD and SUD should begin with inpatient 
detoxification combined with ADHD medication. Competently appliedthis 
approach both ensures abstinence and improves the chances of successful 
treatment 28. A positive effect on the course of the addiction can only be expected 
from long-term effective treatment of ADHD, leading to clinically significant 
improvement in ADHD symptomatology (Frances Levin, personal communication).
Research 
One of the most reassuring demonstrations of the present project is that clinical 
research is quite feasible in patients with serious addictive disorders. Nonetheless, 
serious effort is required; the serious difficulties these patients have in managing 
their lives must be taken into account. The study clearly benefited from from the 
patience and understanding of the research assistants, and from their trusting 
relationships with the participants.
 The extensive pathology we found in the patients illustrates the need for 
additional research. As in other fields of medicine, relevant research data can 
pave the way for greater clinical interest in, and ultimately better treatment of, 
the psychiatric comorbidity of these difficult patients. It would be useful to try 
to replicate the present results with comparable patient groups, exploring the 
association between childhood externalising disorders and SUDs. A more 
elaborate dimensional approach to describing these disorders would help 
determine their relative contribution to the development of addiction. Further 
study of any CD history in ADHD adults, regardless of the presence of addiction, 
would be necessary to confirm the primary conclusions from the present results: 
(1) that the combination of ADHD with CD is the predominant presentation of 
ADHD in SUD patients, and (2) that, in general, ADHD in patients who also 
present with a CD history is more complex, and therefore more difficult to treat, 
than it is in adult ADHD patients without such comorbidity. 
 Our exploratory investigation into the genetics of ADHD and SUD shows that 
even though most of the hereditary and pathophysiological factors in both disorders 
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markers for SUD vulnerability will most likely not only confirm but also refine 
this risk assessment, offering the possibility of more effective preventive 
measures. 
 Despite early optimistic reports 48;49, longitudinal research has failed to 
consistently demonstrate a protective effect of ADHD treatment on the 
development of addiction 50-55. In part, these conflicting results can be attributed 
to clear differences in methodology (and quality). Most had a high percentage of 
participants discontinue their ADHD treatment, which  can be seen as indirect 
evidence of the need for continuous long-term treatment – ADHD is chronic by 
definition – to obtain any durable protective effect 50. There are indications that 
an early start to ADHD medication is associated with greater protection 56. 
Genetic differences might help explain differences in the efficacy of relevant 
medications. On the other hand, risk reduction might be attributable to 
treatments other than stimulant medication: more specifically, in the MTA study 
there was a reduction in risk of problematic substance use for those patients 
treated with behaviour therapy; medication had no effect one way or the other 
53. In the absence of clear evidence to the contrary, the best option for preventing 
problematic substance use in ADHD youngsters remains early identification and 
long-term treatment of the disorder, preferably a combination of medication and 
behaviour therapy 57. 
Conclusion
This dissertation has clearly illustrated that addiction is a lifelong disorder with 
multiple causes and influences. The concept of the externalising disorders 
spectrum is useful for studying the origins of addiction and the precursors of 
problematic substance use. Despite the large influence of environmental and 
socio-economic factors, addiction is first and foremost a brain disorder. The 
present study has amply demonstrated how psychiatric comorbidity is part and 
parcel of SUDs. Psychiatric comorbidity, as defined in this study, is obviously an 
abstraction, very useful for identifying different aspects of a chronic psychiatric 
disorder but nevertheless a simplification of a complex psychopathology. 
However this dissertation also shows that psychiatric comorbidity is a harsh 
reality, both for patients and their treatment teams. A better understanding of 
the complex interrelations between the different disorders offers new 
perspectives, not only for improving treatment response and quality of life for 
these chronic psychiatric patients, but also for preventing and limiting future 
pathology in younger individuals. 
Prevention
Providers of mental health care should see as their primary goal to take optimal 
advantage of every opportunity for prevention. At the very least, the scourge of 
externalising disorders offers the opportunity to identify, at an early age, 
individuals at increased risk for serious psychiatric pathology, including 
addiction 33. These problems are anything but inconspicuous, and effective 
treatments are available for both ADHD and CD 34-39. It is not realistic to expect 
the prevention of all adult psychopathology, but it is realistic to expect a 
reduction of adult psychiatric comorbidity in both prevalence and intensity 40;  if 
we can’t prevent problematic substance use, let’s at least postpone it. 
 In more than one way, our patient sample exhibited the “natural course” of 
externalising disorders; lacking the benefit of present-day knowledge, all 
participants grew up without  the necessary treatment and prevention facilities. 
This situation has improved greatly in recent years; childhood psychiatric 
disorders are recognised as such, and treatment is more universally available. 
Nevertheless, adequate treatment is not a straightforward undertaking: the 
patients with the most severe disorders and most in need of treatment are the 
very ones that are hardest to reach and keep in treatment.
 Given our present knowledge about the etiology and pathogenesis of SUDs, 
preventive measures should be aimed at diminishing the negative gen x 
environment interactions; identifying at-risk persons at an early age, assessing 
their specific vulnerabilities, improving their coping skills, and promoting their 
resilience, while at the same time mitigating negative environmental influences. 
Preventive strategies such as the employment of skills-based programs aimed at 
reducing problematic substance use have been developed and proven valuable 41. 
It is noteworthy that these resilience-promoting programs are aimed at 
ameliorating the same deficient functions that are often present in children 
with externalising disorders: inhibitory control, planning, problem solving, 
emotional regulation, and attention span 42. From a theoretical point of view, our 
present understanding of the importance of adolescence as a crucial period in 
the development of problematic substance use suggests that these protective 
measures must be effective before the end of primary school and before puberty. 
If early initiation in drug use indeed confers a higher risk for SUDs in later life 
43-45, simply delaying the onset of drug use can be a primary prevention strategy. 
Some studies have suggested a developmental pathway starting with ADHD and 
leading to CDs and subsequent SUD 46;47. Thus, early intervention in children 
with ADHD may prevent the development of CD and the subsequent onset of 
problematic substance use.
 We already know which patients are at greatest risk: those with a family 
history of addiction and/or with both ADHD and CD 13.  The future use of genetic 
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Inleiding
Dit promotie-onderzoek vloeit voort uit mijn ervaringen als consulent psychiater 
in de verslavingszorg. Verslaving, het ongecontroleerd gebruik van psycho-actieve 
middelen is één van de meest voorkomende menselijke problemen. In mijn 
klinisch werk is vanaf het begin de verwevenheid met andere psychiatrische 
stoornissen opvallend geweest. Dit is ook de reden waarom dit onderzoekspro-
ject gewijd is aan psychiatrische comorbiditeit: het samengaan van verschillende 
psychiatrische stoornissen. Het begrijpen van deze samenhang wordt bemoeilijkt 
door de beperkingen in onze kennis van de etiologie van psychiatrische 
stoornissen. Psychiatrische comorbiditeit bestaat enkel op descriptief niveau. We 
weten niet of de verschillende syndromen die we bij één individu beschrijven, 
een reële weerspiegeling zijn van verschillende gelijktijdig optredende 
ziektebeelden, dan wel uiteenlopende manifestaties van één enkele stoornis. De 
weelderige comorbiditeit die ontstaat bij het gebruik van het vigerende classifica-
tie-systeem, de DSM-IV-TR, heeft desondanks wel waarde om de uitgebreide 
variatie in psychiatrische symptomatologie systematisch in kaart te brengen. 
Een poging tot ontwarring van deze boeiende complexiteit wordt in dit 
proefschrift ondernomen, door te focussen op een beperkt aantal stoornissen. 
 Verslaving is een neurobiologische aandoening, het eindresultaat van een 
langdurig interactief proces waarin een groot aantal biologische (deels genetisch 
bepaalde), psychologische en sociaal-maatschappelijke factoren en rol spelen. 
Cruciaal hierbij is de initiatie in het middelengebruik, die bij de meeste 
chronische verslavinggeschiedenissen plaats heeft in de adolescentie, een 
periode waarin het individu steeds meer autonomie ontwikkelt, maar nog niet 
over de vaardigheden en de beheersing beschikt om al deze ervaringen in goede 
banen te leiden. Een vroegere beginleeftijd van het middelengebruik is niet 
alleen een aanwijzing voor meer ernstige problematiek bij de adolescent en/of bij 
de omgeving, maar ook een voorspeller voor verslaving op latere leeftijd. 
 Het spreekt voor zich dat psychiatrische stoornissen die zich in deze cruciale 
leeftijdsfase manifesteren, een sterke invloed op dit initatieproces en op de 
ontwikkeling van problematisch middelengebruik kunnen hebben. In dit onder-
zoeksproject komen twee stoornissen meer uitgebreid aan bod. In de eerste 
plaats de Gedragsstoornis (Conduct Disorder, voortaan aangeduid met CD), 
gekenmerkt door het optreden van antisociaal gedrag vanaf vroege leeftijd. Deze 
stoornis blijkt een belangrijke risicofactor te zijn voor psychiatrische 
problematiek op volwassen leeftijd, en kan leiden tot de ontwikkeling van een 
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Het project heeft geprobeerd een antwoord te formuleren op de volgende onder-
zoeksvragen:
(1)  Wat is het voorkomen en de diversiteit van de psychiatrische comorbiditeit in een 
populatie van ernstig verslaafde patiënten en in welke mate beïnvloedt deze comorbiditeit 
het algeheel functioneren, de ernst van de verslavingsproblematiek en de levenskwaliteit?
De hypothese hierbij is dat de psychiatrische comorbiditeit in de onderzoekspo-
pulatie erg prevalent zal zijn. In het onderzoek zal de relevantie van deze 
comorbide pathologie worden geïllustreerd door systematisch de invloed ervan 
op het niveau van functioneren, de ernst van de problematiek en de levenskwaliteit 
na te gaan.
(2)  Wat zijn de prevalentie en de karakteristieken van CD en ADHD in in een populatie 
verslaafde patiënten? 
Op basis van eerder onderzoek is te verwachten dat een voorgeschiedenis met CD 
aanwezig is bij een groot aantal deelnemers, en dat ADHD vastgesteld wordt bij 
een significante minderheid van de onderzoeksgroep. De verwachting is ook dat 
beide stoornissen vaak samen voorkomen. 
(3)  Wat is de invloed van CD en ADHD op de aanwezigheid van psychiatrische comorbiditeit 
bij in een populatie verslaafde patiënten?
De hypothese is dat de aanwezigheid van elk van deze stoornissen de prevalentie 
van andere psychiatrische stoornissen vergroot, en mede op die manier bijdraagt 
tot een meer ernstig beloop van de verslaving. 
(4)  Wat is de rol van CD en ADHD in de ontwikkeling van een verslaving?
De hypothese is dat beide stoornissen, en CD hierbij meer dan ADHD, bijdragen 
tot een verhoogd risico op problematisch middelengebruik, ondermeer door een 
eerdere initatie in middelengebruik. De verwachting is dat het grootste risico 
hierbij uitgaat van de combinatie van beide stoornissen. In dit onderzoek wordt 
nagegaan of de invloed van beide stoornissen in dit proces vergelijkbaar of toch 
verschillend is. 
(5)  Erfelijkheid: in welke mate wordt de kwetsbaarheid voor ADHD en verslaving bepaald 
door gemeenschappelijke genetische factoren?
De verwachting is dat in het onderzoek een gedeeltelijk gemeenschappelijke 
basis van ADHD en verslaving kan bevestigen. Dit betekent dat variaties in 
sommige genen het risico op beide stoornissen verhogen, en dat andere genen 
enkel voor één van beide stoornissen coderen. 
antisociale persoonlijkheidsstoornis. Daarnaast is CD al veel langer bekend als 
een belangrijke risicofactor voor de ontwikkeling van een verslaving.
 De tweede stoornis is de Aandachtstekortstoornis met Hyperactiviteit (Attention 
Deficit/Hyperactivity Disorder, beter bekend als ADHD). Het frequent voorkomen 
van deze stoornis bij verslaafde patiënten (20 tot 30%) is een aanwijzing voor het 
verhoogde risico dat jonge patiënten met ADHD lopen op het ontwikkelen van 
een verslaving. Beide stoornissen, CD en ADHD, komen vaak samen voor, en 
hoewel CD de grotere risicofactor voor verslaving vormt, blijken patiënten met 
de beide stoornissen het grootste risico te lopen. 
Onderzoekspopulatie
Het grootste deel van dit onderzoek werd uitgevoerd bij een groep opiaat-ver-
slaafde patiënten, in chronische onderhoudsbehandeling met methadon. 
Opiaten zijn vanuit de oudheid bekend om hun pijnstillende maar ook hun 
verslavende eigenschappen. Opiaatverslaving wordt beschouwd als een zeer 
ernstige verslaving, waarbij het bereiken van stabiele abstinentie slechts voor 
een beperkt aantal patiënten weggelegd is. Heroïne is vanaf de jaren ’70 in 
Westerse landen het meest misbruikte opiaat. De standaardbehandeling van opi-
aatverslaving is een substitutie-behandeling met methadon, een synthetisch 
opiaat, dat de zucht naar heroïne coupeert. Deze inmiddels beproefde en goed 
onderbouwde onderhoudsbehandeling (Methadone Maintenance Therapy, MMT) 
heeft geleid tot een duidelijk verbeterd perspectief voor deze ernstige verslaving. 
Ondanks deze vorderingen blijft opiaatverslaving gekenmerkt door een sterk 
verkorte levensverwachting. Dit is niet enkel het gevolg van de vele somatische 
problemen (HIV, Hepatitis C, COPD), maar ook van het veelvuldig voorkomen van 
vaak complexe psychiatrische stoornissen bij deze patiënten.
Vraagstelling
In dit dissertatie-onderzoek is de rol van de gedragsstoornissen CD en ADHD in 
de ontwikkeling van verslaving verder onderzocht. Op basis van de literatuur is 
de verwachting een hoge prevalentie van  beide stoornissen te vinden in de 
beschreven onderzoekspopulatie. Een verdere beschrijving van de klinische en 
psychosociale kenmerken van de patiënten met en zonder deze stoornissen kan 
aanwijzingen bieden op welke manier deze stoornissen invloed uitoefenen op de 
ontwikkeling van een verslaving. Een vergelijking van het voorkomen van een 
klein aantal genetische markers in deze patiëntenpopulatie en in andere onder-
zoeksgroepen met en zonder ADHD heeft ons de mogelijkheid geboden de ge-
meenschappelijke en specifieke erfelijkheid van ADHD en verslaving te verkennen. 
In een apart onderzoeksproject werd de behandelbaarheid van ADHD bij verslaafde 
patiënten nagegaan. 
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Hoofdstuk 5 combineert genetische gegevens uit het beschreven onderzoekspro-
ject met gegevens uit eerder onderzoek van ADHD patiënten en van gezonde con-
trolepersonen. Op deze manier was het mogelijk de prevalentie van  6 genetische 
markers voor ADHD en/of verslaving te vergelijken in verschillende subgroepen 
met ADHD en/of verslaving. 
 Vergeleken met controlepersonen zonder ADHD, bleken de risico genotypen 
voor DHB (Dopamine β hydroxylase) en voor OPRM1 (coderend voor de μ-opiaat 
receptor) vaker te komen bij de deelnemers met ADHD (met en zonder bijkomende 
verslaving). Het DBH risico genotype bleek geassocieerd met de ADHD diagnose, 
en kwam in de hoogste frequentie voor bij patiënten met enkel ADHD (zonder 
verslaving). Het OPRM1 risico genotype was het sterkst geassocieerd met de 
combinatie ADHD en verslaving. 
In hoofdstuk 6 wordt verslag gedaan van een eerder onderzoek naar de 
effectiviteit van ADHD medicatie bij 25 patiënten met comorbide verslaving. Zij 
namen deel aan een dubbelblinde, multiple-cross-over onderzoek, waarbij de 
effectiviteit van methylfenidaat in een vast doseringsschema vergeleken werd 
met placebo. Negentien deelnemers wisten het onderzoek af te ronden. Een 
positief effect van de behandeling in vergelijking met placebo kon niet worden 
aangetoond. De positieve reactie op actieve behandeling (bij 9 deelnemers: 36%) 
was niet significant hoger dan op placebo (vijf deelnemers: 20%). 
Discussie
Beantwoording van de onderzoeksvragen
(1)  Het voorkomen  en de diversiteit van de psychiatrische comorbiditeit bij verslaafde 
patiënten
Door het aantonen van een breed scala aan psychiatrische stoornissen bij 
nagenoeg alle patiënten, heeft dit onderzoek de te verwachten uitgebreide 
psychiatrische comorbiditeit bij chronische MMT-populatie bevestigd. Deze 
resultaten zijn een aanwijzing in welke mate de aanwezige psychiatrische 
problematiek de prognose en behandelbaarheid van de opiaatverslaving 
beïnvloedt: de behandeling van deze chronische verslaving is onmogelijk zonder 
gelijktijdige aanpak van deze comorbide stoornissen. Aan de andere kant bieden 
deze resultaten uitzicht op de mogelijkheid door middel van systematische 
aanpak van deze psychiatrische problemen de levenskwaliteit en de prognose 
van deze patiënten drastisch te verbeteren. 
 Een beperking van dit onderzoek is dat onvoldoende gegevens verzameld zijn 
over het tijdsverloop van de verschillende stoornissen, zodat een eventueel 
(6)  Wat is de effectiviteit van de standaard-medicatie voor ADHD (methylfenidaat) bij 
patiënten met zowel ADHD als verslaving?
Gezien de beschreven complexe interactie tussen ADHD en verslaving (waarbij 
ook vaak sprake is van CD), is de verwachting dat de standaard-medicatie bij 
verslaafde ADHD- patiënten minder effectief zal zijn. 
Resultaten –overzicht van dit proefschrift
Hoofdstuk 2 geeft een uitgebreide beschrijving van de psychosociale en 
psychiatrische toestand van de onderzoekspopulatie. Met name komt de uitgebreide 
psychiatrische comorbiditeit aan bod, en de invloed daarvan op de levenskwaliteit 
van deze patiënten.  
 Psychiatrische comorbiditeit werd aangetoond bij 78% van de 193 deelnemers. 
Stemmingsstoornissen (60%) en angststoornissen (46%) kwamen het meest voor. 
De meerderheid van de deelnemers (70%) had naast de opiaatverslaving nog 
andere verslavingsdiagnosen. Een screening op persoonlijkheidsstoornissen viel 
positief uit bij 65% van de deelnemers, en een antisociale persoonlijkheidsstoor-
nis werd vastgesteld bij 34.1%. De levenskwaliteit van deze patiëntengroep was 
ernstig verlaagd, tot het niveau van patiënten met chronische psychiatrische en 
lichamelijke aandoeningen. De statistische analyse toonde aan dat de psychiatrische 
comorbiditeit verantwoordelijk was voor 32% van de variatie in levenskwaliteit.  
Hoofdstuk 3 beschrijft de prevalentie van ADHD in de onderzoekspopulatie. 
Een voorgeschiedenis van ADHD op kinderleeftijd werd aangetoond bij 68 
deelnemers (35.2%). Persisterende ADHD werd gevonden bij 48 deelnemers 
(24.9%). De patiënten met ADHD hadden significant hogere probleemscores, een 
lagere leeftijdskwaliteit, meer comorbide verslavingsdiagnosen en meer 
psychiatrische comorbiditeit. Hoewel zowel CD als ADHD in de statistische 
analyse een bijdrage leverden aan de probleemscores, de verslavingsproblema-
tiek, en de bijkomende psychopathologie, bleek ADHD, onafhankelijk van ADHD, 
de kans op psychiatrische comorbiditeit aanzienlijk te verhogen. 
Hoofdstuk 4 gaat nader in op het voorkomen van een voorgeschiedenis van CD 
bij de deelnemers en de gevolgen daarvan op volwassen leeftijd. 
 Een voorgeschiedenis van CD werd aangetoond bij 116 van de 193 deelnemers 
(60.1%). Patienten met CD hadden significant hogere probleemscores, meer 
comorbide verslavingsdiagnosen en meer psychiatrische comorbiditeit. De 
gelijktijdige aanwezigheid op ADHD bleek het risico op psychiatrische 
comorbiditeit te verhogen. 
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(4)  De rol van CD en ADHD in de ontwikkeling van een verslaving
In het onderzoek werd bevestigd dat deelnemers met CD in de voorgeschiedenis 
op een jongere leeftijd met middelengebruik beginnen, en een meer ernstige 
verslaving hebben, in vergelijking met de deelnemers zonder CD. De aanwezigheid 
van ADHD heeft een vergelijkbaar maar minder uitgesproken effect op de ernst 
van de verslaving. 
 Deze resultaten bevestigen dat het optreden van opiaatverslaving op 
volwassen leeftijd sterk gekoppeld is aan psychopathologie op jeugdige leeftijd. 
Vanuit ontwikkelingsperspectief kunnen de verslaving en de comorbide 
psychiatrische stoornissen beschouwd worden als een uitbreiding en een 
complicatie van een chronische psychiatrische stoornis, die al op kinderleeftijd 
begint. De resultaten zijn in overeenstemming met eerder onderzoek, wat 
aangetoond heeft dat CD het grootste risico op latere verslaving meebrengt. De 
invloed van ADHD is in vergelijking hiermee duidelijk kleiner. Wat in deze pa-
tientenpopulatie sterk aan het licht gekomen, is de sterke verwevenheid van 
beide stoornissen, waardoor het risico op latere verslaving en psychopathologie 
nog verder verhoogd wordt. 
(5)  Erfelijkheid: gemeenschappelijke genetische factoren in de kwetsbaarheid voor ADHD 
en verslaving
Ondanks de bescheiden onderzoeksopzet en het beperkt aantal bestudeerde 
risicogenen, bleek het toch mogelijk gemeenschappelijke elementen in de 
genetische basis van ADHD en SUD aan te tonen. In vergelijking met controleper-
sonen zonder ADHD was het voorkomen van de risico genotypen van DBH en 
OPRM1 hoger bij patiënten met ADHD. Evenwel was het DBH risico genotype 
geassocieerd met de ADHD diagnose, het OPRM1 genotype daarentegen met de 
combinatie ADHD en SUD. Deze resultaten zijn in overeenstemming met het 
concept van het spectrum van externaliserende stoornissen, waarbij een ge-
meenschappelijke genetische basis voor de verschillende stoornissen binnen het 
spectrum wordt verondersteld. Deze resultaten suggereren ook dat de 
kwetsbaarheid voor verslaving bij patiënten met ADHD ook ten dele genetisch 
bepaald is; een betere kennis van deze genetische mechanismen laat niet alleen 
vroegtijdige identificatie van risicopatiënten toe, maar mogelijk ook gerichte 
preventieve interventies. 
(6)  De effectiviteit van de standaard-medicatie voor ADHD (methylfenidaat) bij patiënten 
met zowel ADHD als verslaving
Slechts 9 van de 25 deelnemers hadden duidelijk baat bij het gebruik van 
methylfenidaat voor hun ADHD symptomen. Met het verstrijken van de jaren 
sinds het verrichten van dit onderzoek zijn de redenen van het negatief resultaat 
causaal verband onduidelijk blijft. Om dit probleem te omzeilen is het verdere 
onderzoek gericht op twee stoornissen met manifestatie vanaf de jeugd. 
(2)  Prevalentie en karakteristieken van CD en ADHD bij verslaafde patiënten
Een voorgeschiedenis van CD werd aangetoond bij de meerderheid van de 
deelnemers (60.1%). Persisterende ADHD, in de meeste gevallen niet eerder gedi-
agnosticeerd, werd vastgesteld bij ongeveer een kwart van de deelnemende 
patiënten (24.9%). Deze bevindingen sluiten aan bij eerdere onderzoeksresulta-
ten en bevestigen de belangrijke etiologische rol van deze stoornissen in de 
ontwikkeling van ernstige verslavingen. Deze externaliserende stoornissen 
kunnen beschouwd worden als een etiologisch model voor verslaving: een 
psychiatrische stoornis op kinderleefijd treedt op als voornaamste risicofactor 
voor problematisch middelengebruik, en zet een ontwikkelingstraject in gang, 
wat uiteindelijk tot verslaving leidt. De uitgebreide en diverse psychiatrische 
pathologie in deze patiëntengroep illustreert op duidelijke wijze dat verslaving 
in de eerste plaats een psychiatrische stoornis is.  
 Drie kwart van de deelnemers met ADHD had ook een voorgeschiedenis van 
CD. Deze bevinding suggereert dat ADHD in combinatie met CD de meest 
voorkomende klinische presentatie van ADHD is bij patiënten met ernstige 
verslavingen. 
Dit zou erop wijzen dat ADHD bij volwassenen met verslaving een meer complexe 
aandoening is dan bij volwassenen zonder verslaving, en vanaf het begin 
verweven is met meer ernstige gedragsproblematiek. Deze grotere complexiteit 
kan een verklaring zijn voor de lagere effectiviteit van de gebruikelijke ADHD 
medicatie bij deze patiëntengroep. 
(3)  De invloed van CD en ADHD op psychiatrische comorbiditeit bij verslaving
In vergelijking met patiënten zonder deze stoornissen, hadden deelnemers met 
ADHD of CD een meer ernstige verslaving, gekenmerkt door meer psychiatrische 
comorbiditeit, meer ernstige dysfunctie en lagere levenskwaliteit. Beide 
stoornissen dragen bij aan een toename in psychiatrische comorbiditeit, maar 
niet op volledig identieke wijze. Een voorgeschiedenis van CD predisponeert 
vooral tot antisociaal gedrag en persoonlijkheidsstoornissen. ADHD lijkt de kans 
op zowel internaliserende als externaliserende psychiatrische stoornissen te 
vergroten. 
 Patienten met zowel ADHD als CD hadden de hoogste probleemscores, wat 
aansluit bij de hypothese dat deze combinatie op synergistische wijze het risico 
op verslaving verhoogt, ondermeer door de toename aan psychiatrische 
comorbiditeit, met name persoonlijkheidsstoornissen.  
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duidelijk aangetoond dat verslaving een chronische stoornis is, waarbij de eerste 
manifestaties al op jonge leeftijd beginnen, en het middelengebruik vroeg in de 
adolescentie van start gaat. De hier beschreven patiënten zijn natuurlijk 
voorbeelden van een meer negatief ontwikkelingstraject. Toch is voorstelbaar 
dat een vergelijkbaar ontwikkelingspatroon ook aan te tonen is bij minder 
ernstige verslavingen, waarbij psychiatrische stoonrissen van bij de start een rol 
spelen in het ontstaan van problematisch middelengebruik. 
Psychiatrische evaluatie en behandeling
Voor zover dit nog nodig was, heeft dit onderzoek opnieuw aangetoond dat de 
comorbide psychiatrische problematiek een wezenlijk deel is van elke meer 
ernstige en chronische verslaving. Effectieve behandeling van de verslaving is 
daarom onmogelijk zonder dat deze psychiatrische comorbiditeit adequaat 
geëvalueerd en behandeld wordt. Helaas ontbreekt hiervoor de psychiatrische 
expertise in grote delen van de verslavingszorg. Dit blijkt ook samen te hangen 
met de stigmatisatie en de negatieve vooroordelen die opspelen bij verslaafde 
patiënten, zelfs bij hulpverleners, die beter zouden moeten weten. 
 Enkel een gezamelijke inspanning van alle partijen in de GGz, zowel de ver-
slavingsinstellingen als de psychiatrische instituten, kan de negatieve gevolgen 
van de categorisatie van de zorg voor de complexe verslaafde patiënten verhelpen. 
Dit onderzoek heeft niet alleen mogen aantonen hoe hoog de nood is, maar ook 
dat gedegen en wetenschappelijk interessant onderzoek desondanks goed 
mogelijk is. 
 Wat effectieve behandeling van ADHD aan de prognose van verslaafde 
patiënten kan verbeteren, blijft in dit onderzoek en in de wetenschappelijke 
literatuur voorlopig onbeantwoord. De negatieve onderzoeksresultaten geven 
wel aan in welke richtingen gezocht moet worden: zo vroeg mogelijk in de loop 
van de verslaving ADHD opsporen en behandelen, met effectieve medicatie (dus 
waarschijnlijk niet enkel methylfenidaat) en bij voorkeur tijdens stabiele 
abstinentie. Voor zover de behandeling van ADHD enig effect kan hebben op de 
prognose van de verslaving, zal dit alleen gebeuren wanneer de ADHD-symptomen 
volledig en langdurig gestabiliseerd zijn. 
Onderzoek
Verslaafde patiënten hebben af te rekenen met vooroordelen, en wetenschappe-
lijke feiten zijn een effectief middel om deze te bekampen. Dit dissertatie-project 
heeft alvast aangetoond dat gedegen wetenschappelijk onderzoek wel degelijk 
mogelijk is bij deze als lastig beschouwde patiëntenpopulatie. De hoop is dat 
deze resultaten bijdragen tot een beter begrip van de complexe psychopathologie 
van deze patiënten, en uiteindelijk ook tot meer effectieve behandeling. 
van dit onderzoek alleen maar duidelijker geworden:
- alle deelnemers waren ten tijde van het onderzoek opgenomen voor 
behandeling van hun verslaving, wat wijst op meer ernstige verslavings-
pathologie. De psychiatrische comorbiditeit van de deelnemers is evenwel 
niet systematisch geëvalueerd, waardoor het aandeel hiervan in het 
negatieve onderzoeksresultaat onduidelijk blijft. 
- de voornaamste beperking van de studie was het gebruik van een vast 
medicatieschema met een einddosis, waarvan we nu weten dat deze 
suboptimaal tot zelfs ineffectief is voor een aantal patiënten.
- verder maakte een flink placebo-effect het nog moeilijker een significante 
meerwaarde van de actieve behandeling aan te tonen.
  Hoewel de klinische setting wel bijgedragen heeft aan het placebo effect, 
had dit wel het voordeel dat abstinentie tijdens het onderzoek beter 
gewaarborgd was, dit in tegenstelling tot de meeste onderzoeken, uitgevoerd 
bij ambulante patiënten. 
Generaliseerbaarheid van de onderzoeksresultaten
Gezien de complexe en ernstige problematiek van de onderzochte patiënten-
populatie, zijn de onderzoekers terecht erg tevreden met een deelnemerspercentage 
van bijna 63% van de beoogde patiëntengroep. Toch ontbreekt informatie over 
bijna één derde van deze populatie. De algemene indruk is dat deze patiënten om 
verscheidene redenen niet aan het onderzoek deelnamen, maar dat zij in grote 
lijnen vergelijkbare (en misschien zelfs ernstigere) problemen hadden dan de hier 
beschreven deelnemers. Wel zijn door het gebruik van uitgebreide Nederlandstalige 
onderzoeksinstrumenten allochtone patiënten ondervertegenwoordigd. 
 De samenstelling van de onderzoekspopulatie, met vooral patiënten van 
middelbare leeftijd is representatief voor de huidige MMT populatie in Nederland. 
Een vergelijkbare samenstelling is te verwachten in de meeste West-Europese 
landen. Vergelijking met andere landen wordt bemoeilijkt door verschillen in 
demografie, beschikbaarheid van middelen en van behandelmogelijkheden. 
 Omdat opiaatverslaving specifieke kenmerken heeft (met name ook de negatieve 
prognose op lange termijn) zijn de hier beschreven resultaten niet gelijk uit te 
breiden naar elke populatie verslaafde patiënten. In het licht van het dimensioneel 
karakter van zowel verslaving als de andere externaliserende stoornissen is het 
zeker interessant na te gaan of vergelijkbare patronen ook te vinden zijn in 
 patiëntenpopulaties met minder ernstige verslavingen. 
Consequenties van dit onderzoek
De hier beschreven onderzoeksresultaten bevestigen de relevantie van de exter-
naliserende stoornissen in de ontwikkeling van verslaving. Het onderzoek heeft 
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wel vertraagd worden, wat hoop geeft op minder ernstige manifestaties op 
volwassen leeftijd.
 Op basis van de risicofactoren die in dit proefschrift besproken zijn, is 
bekend waar de preventieve maatregelen op gericht moeten zijn: identificatie 
van risicopatiënten op zo vroeg mogelijke leeftijd, en het bieden van gerichte 
hulp in het versterken van hun vaardigheden en mentale veerkracht, en in het 
verminderen van negatieve omgevingsomstandigheden. Het effect van deze 
preventieve maatregelen moet bij voorkeur al aanwezig zijn voor deze jonge 
patientjes de roerige periode van de puberteit ingaan. Dit onderzoek heeft 
opnieuw aangetoond dat kinderen met zowel ADHD als CD het grootste risico 
lopen. Sommige onderzoeken suggereren dat een vroegtijdige behandeling van 
ADHD de verdere ontwikkeling van CD voorkomt, en daarmee het risico op 
problematisch middelengebruik in belangrijke mate kan verminderen. 
 De realiteit is evenwel weerbarstig: ondanks de (wetenschappelijk bewezen) 
ervaring dat ADHD op kinderleeftijd uitstekend te behandelen is, is longitudinaal 
onderzoek er (nog steeds) niet in geslaagd een beschermend effect van de 
behandeling van ADHD op het optreden van verslaving aan te tonen. Bij veel van 
de uitgevoerde onderzoeken bleken een groot aantal deelnemers hun behandeling 
in de loop van het onderzoek te staken. Op deze manier zijn de gerapporteerde 
negatieve bevindingen een indirect bewijs voor de noodzaak van langdurige en 
effectieve behandeling van deze patiënten. ADHD is per slot van rekening een 
chronische stoornis, en in de dagelijkse praktijk raken veel patiënten uit beeld 
rond de puberteit, net de periode waarin een beschermende invloed van de 
ADHD-behandeling het meest aangewezen is. Hierbij moet niet enkel aan 
medicatie gedacht worden, maar ook aan gedragstherapeutische interventies. 
Hiervoor is verder onderzoek aangewezen, in de eerste plaats replicatie van de 
huidige bevindingen in vergelijkbare patientenpopulaties. Een meer uitgewerkte 
dimensionele benadering kan de associatie tussen de verschillende externalise-
rende stoornissen en hun aandeel in de ontwikkeling van een verslaving nog 
meer helder in kaart brengen.
 Het exploratieve onderzoek naar de gemeenschappelijke genetische basis 
van ADHD en verslaving heeft aangetoond dat hier duidelijk nog meer te vinden 
is. Dit zou niet alleen kunnen leiden tot de identificatie van een bepaald subtype 
van ADHD met verhoogde genetische kwetsbaarheid voor verslaving, maar ook 
tot een beter begrip van de pathogenese van beide stoornissen. 
De methylfenidaat pilot study is een waardevolle leerervaring geweest, waaruit 
duidelijke lessen te halen zijn hoe het een volgende keer beter te doen. Dat dit 
niet eenvoudig is, blijkt uit de teleurstellende resultaten van andere placebo-ge-
controleerde onderzoeken naar het effect van methylfenidaat bij verslaafde 
patiënten, die sindsdien verschenen zijn. Dit zou het signaal mogen zijn voor een 
koerswijziging.
 Naast alle eerder genoemde argumenten moet ook nog rekening gehouden 
worden met de mogelijkheid dat methylfenidaat bij deze patiëntengroep net 
minder effectief is, dan bij volwassenen zonder verslaving. Dit pleit voor 
gecontroleerd onderzoek met andere medicijnen, met dexamfetamine als eerste 
kandidaat. Een andere benadering, ingegeven door de heterogeniteit van de pa-
tiëntenpopulatie, is een prospectief longitudinaal onderzoek naar de behandeling 
van ADHD bij verslaafde patiënten op basis van een helder behandelprotocol, 
waar een systematisch medicatiebeleid onderdeel van uitmaakt. Over langere 
tijd worden dan ADHD symptomatologie, verslavingskenmerken en algeheel 
functioneren bijgehouden. Hoewel de bewijskracht van een dergelijk onderzoek 
minder robuust is dan van een placebo-gecontroleerd onderzoek, is op die 
manier ook aan te tonen hoe goed (of slecht)  ADHD bij verslaafde patiënten te 
behandelen is. Bovendien zouden de ervaringen met dit medicatieprotocol ook 
leiden tot heldere richtlijnen voor de praktijk. 
Preventie
De vaststelling dat volwassen patienten nog steeds lijden aan de gevolgen van 
een stoornis die op jonge leeftijd begonnen is, doet onmiddellijk de vraag rijzen 
naar de mogelijkheden van preventieve maatregelen. Zeker voor ADHD geldt dat 
het een goed behandelbare aandoening is; ook voor CD zijn goede behandelings-
mogelijkheden beschikbaar. Hiermee is niet alle problematiek op volwassen 
leeftijd te voorkomen. Een realistische verwachting mag zijn dat hiermee een 
vermindering van de psychiatrische comorbiditeit kan bereikt worden; 
verslaving zal niet volledig te voorkomen zijn, maar mogelijk kan de ontwikkeling 
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Conclusie
Dit dissertatie-onderzoek heeft duidelijk aangetoond dat verslaving een levens - 
lange aandoening is, en dat psychiatrische comorbiditeit inherent aan verslaving 
is. Het begrip comorbiditeit, zoals in dit onderzoek gehanteerd, is een nuttige 
abstractie om diverse aspecten van psychiatrische stoornissen te identificeren, 
maar een vereenvoudiging van deze complexe psychopathologie. De beperkte 
 levenskwaliteit van de deelnemers aan dit onderzoek benadrukt de nood aan 
meer effectieve behandeling. Dit onderzoek heeft eens te meer de belangrijke rol 
aangetoond van de vroege voorlopers ADHD en CD bij de ontwikkeling van 
ernstige verslavingen. Een beter begrip van de complexe onderlinge relaties 
tussen de verschillende stoornissen in het externaliserende spectrum biedt 
uitzicht op meer effectieve behandeling van deze chronische psychiatrische 
patiënten, maar ook voor het voorkomen van toekomstige pathologie bij jongere 
individuen.
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Sinds ik in 2005 aan dit proefschrift ben beginnen werken is de wereld enorm 
veranderd: mijn vader is overleden, mijn zoons zijn door de middelbare school 
gevlogen en bijna de deur uit, de wereldeconomie is ingestort onder de 
schuldencrisis, BHV is gesplitst, de Arabische Lente is vergangen, de euro is van 
zijn voetstuk gevallen en psychiatrische patienten moeten een eigen bijdrage 
betalen om behandeld te mogen worden. In het meewarig licht van al deze 
problemen, is het werken aan dit proefschrift voor mij in al die jaren een 
proeftuin van betrekkelijke rust geweest, waar uitdagingen en problemen 
misschien wel veelvuldig maar in ieder geval concreet en oplosbaar waren. 
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en dit onderzoek hebben gefaciliteerd door mij tijd en ruimte beschikbaar te 
stellen. Beste Roel en Paul, ik dank jullie voor deze royale steun en het vertrouwen 
dat jullie hierbij in mij uitgesproken hebben.
 Ik wil de leden van de manuscriptcommissie, Giel Hutschemaekers, Rutger-Jan 
van der Gaag en Geert Dom hartelijk bedanken voor hun bereidheid dit proef- 
schrift te beoordelen, en nog meer voor hun positieve waardering, die deze 
openbare verdediging mogelijk heeft gemaakt. Het feit dat Vlaamse expertise is 
aangesproken om tot dit oordeel te komen, doet mij veel deugd. Ik ben bijzonder 
vereerd dat Sandra Kooij, Wim van den Brink, Boukje Dijkstra en Aart Schellekens 
gelijk ingegaan zijn op de uitnodiging om te opponeren. Dat mij hiermee de 
gelegenheid geboden is dit proefschrift te verdedigen in aanwezigheid van 
zoveel bekenden, voelt als een bijzonder voorrecht, wat ik zeer waardeer. 
 In dit onderzoeksproject zijn meerdere persoonlijke belangstellingsgebieden 
samengekomen. Een rode draad in het verhaal is de stoornis ADHD bij volwassenen, 
die mij nu al meer dan 15 jaar intensief bezighoudt. Op meerdere manieren heb 
ik gebruik mogen maken van het indrukwekkende pionierswerk dat Sandra 
Kooij op dit gebied heeft verricht. Lieve San, zonder jouw tomeloze inzet zou 
ADHD bij volwassenen nog lang niet de formele status hebben gekregen die het 
nu in het psychiatrische werkveld geniet. ik ben blij dat dit proefschrift daarin 
nu ook een bijdrage levert. 
 Dat mijn wetenschappelijke belangstelling uiteindelijk toch vorm gekregen 
heeft in een echt onderzoek heb ik vooral danken aan Cor de Jong. Beste Cor, 
mijn dank dat jij mijn belangstelling hebt herkend en gestimuleerd; meer dan 
eens heb je mij flinke impulsen gegeven om er ook werk van te maken. Mijn dank 
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 Volwassenen met ADHD 
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 Uit deze weelde van gegevens significante bevindingen halen, was een taak, 
die me aanvankelijk te machtig was. Dank zij Cor kwam ik in contact met Paul 
Krabbe, die mij mijn gebrek aan statistische slagvaardigheid vergaf en bereid 
was me wegwijs te maken in SPSS, en die me ondertussen ook nog de principes 
van een sobere lay-out duidelijk maakte. Beste Paul, mijn voorliefde voor een 
schreefloze letter is een blijvend aandenken aan onze contacten. 
 Omdat bij het onderzoek ook genetisch materiaal verzameld was, mocht ik 
kennismaken met het boeiende veld van het genetisch onderzoek. Dat ik in dit 
snel ontwikkelend en alsmaar gecompliceerder wordend onderzoeksveld niet 
verder ben verdwaald, heeft alles te maken met Barbara Franke; zij heeft mij 
geholpen de patronen te herkennen en exact te beschrijven. Mijn statistische 
onbeholpenheid bleek geen bezwaar voor Alejandro Arias Vasquez, die mij 
hierbij verder ondersteunde. Beste Barbara en Alejandro, dank zij jullie heb ik 
mijn koudwater vrees voor het genetisch onderzoek in de psychiatrie redelijk 
leren overwinnen. Met de toenemende aandacht dat dit onderzoeksveld in de 
toekomst zal blijven krijgen, zal ik graag aan jullie blijven denken.
Dit proefschrift is ook een product van zijn tijd. Omdat ik op de lagere school 
nog net de inktpot uit de lessenaar heb zien verdwijnen, kan ik mij dankbaar 
verbazen over alle technische innovaties, die mij bij het schrijven van dit 
proefschrift enorm geholpen hebben. Op de middelbare school leerde ik blind 
typen, niet vermoedend dat de typmachine zou verdwijnen, maar het klavier 
zou blijven bestaan, gekoppeld aan een Personal Computer waarop ik dit 
proefschrift helemaal heb uitgetikt. Overleg met promotoren en deskundigen 
verliep niet meer met telefoons of brieven, maar bliksemsnel via email. Het 
meest verbijsterende is voor mij wel het statistiekprogramma SPSS geweest, dat 
elke berekening die ik maar kon bedenken, onmiddellijk heeft uitgevoerd, maar 
mij alleen niet kon vertellen of het wel zin had. Waarmee het programma mij 
wel confronteerde met de vraag of ik zelf wel wist waar ik mee bezig was … 
 Mijn toegang tot de wetenschap was Pubmed, de database van de National 
Library of Medicine van de Verenigde Staten: voor iemand die nog in de 
bibliotheek de maandelijkse uitgaven van de Index Medicus raadpleegde, blijft 
het een verbazend voorrecht gelijk bij alle vakliteratuur te kunnen. Het 
wereldwijde web maakt inzage in alle tijdschriften mogelijk, en bijna alle 
auteurs zijn graag bereid een kopie van hun artikel per mail op te sturen. Hun 
bemoedigende boodschap, die de kopie vaak vergezelde, kan ik nu beter 
begrijpen: artikelen zijn er om gelezen te worden. In alle andere gevallen was de 
Vakbibliotheek van Reinier van Arkel graag bereid voor mij de meest onmogelijke 
artikelen te achterhalen. Dank ben ik ook verschuldigd aan het programma 
Reference Manager, wat al mijn literatuurverwijzingen geduldig heeft bijgehouden; 
ook aan jou, omdat jij ook het fundament hebt gelegd voor dit onderzoeksproject. 
 Een eerste vingeroefening is de Ritalin Pilot Study geweest, waarmee nog maar 
eens aangetoond is hoe dankbaar nieuwe ontwikkelingen op een gepaste wijze 
te toetsen, namelijk door onderzoek te verrichten. Het is toen dat ik voor het 
eerst mocht kennismaken met het enthousiasme en het praktisch vernuft van 
Cor Verbrugge. Beste Cor, bij dit eerste onderzoek ben jij het manusje-van-alles 
geweest, waardoor het onderzoek ook uitgevoerd kon worden. Je vriendelijke be-
reidwilligheid op elk moment blijft een warme herinnering. Een even onmisbaar 
persoon is Boukje Dijkstra geweest, want zij heeft me in niet geringe mate 
moeten helpen bij de data-analyse, waar ik toen nog weinig kaas van gegeten 
had: ik mocht voor het eerst ervaren dat een clinicus niet automatisch een goed 
onderzoeker is. Beste Boukje, mijn hartelijke dank voor deze wijze les, want hij 
is me in het vervolg nog goed van pas gekomen. 
 De volgende stap werd het opzetten van het onderzoeksprotocol, en pas 
gaande het onderzoek is mij duidelijk geworden hoe belangrijk een goede voor- 
bereiding is. Naast Cor de Jong is het Jan Buitelaar geweest die mij de principes 
van klinisch onderzoek heeft proberen duidelijk te maken. De praktijk is een 
strenge leerschool gebleken: beste Jan, mijn dank voor je kritische vragen, je 
gerichte opmerkingen en je wijze adviezen. Ik neem mij voor ze bij een volgend 
onderzoek beter in praktijk te brengen. 
 Dank zij de bemiddeling van Cor de Jong diende zich uiteindelijk de 
mogelijkheid aan tot een meer grootschalig onderzoek, en dit had alles te maken 
met de ambities van Mijke van Gogh en Lieke Knapen, destijds bezig met hun 
opleiding Geestelijke Gezondheidskunde. Zij waren op zoek naar een mooie 
uitdaging voor hun afstudeerscriptie, en hebben dit meer dan waargemaakt in 
dit onderzoeksproject. Hun bijdrage is een cruciale factor geweest in het 
welslagen van het project. Het groot aantal deelnemers onder de patiënten van 
de Kanaaldijk is in de eerste plaats toe te schrijven aan het vertrouwde contact 
dat zij met deze klanten hadden opgebouwd (en hun niet aflatende ijver deze 
klanten op te sporen en bij het onderzoek te halen). Lieve Lieke en Mijke, mijn 
hartelijke dank voor jullie inzet en overtuigingskracht, en voor het verzamelen 
van alle gegevens en het opstellen van de databestand. 
 Uiteindelijk is dit onderzoek natuurlijk niet mogelijk zonder de deelname 
van de patienten zelf. Hun gegevens worden in dit verslag op anonieme en 
abstracte wijze vermeld, waardoor het menselijk lijden gesteriliseerd en 
verborgen wordt en onze betrokkenheid de vorm krijgt van wetenschappelijke 
interesse. Ik blijf hen niet alleen mijn dank maar ook mijn respect verschuldigd 
dat zij bereid zijn geweest zich voor dit onderzoek beschikbaar te stellen. Mijn 
dank ook aan alle medewerkers van de Kanaaldijk, die mij met een mengeling 
van nieuwsgierigheid en scepsis, maar altijd met hartelijkheid hebben ontvangen. 
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éénmaal ik wist wat al die abstracte commando’s betekende, werkte het getrouw 
alle literatuurlijsten af. 
 Via het web kwam ik ook in contact met John Palmer (jap1044@yahoo.com), 
een minzame Amerikaan (Durham, NC) met een achtergrond in de α- weten-
schappen. Geduldig en zorgvuldig heeft hij mijn teksten bijgeschaafd, dat ze wat 
meer op leesbaar Engels gingen lijken. The credits go to you, John. If the text of 
this dissertation remains somewhat obnoxious to the English language, the fault 
is mine alone. 
 Toch wil ik op deze plek vooral mijn dank uitspreken aan al die mensen die 
bereid zijn hun kennis en informatie via het wereldwijde web voor eenieder 
belangeloos beschikbaar te stellen. Een vermelding hier is het minste wat ik kan doen.
In het werken aan dit proefschrift heb ik mij nooit eenzaam hoeven voelen, 
omdat ik voortdurend in contact kwam met collega’s, die belangstellend 
informeerden naar mijn vorderingen, en steeds bereid waren me aan te moedigen 
. In de eerste plaats zijn dat de collega’s uit het Netwerk ADHD bij volwassenen 
geweest: naast Sandra Kooij ook Anne van Lammeren, Nannet Buitelaar, Patricia 
van Wijngaarden en Lex Pull. Lieve Anne, Nannet, Patricia en Lex, ook waren de 
contacten altijd te kort, ook voor dit proefschrift zijn ze heel waardevol gebleken. 
Met de fusie met het Kinderartsennetwerk kwamen er in het ADHD Netwerk 
nieuwe collega’s bij: Rob Rodriguez Pereira, Ellen Fliers, Michiel Noordzij en Leo 
van Oudheusden. Ik ben blij hen hier te laten zien hoeveel hun collegiale 
ondersteuning mij geholpen heeft. 
 Een belangrijke bron van stimulans en inspiratie is mijn deelname aan de 
regelmatige vergaderingen van ICASA (the International Collaboration on ADHD 
and Substance Abuse) in binnen- en buitenland. Het is bijzonder enthousiasme-
rend collega’s uit andere landen tegen te komen die in hetzelfde onderzoeksge-
bied bezig zijn. Dat ICASA zo ver gekomen is dat binnenkort de eerste onder-
zoeksresultaten van een internationaal prevalentieonderzoek naar ADHD bij 
verslaafde patiënten, heeft alles te maken met de niet aflatende ijver van Geurt 
van de Glind, onder het bezielende mentorschap van Wim van den Brink. Beste 
Geurt, onze wegen hebben zich herhaaldelijk gekruisd. We hadden samen niet 
kunnen bedenken dat onze gemeenschappelijke belangstelling naar ADHD bij 
verslaving zo’n mooi avontuur zou gaan opleveren. Geurt, voor wat ik heb 
bijgedragen, heb je mij erg veel in de plaats gegeven. Ik vind het geweldig wat jij 
hierbij allemaal opgebouwd ben. Ik kijk uit naar het moment dat jij ook mag 
gaan oogsten. Beste Wim, het is een inspirerend voorrecht je regelmatig aan het 
werk te mogen zien bij lezingen en vergaderingen. Nog leuker zijn de discussies 
aan de eettafel, waar we vele gemeenschappelijke interessen (waaronder mooie 
wijn) aan bod mogen laten komen. 
De combinatie van klinisch werk en onderzoek heeft voor mij goed uitgepakt. Ik 
ben ervan overtuigd dat ik deze onderzoeksactiviteiten mij geholpen hebben 
mijn patiëntenwerk nog beter te waarderen en uit te voeren. Hierbij heb ik 
dankbaar gebruik gemaakt van de ondersteuning en de belangstelling van 
diverse collega’s in twee instellingen, zowel Reinier van Arkel als Novadic- 
Kentron. Bij Novadic-Kentron ben ik altijd onder de indruk geweest van de 
betrokkenheid van de hulpverleners bij hun werk, ook al waren de patiënten 
lang niet altijd makkelijk en de resultaten te vaak tegenvallend. Ik heb er erg 
veel geleerd, hopelijk is dit proefschrift hier enig bewijs van. Mijn dank voor al 
die jaren vriendelijke en collegiale samenwerking. Ik ben erg blij dat Reinier van 
Arkel mij sinds een aantal jaren de gelegenheid biedt mijn specifieke 
belangstelling voor ADHD bij volwassenen in een een specifiek behandel-
programma toe te passen, samen met collega’s die deze belangstelling delen. 
Beste Nurcan, Bregje, Anita, Paul en Wouter (en niet te vergeten Anita) het is een 
dagelijks plezier met jullie te mogen samenwerken: mijn hartelijke dank 
hiervoor. 
 Bij een onderneming van lange adem is de steun van vrienden en familie 
onontbeerlijk. Deze achterban was altijd beschikbaar om ontspanning en 
afwisseling te bieden. De meeste reacties op het onderzoeksproject waren 
positief: een indrukwekkend voornemen, waar je beleefd tegenaan kijkt, ook al 
ben je niet gelijk overtuigd van de zin ervan. Ik ben dankbaar voor deze blijken 
van betrokkenheid en waardering, het heeft me steeds aan de gang gehouden. 
Veel steun heb ik gehad aan mijn vaste intervisiegroep van de vrijdagavond: 
zorgvuldig in hun kritiek, spaarzaam in hun lof hebben ze mij elke keer opnieuw 
kordaat gewezen op mijn tekorten en verbeterpunten: hoofd recht houden, goed 
omkijken, koppie erbij houden, op het juiste moment op de juiste plaats 
verschijnen. De sessies waren voor mij niet altijd even productief, het plezier was 
er niet minder om. 
 Gedurende het hele onderzoekstraject kon ik rekenen op mijn familie 
(warme én kouwe kant), in afstand veraf, maar in betrokkenheid altijd 
beschikbaar. In deze stad, waar het voor mij allemaal begonnen is, weet ik mij 
gesteund door de dankbare herinnering aan mijn ouders. Zij waren er hier zeker 
graag bij geweest, ik zal er ook voor hen een mooie dag van maken. Met al deze 
hulp en aanmoediging die ik in al deze jaren heb gekregen, kon het ook niet 
misgaan. Veel heb ik geleerd met dit proefschrift, maar nog veel meer daarbuiten. 
Dat ik hier nu aan de eindstreep sta, omringd door familie, vrienden en 
kennissen, geeft dan ook enorm veel voldoening, en daar ga ik met volle teugen 
van genieten. Bedankt, iedereen. 
 Tot slot het thuisfront, dat bepaald niet stilgestaan heeft in de afgelopen 
jaren. Voor alle uren die ik in de eenzaamheid van mijn studeerkamer heb 
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Pieter-Jan Carpentier (Nijmegen, 1956) is psychiater (medicijnenstudie: Universiteit 
Antwerpen, 1981; registratie als psychiater: 1988). Hij is programmaleider van 
het behandelprogramma ADHD bij volwassenen van de Reinier van Arkel Groep 
te ’s-Hertogenbosch; van 1998 tot 2010 was hij als consulent verbonden aan 
 Novadic-Kentron, netwerk voor verslavingszorg in Noord-Brabant.
 Hij raakte toenemend geïnteresseerd in het onderwerp ADHD bij volwassenen, 
in het bijzonder in combinatie met verslaving, op basis van klinische ervaringen 
met deze patiënten. Sinds meer dan 10 jaar is hij actief in het stimuleren van 
verbeterde diagnostiek en behandeling van deze patiëntengroep. Hij was actief 
betrokken bij het ontwikkelen van het Protocol ADHD bij verslaving, een richtlijn 
voor screening en behandeling van ADHD in verslavingsinstellingen (Trimbos 
Instituut, Utrecht, 2000 – 2004). Hij is lid van de monodisciplinaire richtlijncom-
missie ADHD bij volwassenen en de multidisciplinaire richtlijncommissie Opiaa-
tafhankelijkheid.
 Hij is lid van ICASA (International Consortium ADHD and Substance Abuse), 
een internationale contactgroep die onderzoek naar ADHD bij verslaving stimuleert. 
 Hij is oprichter en hoofdredacteur van de Ark, het intern voorwetenschappelijk 
tijdschrift van de Reinier van Arkel groep. Verder verzorgt hij samen met Paul van 
Dongen de cyclus Film en Psychiatrie in filmhuis de Verkadefabriek te ’s-Hertogen-
bosch. Hij vermaakt zich met zaalvoetbal, oenologie en mycofagie. 
mogen doorbrengen, mijn hartelijke dank. Ik ben blij dat het leven ondertussen 
gewoon doorgegaan is omdat relativering een belangrijke voorwaarde voor 
gedegen onderzoek is. Dat ik hier uiteindelijk niet teveel van heb gemist, heeft 
alles te maken met de de onmisbare aanwijzingen van Bieke voor en achter de 
schermen. Beste Jan en Thomas, mijn hartelijke dank, het is een voorrecht samen 
met jullie op te groeien. Liefste Bieke, je nuchtere commentaren in elke fase van 
dit lange project hebben mij geholpen mijn voeten op de grond te houden en te 
onthouden wat er belangrijk is in het leven. En dat wil ik samen met jou in stand 
houden. Dankjewel.
 
Si può dimostrare che questa storia, del tutto arbitraria, è tuttavia vera.  
Potrei raccontare innumerevoli storie diverse, e sarebbero tutte vere:  
tutte letteralmente vere, nella natura dei trapassi, nel loro ordine e nella loro 
data. Il numero degli atomi è tanto grande che se ne troverebbe sempre uno la 
cui storia coincida con una qualsiasi storia inventata a capriccio. Potrei 
raccontare storie a non finire, di atomi di carbonio che si fanno colore o 
profumo nei fiori; di altri che da alghe minute a piccoli crostacei, a pesci via via 
più grossi, ritornano anidride carbonica nelle acque del mare, in un perpetuo 
spaventoso girotondo di vita e di morte, in cui ogni divoratore è 
immediatamente divorato; di altri che raggiungono invece una decorosa 
semi-eternità nelle pagine ingiallite di qualche documento d’archivio, o nella 
tela di un pittore famoso; di quelli a cui toccò il privilegio di far parte di un 
granello di polline, e lasciarono la loro impronta fossile nelle rocce per la 
nostra curiosità; di altri ancora che discesero a far parte dei misteriosi 
messaggeri di forma del genere umano, e parteciparono al sottile processo di 
scissione duplicazione e fusione da cui ognuno di noi è nato. Ne racconterò 
invece soltanto ancora una, la più segreta, e la racconterò con l’umiltà e il 
ritegno di chi sa fin dall’inizio che il suo tema è disperato, i mezzi fievoli, e il 
mestiere di rivestire i fatti con parole fallimentare per sua profonda essenza. 
 
E’ di nuovo tra noi, in un bicchiere di latte. E’ inserito in una lunga catena, 
molto complessa, tuttavia tale che quasi tutti i suoi anelli sono accetti al corpo 
umano. Viene ingoiato: e poiché ogni struttura vivente alberga una selvaggia 
diffidenza verso ogni apporto di altro materiale di origine vivente, la catena 
viene meticolosamente frantumata, e i frantumi, uno per uno, accettati o 
respinti. Uno, quello che ci sta a cuore, varca la soglia intestinale ed entra nel 
torrente sanguigno: migra, bussa alla porta di una cellula nervosa, entra e 
soppianta un altro carbonio che ne faceva parte. Questa cellula appartiene a un 
cervello, e questo è il mio cervello, di me che scrivo, e la cellula in questione, ed 
in essa l’atomo in questione, è addetta al mio scrivere, in un gigantesco 
minuscolo gioco che nessuno ha ancora descritto. E’ quella che in questo 
istante, fuori da un labirintico intreccio di sì e di no, fa sì che la mia mano 
corra in un certo cammino sulla carta, la segni di queste volute che sono segni; 
un doppio scatto, in su e in giù, fra due livelli d’energia guida questa mia 
mano ad imprimere sulla carta questo punto: questo.
Primo Levi (1919 – 1987)
Il sistema periodico: Carbonio

